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 Abstract 
CONTROLLING PLATELET SECRETION TO MODULATE HEMOSTASIS AND THROMBOSIS  
Upon vascular injury, activated blood platelets fuse their granules to the plasma 
membrane and release cargo to regulate the vascular microenvironment, a dynamic 
process central to platelet function in many critical processes including hemostasis, 
thrombosis, immunity, wound healing, angiogenesis etc. This granule-plasma membrane 
fusion is mediated by a family of membrane proteins- Soluble N-ethyl maleimide 
Attachment Receptor Proteins(SNAREs). SNAREs that reside on vesicle (v-SNAREs) 
/Vesicle-Associated Membrane Proteins(VAMPs) interact with target/t-SNAREs forming 
a trans-bilayer complex that facilitates granule fusion. Though many components of 
exocytic machinery are identified, it is still not clear how it could be manipulated to 
prevent occlusive thrombosis without triggering bleeding. My work addresses this 
question by showing how the rates and extents of granule secretion could be regulated 
by various v-SNAREs. We also show that the granule cargo decondensation is an 
intermediate to secretion that also contributes to rates of cargo release. 
Platelets contain four major VAMP isoforms (-2, -3, -7, and -8), however, VAMP-8 and -7 
play a primary role while VAMP-2 and -3 are ancillary in secretion. To exploit this 
heterogeneity in VAMP usage, platelet-specific V-2/3-/- and V-2/3/8-/- mouse models 
were generated and characterized to understand how secretion influences hemostasis. 
We found that each VAMP isoform differentially contributes by altering the rates and 
extents of cargo release. The loss of VAMP-2 and -3 had a minimal impact while the loss 
of VAMP-2, -3 and -8 significantly reduced the granule secretion. Platelet activation and 
aggregation were not affected though the spreading was reduced in V-2/3/8-/- platelets 
indicating the importance of secretion in spreading. Though coagulation pathways were 
unaltered, PS exposure was reduced in both V-2/3-/- and V-2/3/8-/- platelets suggesting 
diminished procoagulant activity. In vivo experiments showed that V-2/3/8-/- animals 
bled profusely upon tail transaction and failed to form occlusive thrombus upon arterial 
injury while V-2/3-/- animals did not display any hemostatic deficiency. These data 
suggest that about 40-50% reduction in secretion provides protection against 
thrombosis without compromising hemostasis and beyond 50% secretion deficiency, the 
animals fail to form functional thrombi and exhibit severe bleeding. Additionally, 
detailed structural analysis of activated platelets suggests that the post-stimulation 
cargo dissolution depends on an agonist concentration and stimulation duration. This 
process is VAMP-dependent and represents intermediate steps leading to a full exodus 
of cargo. Moreover, we also show that VAMP-8 is important for compound fusion 
events and regulates fusion pore size.  
This is a first comprehensive report that shows how manipulation of the exocytic 
machinery have an impact on secretion and ultimately on hemostasis. These animals 
will be instrumental in future investigations of platelet secretion in many other vascular 
processes. 
Keywords: Platelet SNAREs, granule exocytosis, cargo release, hemostasis, thrombosis, 
decondensation 
 
Smita Joshi 
March 1st, 2018 
 
  
  
 
 
 
 
 
 
CONTROLLING PLATELET SECRETION TO MODULATE HEMOSTASIS AND THROMBOSIS  
 
 
 
 
By 
 
Smita Joshi 
 
 
 
 
 
 
Dr. Sidney W. Whiteheart 
Director of Dissertation 
 
Dr. Trevor Creamer 
Director of Graduate Studies 
 
March 1st, 2018 
 
 
 
 
 
 
 
  
 
                                                        
 
 
 
 
 
 
 
 
                                                             To my family 
iii 
 
Acknowledgements 
First and foremost, I would like to express my gratitude to my mentor and chair 
of my committee, Dr. Sidney W. Whiteheart for his expertise, enthusiasm, and guidance 
to support the work presented in this dissertation. I appreciate the time he invested in 
training me as a scientist and great efforts he took to improve my communication skills. 
I especially appreciate his incredible patience when experiments wouldn't work, and 
everything seemed standstill. I am thankful for his faith in me when it was difficult for 
me to believe that I could accomplish this. He has been an excellent role model on 
professional and person level and will have a lifelong impact on me. I would also like to 
express my appreciation for each member of my dissertation committee, Dr. Rebecca 
Dutch, Dr. Brett Spear, Dr. Zhenyu Li, as well as outside examiner Dr. Scott Gleeson for 
their critical advice to better my work. I would also like to thank Dr. Whiteheart and Dr. 
Dutch for providing me an advice on parenting whenever needed. I want to express my 
gratitude to Dr. Skip Waechter and Dr. Craig VanderKooi for their time and efforts to 
improve my student seminar presentations over the years. Your constructive comments 
have made a tremendous improvement in how I see my work. 
I would also like to thank all our collaborators who have presented opportunities 
to seek answers to exciting questions. I would like to thank Dr. Brian Storrie and Irina 
Pokrovskaya, for an incredibly productive collaboration to study the structural 
components of platelet granule secretion. Without their help, second part of this 
dissertation wouldn’t have been possible. I thank Dr. Brian Cobb for IgG sialylation 
project, Dr. Qingjun Wang for platelet autophagy and platelet metabolomics projects 
and Dr. Zhenyu Li and his lab for providing reagents, instruments, and teaching me 
carotid injury assay. 
To all the members of the Whiteheart laboratory, both past, and present, you all 
have been instrumental in my success. Though I haven’t met all members, the stories 
and pictures have kept alive their legends so much that I do feel like they have taught 
me valuable lessons. I especially thank Dr. Qiensheng Ren whose work provided a solid 
iv 
 
platform to build my project. I thank Dr. Elena Matveeva who remains a constant source 
of support. I thank Dr. Zubair Karim for valuable advice and challenging discussions, Dr. 
Shaojing Ye, Dr. Deepa Jonnalagadda and Dr. Yunjie Huang for teaching me various 
techniques in early years in the lab. I thank Dr. Jinchao Zhang and Dr. Meenakshi 
Banerjee for critical comments on my work and helpful discussions. Your support has 
been invaluable in my graduate journey. I thank new members of the lab - Dr. Harry 
Chanzu, Laura Tichacek, and Ming Zhang for their support. I also want to thank my high 
school students Jimmy Chen and Akhil Kesaraju for their drive and for teaching me 
about school education. I also want to express my appreciation for the biochemistry 
students ahead of me for their advice and helpful suggestions. I was fortunate to have 
valuable friendships in graduate school to help me survive- thanks to Karine Oben, Hye 
In Jang. Katie Withers, Stacy Webb, and Caitlyn Reidmann. Your support has been 
invaluable. 
Lastly, I wouldn’t be here without the support of my family. I want to express my 
gratitude to my late grandmother who would have been very proud of me. I want to 
thank my parents for always believing in me. I thank my siblings, and siblings-in-law for 
encouraging and supporting me through this journey. Special thanks to my parents-in-
law who helped me by taking care of my children when I was lost in the first year of IBS 
program. I thank them for their incredible support when needed the most. I thank my 
husband Nilesh who has been a source of constant support and motivation. He not only 
encouraged me to apply to graduate school but also supported me every way possible 
to reach this day today. He is the sole reason I am standing here today. Lastly, I want to 
thank my biggest source of motivation and joy- my lovely children- Gauri and Ishaan for 
their unconditional love, support and the sacrifices they made to help me reach to this 
destination. Here is to you all! 
v 
 
TABLE OF CONTENTS 
Acknowledgements ............................................................................................................. iii 
List of Tables ........................................................................................................................ x 
List of Figures ...................................................................................................................... xi 
Abbreviations .................................................................................................................... xiii 
Chapter 1 Introduction ....................................................................................................... 1 
Platelet cell biology ......................................................................................................... 1 
Platelet structure ............................................................................................................. 1 
Platelet biogenesis .......................................................................................................... 4 
Platelet granule biogenesis ............................................................................................. 4 
A) Dense granule biogenesis ....................................................................................... 4 
B) Alpha-granule biogenesis ........................................................................................ 7 
Platelet receptors and intracellular signaling pathways ............................................... 11 
Initiation phase .......................................................................................................... 11 
Extension phase ......................................................................................................... 15 
Stabilization phase ..................................................................................................... 18 
Negative regulation of platelet activation and thrombus growth ................................ 19 
Subsection Two:  Hemostasis and thrombosis ............................................................. 20 
Coagulation cascade .................................................................................................. 20 
Role of platelets in coagulation ................................................................................. 21 
PS exposure in platelets ............................................................................................ 21 
Thrombus architecture .................................................................................................. 25 
Platelets influence vascular microenvironment ........................................................... 28 
Subsection Three: Mechanisms of secretion ................................................................ 29 
Mechanism of platelet secretion ............................................................................... 29 
Granule-plasma membrane fusion ...................................................................... 32 
v-SNAREs in platelets ................................................................................................. 32 
VAMPs/v-SNAREs in platelets .................................................................................... 41 
t-SNAREs in platelets ................................................................................................. 43 
SNARE heterogeneity in exocytosis ........................................................................... 43 
Subsection Four: Intracellular trafficking in platelets ................................................... 47 
vi 
 
Clathrin-dependent endocytosis- .............................................................................. 47 
Clathrin-independent endocytosis- ........................................................................... 48 
SNAREs in intracellular trafficking in platelets- ......................................................... 48 
Subsection Five: SNARE regulatory proteins ................................................................. 53 
Munc18b .................................................................................................................... 53 
STXBP5/Tomosyn 1 .................................................................................................... 54 
Tethering and docking factors ...................................................................................... 55 
Rab27 ......................................................................................................................... 55 
Munc13-4 ................................................................................................................... 55 
Synaptotagmin-like proteins ..................................................................................... 57 
Sorting complexes ..................................................................................................... 57 
NSF and SNAPs ........................................................................................................... 58 
Actin cytoskeleton in platelet secretion .................................................................... 58 
Post-translational modifications of the secretory machinery ...................................... 59 
Subsection Six: Importance of platelet secretion ......................................................... 60 
Subsection Seven: Future directions ............................................................................. 61 
The focus of the dissertation......................................................................................... 64 
Chapter 2 Materials and Methods .................................................................................... 66 
Materials ....................................................................................................................... 66 
Reagents .................................................................................................................... 66 
Antibodies .................................................................................................................. 66 
Methods ........................................................................................................................ 66 
Murine Strains and Genotyping ................................................................................ 66 
Genomic DNA isolation from mouse tail tip .............................................................. 70 
Platelet preparation from mouse blood .................................................................... 71 
Whole blood count to study hematological parameters .......................................... 71 
Platelet counting ........................................................................................................ 71 
Secretion measurement from mouse platelets ........................................................ 71 
Platelet aggregometry ............................................................................................... 73 
Platelet ATP release ................................................................................................... 73 
Flow cytometry Analysis ............................................................................................ 74 
vii 
 
Western blotting and quantification ......................................................................... 74 
Antibody Arrays ......................................................................................................... 75 
Spreading Assays ....................................................................................................... 75 
Tail Bleeding Assay .................................................................................................... 76 
FeCl3-induced arterial thrombosis assay ................................................................... 76 
Coagulation assays .................................................................................................... 77 
Electron microscopy studies of mice platelets .......................................................... 77 
High-pressure freezing (HPF)/Freeze Substitution (FS) ............................................. 78 
Freeze substitution dehydration ............................................................................... 78 
Thin section TEM ....................................................................................................... 79 
Electron microscopy and image handling ................................................................. 79 
Semi-thick section transmission electron tomography ............................................. 79 
Tomogram reconstructions ....................................................................................... 79 
Statistical Analysis ..................................................................................................... 79 
Study Approval .......................................................................................................... 80 
Chapter 3 Fine-tuning hemostasis and thrombosis by altering platelet secretion .......... 81 
Introduction ................................................................................................................... 81 
Results ........................................................................................................................... 83 
Generation of platelet-specific V-2/3-/- and V-2/3/8 -/- mouse model ...................... 83 
SNAREs in V-2/3-/-, V-8+/-(2/3) -/-.and V-2/3/8 -/- platelets ......................................... 86 
Role of VAMPs in platelet secretion .......................................................................... 90 
Role of VAMP-8 in platelets granule secretion ......................................................... 90 
Role of VAMP-2 and VAMP-3 in platelets granule secretion .................................... 91 
Secretion deficiency in V-2/3/8-/- platelets ............................................................... 91 
V-2/3-/- and V-2/3/8-/- have diminished integrin αIIbβ3 levels but not integrin 
activation ................................................................................................................... 96 
Integrin activation and aggregation are not altered in V-2/3/8-/-platelets ............... 98 
V-8-/-  and V-2/3/8-/-  platelets show defective spreading ....................................... 100 
V-2/3/8-/-  animals have a severe hemostatic deficiency ........................................ 104 
Conclusions .................................................................................................................. 110 
Chapter 4 Alpha-granule cargo decondensation is VAMP-dependent .......................... 111 
viii 
 
Introduction ................................................................................................................. 111 
Results ......................................................................................................................... 112 
Condensation and decondensation of alpha granules ............................................ 112 
Alpha-granule decondensation is time-dependent ................................................ 115 
Arresting secretion intermediates ........................................................................... 118 
Granule decondensation is VAMP-dependent ........................................................ 120 
Alpha-granule decondensation is linked to granule-plasma membrane and granule-
granule fusion .......................................................................................................... 126 
VAMP-8 depletion is associated with decreased fusion pore diameter ................. 130 
Conclusions .................................................................................................................. 133 
Chapter 5 Role of VAMPs in intracellular trafficking ...................................................... 134 
Introduction ................................................................................................................. 134 
Results ......................................................................................................................... 135 
Fibrinogen levels are decreased in V-2/3-/- and V-2/3/8-/- platelets ....................... 135 
Selected dense granule, alpha-granule, and lysosomal cargoes were unaltered in V-
8-/-, V-2/3-/- and V-2/3/8-/- platelets ......................................................................... 135 
V-2/3/8-/- platelets have smaller alpha-granules ..................................................... 139 
V-2/3-/- and V-2/3/8-/- platelet granules have a trafficking defect .......................... 141 
Conclusions .................................................................................................................. 142 
Chapter 6 Discussion ....................................................................................................... 147 
Overview ..................................................................................................................... 147 
Part I- Titrating VAMPs to achieve hemostatic balance.............................................. 148 
Quantification of VAMPs in murine strains ............................................................. 149 
Secretion and hemostatic balance .......................................................................... 150 
Mass action and/or intrinsic property ..................................................................... 150 
Thrombus architecture and secretion deficiency.................................................... 155 
Implications of the rate and extent of granule secretion ....................................... 156 
Limitations of the study .............................................................................................. 157 
Part II- Titrating VAMPs to study the nature of fusion event ..................................... 164 
Decondensation of granule cargo ........................................................................... 165 
Granule cargo scaffold ............................................................................................. 166 
ix 
 
The nature of fusion – simple vs compound ........................................................... 167 
Part III- Role of VAMPs in intracellular vesicle trafficking ........................................... 170 
Role of VAMPs in endocytosis ................................................................................. 172 
Chapter 7 Summary and future directions ..................................................................... 174 
Summary of the work .................................................................................................. 174 
Importance of the work .............................................................................................. 175 
Future directions ......................................................................................................... 175 
References ...................................................................................................................... 180 
Vita .................................................................................................................................. 216 
 
  
x 
 
List of Tables 
 
Table 1.1 Summary of major granulopathies affecting dense and alpha granules in 
platelets ............................................................................................................................ 10 
Table 1.2 Secretory machinery in platelets ...................................................................... 37 
Table 1.3 Summary of various molecules crucial for platelet secretion .......................... 50 
Table 5.1 Summary of cargo levels in V-8-/-, V-2/3-/- and V-2/3/8-/- platelets ................ 146 
Table 6.1 Summary of characterization of VAMP KO strains ......................................... 152 
Table 6.2 Percent identity matrix of mouse VAMP-2, VAMP-3, VAMP-7, and VAMP-8 
proteins created by Clustal2.1 ........................................................................................ 159 
Table 6.3 Percent identity matrix of SNARE domains of mouse VAMP-2, VAMP-3, VAMP-
7, and VAMP-8 proteins created by Clustal2.1 ............................................................... 161 
Table 6.4 Percent identity matrix of transmembrane domains of mouse VAMP-2, VAMP-
3, VAMP-7, and VAMP-8 proteins created by Clustal2.1 ................................................ 163 
 
  
xi 
 
List of Figures 
Figure 1.1. Schematic of a resting platelet ......................................................................... 2 
Figure 1.2. Platelet secretion affects the vascular microenvironment ............................ 14 
Figure 1 3. Intrinsic and extrinsic coagulation pathways of coagulation ......................... 24 
Figure 1 4. Platelet activation influences thrombus architecture .................................... 27 
Figure 1.5. Pathway of SNARE-mediated platelet granule release .................................. 31 
Figure 2.1. Conditional expression of tetanus toxin light chain ....................................... 68 
Figure 3.1. Characteristics of blood cells from WT and VAMP deficient animals ............ 84 
Figure 3.2. Ultrastructure of resting VAMP-deficient platelets ........................................ 85 
Figure.3.3. Generation of V-2/3-/- and V-2/3/8-/- animals ................................................ 88 
Figure. 3.4. The loss of VAMP-2, -3, and -8 affects the kinetics and the extent of platelet 
secretion ........................................................................................................................... 94 
Figure. 3.5. Granule secretion is not affected in V-8+/-(2/3)-/- platelets ........................... 95 
Figure 3.6. Platelets from V-2/3/8-/- mice have lower P-selectin and LAMP-1 exposure 
but a little defect in integrin αIIbβ3 activation. .................................................................. 97 
Figure 3.7. Depletion of VAMP-2, -3, and -8 in platelets affects ATP/ADP release, but not 
aggregation ....................................................................................................................... 99 
Figure 3.8. V-8-/- and V-2/3/8-/- platelets have a spreading defect ................................ 102 
Figure 3.9. Hemostasis and thrombus formation are impaired in V-2/3/8-/--animals ... 106 
Figure 3.10. Hemostatic deficiencies indicate no sexual dimorphism in VAMP-deficient 
strains .............................................................................................................................. 108 
Figure 4.1. Condensed and decondensed alpha granules in activated mouse platelets 114 
Figure 4.2. A precursor-product relationship between condensed and decondensed 
granules ........................................................................................................................... 117 
Figure 4.3. A precursor to product relationship between condensed and decondensed 
alpha granules upon thrombin stimulation of wild-type mouse platelets ..................... 119 
Figure 4.4. Granule secretion is differentially affected in V-8-/-, V-2/3-/- and V-2/3/8-/- 
platelets .......................................................................................................................... 122 
xii 
 
Figure 4.5. V-8-/- platelets exhibit delayed and diminished alpha-granule secretion while 
it is essentially blocked in V-2/3/8-/- platelets ................................................................ 123 
Figure 4.6. Quantification of condensed and decondensed granules from V-8-/-, V-2/3-/- 
and V-2/3/8-/- platelets. .................................................................................................. 124 
Figure 4.7. Alpha-granule fusion with the plasma membrane strongly correlates with 
granule decondensation ................................................................................................. 128 
Figure 4.8. VAMP-8 depletion affected fusion pore size. ............................................... 131 
Figure 5.1. Dense, alpha, and lysosomal cargo levels are normal in V-8-/-, V-2/3-/- and V-
2/3/8-/- platelets .............................................................................................................. 137 
Figure 5.2. Dense, alpha and lysosomal cargo levels are normal in V-8+/-(2/3)-/- platelets
......................................................................................................................................... 138 
Figure 5.3. The loss of VAMP-2, -3 and -8 affects alpha granule size but not granule 
numbers per platelet. ..................................................................................................... 140 
Figure 5.4. V-8-/- platelets have a complex granule cargo defect ................................... 143 
Figure 5.5. Granule cargo deficiency in V-2/3-/- platelets ............................................... 144 
Figure 5.6. V-2/3/8-/- platelets have reduced granule cargo levels ................................ 145 
Figure 6.1. Correlating VAMP-mediated exocytosis to platelet function ....................... 153 
Figure 6.2. Sequence alignment of mouse VAMP-2, VAMP-3, VAMP-7, and VAMP-8 
amino acids ..................................................................................................................... 158 
Figure 6.3. Sequence alignment of SNARE domains from mouse VAMP-2, VAMP-3, 
VAMP-7, and VAMP-8 ..................................................................................................... 160 
Figure 6.4. Sequence alignment of transmembrane- domains from mouse VAMP-2, 
VAMP-3, VAMP-7, and VAMP-8 ...................................................................................... 162 
Figure 6.5. Progressive decondensation upon granule fusion decides the rate of granule 
cargo release ................................................................................................................... 169 
Figure 6.6. Intracellular trafficking in platelets ............................................................... 171 
 
  
xiii 
 
Abbreviations 
 
ADP- Adenosine Diphosphate 
ARC- Arthrogryposis, Renal Dysfunction, And Cholestasis Syndrome 
ATP- Adenosine Triphosphate 
BLOC- Biogenesis of Lysosome-Related Organelles Complex 
BMCC-Bone Marrow-Derived Mast Cells 
CHS- Chediak-Higashi Syndrome 
CLEC-2- C-Type Lectin-Like Receptor 2  
CO-IP- Co-Immunoprecipitation 
DAG- Diacylglycerol 
ELISA- Enzyme-Linked Immunosorbent Assay 
FACS- Fluorescent-Activated Cell Sorting 
FHL3- Familial Hemophagocytic Lymphohistiocytosis Type 3 
FHL4- Familial Hemophagocytic Lymphohistiocytosis Type 4 
FHL5 -Familial Hemophagocytic Lymphohistiocytosis Type 5 
FIB-SEM- Focused Ion Beam-Scanning Electron Microscopy 
GLUT- Glucose Transporter 
GPCR-G-Protein-Coupled Receptor 
GPS- Grey Platelet Syndrome 
GSVs- GLUT Storage Vesicles 
GWAS- Genome-Wide Association Studies   
xiv 
 
HPS- Hermansky Pudlack Syndrome 
IP3- Inositol 3 Phosphate 
ITAM-Immunoreceptor Tyrosine-Based Activation Motif 
LAMP- Lysosomal-Associated Membrane Protein 
MIP-1α- Macrophage Inflammatory Protein 
MVB- Multi-Vesicular Body 
NSF- N- Ethylmaleimide Sensitive Factor 
OCS- Open Canalicular System 
PAGE -Polyacrylamide Gel Electrophoresis 
PAR-Protease Activated Receptors 
PF4- Platelet Factor IV 
PGI2- Prostaglandin I2 
PI3K- Phosphatidyl Inositol-3 Kinase 
PLCγ2- Phospholipase γ2 
PDI- Protein Disulfide Isomerase 
RT- Room Temperature 
SLPs- Synaptotagmin-Like-Proteins 
SNAP- Soluble NSF Attachment Proteins 
SNAP- Synaptosome Associated Proteins 
SNARE- Soluble N-Ethylmaleimide- Sensitive Fusion Protein Attachment Receptor 
SNP- Single Nucleotide Polymorphism 
SPD- Storage Pool Deficiency 
xv 
 
STXBP5- Syntaxin Binding Protein 5/ Tomosyn 
TMD- Trans-Membrane Domain 
TNF- Tumor Necrosis Factor 
TXA2- Thromboxane A2 
VAMP-Vesicle Associated Membrane Protein 
vWF- Von Willebrand Factor 
WPB- Weibel- Palade body 
WT- Wild Type 
 
 
1 
 
Chapter 1 Introduction 
Platelet cell biology 
Platelets are discoid, anucleate, cytoplasmic cell fragments that originate from 
megakaryocytes mainly within bone marrow and lungs (Lefrancais, Ortiz-Munoz et al. 
2017). Platelets are minute in size, about 2-3 µm in diameter and 0.5 µm in thickness. 
They circulate in the blood for about 4-5 days for mouse (Manning, Novinger et al. 1996) 
and for about 7-10 days in humans before being eliminated in the spleen (Harker, 
Roskos et al. 2000). Platelets are the most abundant cell type, second only to RBCs 
(average human-1.5-4.5 x105 platelets/µL, average mouse-1.1-1.3 X 106 platelets/µL). 
Platelets contribute to normal hemostasis and, recently, their additional roles in 
inflammation, infection, wound healing, angiogenesis, and metastasis is receiving 
increasing attention (Smyth, McEver et al. 2009, Tesfamariam 2016).  
Platelet structure 
Platelets are metabolically active and contain mitochondria, Golgi apparatus, 
endoplasmic reticulum (also called dense tubular system), granules or vesicles, 
endosomes, autophagosomes (Ouseph, Huang et al. 2015), and peroxisomes. The 
cytoskeleton of platelets includes spectrin-based skeleton, microtubules, and actin 
filaments. These elements maintain the discoid shape of resting platelets. Some of these 
important features of a resting platelet are depicted in a schematic in Figure 1.1. The 
platelet plasma membrane surface area is about 19 µm2 and the total surface area of 
their granules is about 14 µm2 (Fitch-Tewfik and Flaumenhaft 2013). 
The surface of platelets is decorated with five types of integrins -three β1 
integrins facilitate platelet adhesion to matrix proteins- collagen, fibronectin, and 
laminin. Additionally, two β3 integrins- αIIbβ3, and αvβ3 are also present on platelets. 
Considered as the most abundant integrin (about 80,000 copies/platelet) αIIbβ3 binds 
to fibrinogen, von Willebrand Factor/vWF, and fibronectin (Bennett, Berger et al. 2009).  
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Figure 1.1. Schematic of a resting platelet 
Schematic of a resting platelet containing various types of granules, endosomes, and 
mitochondria. Granules shown are- dense granules (membrane protein -vesicular 
monoamine transporter/VMAT, and soluble cargo- serotonin), alpha granules 
(membrane protein – P-selectin, and soluble cargo -Platelet Factor 4/PF4), and lysosome 
(membrane protein- LAMP1, and soluble cargo β-hexosaminidase). Only selective cargo 
is depicted for simplification. 
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The distinct feature of platelet cytoplasm is a presence of discrete types of 
granules (Figure 1.1). The release of these granular content is central to most platelet 
functions because it allows platelets to modulate the vascular microenvironment at sites 
where they are activated. Based on their morphology, contents, and functions, granules 
are classified into three main types- dense (δ-granules/dense bodies), alpha (α), and 
lysosomes. Platelets contain 7-10 dense granules per platelet which contain small 
molecules, e.g., ADP, ATP, serotonin, polyphosphate, and calcium (Eckly, Rinckel et al. 
2016). Holmsen and Weiss measured the intragranular concentrations of these cargoes 
as 65 mM serotonin, 436 mM ATP, 653 mM ADP, 2.2 M calcium, and 326 mM 
pyrophosphate (Holmsen and Weiss 1979, McNicol and Israels 1999). Serotonin/5-
hydroxytryptamine (5HT) is produced by enterochromaffin cells of the intestinal tract 
and is released in plasma. Platelets take up this plasma serotonin by serotonin receptors 
(SERT) present on the plasma membrane. This serotonin is then stored in dense 
granules through the action of vesicular monoamine transporter (VMAT2). It has been 
shown that pharmacological inhibition of SERT by selective serotonin reuptake inhibitors 
(SSRIs- paroxetine and citalopram) significantly diminishes 5HT contents in platelets. 
Carneiro, A.D., and colleagues showed that SERT potentially associates with an 
abundant integrin αIIbβ3 making integrin activation essential for SERT function. The 
group also showed that SERT deficiency significantly affects platelet aggregation. 
(Carneiro, Cook et al. 2008). Dense granule cargoes are immensely critical for 
amplification of the platelet activation signal and recruitment of platelets at the injury 
site. 
Alpha granules are the largest (about 200-500 µm in diameter) and the most 
numerous (40-45/platelet) granules in platelets  (Eckly, Rinckel et al. 2016). Alpha 
granules contain a plethora of proteins with diverse functions, e.g., angiogenic (e.g. 
Vascular Endothelial Growth Factor/VEGF) and anti-angiogenic (endostatin) factors, 
tissue factors, growth factors (Platelet Derived Growth Factor/PDGF, Transforming 
Growth Factor β/TGFβ), mitogens, cytokines (Platelet Factor 4/PF4), proteoglycans 
(serglycin, β- thromboglobulin), adhesive proteins (von Willebrand Factor/vWF, 
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fibronectin, vitronectin, thrombospondin, P-selectin), membrane proteins ( αIIbβ3, GP-
1b-IX) and coagulation factors (factor V, fibrinogen). Release from these granules 
facilitates platelets’ role in angiogenesis, infection, inflammation, metastasis, wound 
healing among many other pathologies. The third type of granule is the lysosome. 
Lysosomes are intermediate in size – about 175-250 nm in diameter. Electron density of 
lysosomes is like alpha granules, making it a challenge to distinguish them. Specific 
cytochemical strains such as arylsulfatase or acid phosphatase are required to 
characterize them (Bentfeld-Barker and Bainton 1982). These degradative 
compartments contain acid hydrolyzes, cathepsins- D and E, carboxypeptidases- A and 
B, collagenase, acid phosphatase, heparinase, and proteases and membrane proteins 
(LAMP-1, LAMP-2) (Rendu and Brohard-Bohn 2001), which may contribute to clot 
remodeling. 
Platelet biogenesis 
Megakaryocytes are myeloid precursor cells that arise from pluripotent 
hematopoietic stem cells and constitute less than 0.1% of the total bone marrow cell 
population. During the maturation process, megakaryocytes undergo endomitosis, a 
chromosomal duplication process that results in increased ploidy without cell division 
(Thon and Italiano 2012). This increased ploidy is important for supporting 
carbohydrate, protein, and lipid synthesis requirements of a large cell (Bluteau, Lordier 
et al. 2009). Mature megakaryocyte contains platelet-specific cytoplasmic organelles 
including granules and cytoskeletal proteins. Upon maturation, these megakaryocytes 
migrate to vascular bed in bone marrow or in lungs (Lefrancais, Ortiz-Munoz et al. 
2017). There they develop pseudopod-like thin, elongated projections, also known as 
proplatelets which mature and release platelets - either in bone marrow sinusoids (Junt, 
Schulze et al. 2007) or in pulmonary capillaries of lungs (Sharnoff and Scardino 1960). 
Platelet granule biogenesis 
A) Dense granule biogenesis 
Dense granules belong to the family of lysosomal-related organelle that includes 
Waibel – Palade bodies in endothelial cells, melanosomes in melanocytes, lamellar 
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bodies in type II lung alveolar cells, lytic granules, chromaffin granules, basophil 
granules, and azurophil granules. These organelles are characterized by the nature of 
their cargoes- they contain acid-dependent hydrolases and an array of lytic enzymes as 
well as cell- type-specific cargo that has a specialized function (Dell'Angelica, Mullins et 
al. 2000). 
Platelet dense granules contain small molecules such as polyphosphates, ATP, 
ADP, serotonin, and calcium that function as secondary agonists in platelet activation 
and recruitment. Dense granules also contain membrane proteins LAMP-1, LAMP-2, and 
CD63/LAMP3. Dense granules contain a vesicular ATPase proton pump that maintains 
the acidic pH of dense granules (~ 5.4 (Dean, Fishkes et al. 1984)). The multidrug 
transporter protein Multidrug resistance protein (MRP4) is thought to transport adenine 
nucleotides into the dense granules (Jedlitschky, Tirschmann et al. 2004). Vesicular 
monoamine transporter 2 (VMAT2)  helps transport serotonin from the platelet cytosol 
to dense granules (Fukami, Holmsen et al. 1984). 
Though many molecules have been identified that potentially play a role in 
dense granule biogenesis in megakaryocytes and platelets, the exact mechanism is still 
elusive. Platelet storage pool deficiencies/SPDs characterized by dense granule 
defects/alpha granule defects/dense and alpha granule defects implicate proteins that 
are involved in the biogenesis of respective granules and have been instrumental in 
illuminating these processes. Several genes/proteins have been identified that are 
linked to dense granule biogenesis defects include proteins that are crucial for 
trafficking, mainly Biogenesis of Lysosome-Related Organelles Complex (BLOC-1(Falcon-
Perez, Starcevic et al. 2002), 2, 3), VPS 33A, AP-3, and LYST. 
In a seminal paper (Hermansky and Pudlak 1959), Hermansky and Pudlak 
characterized a condition that exhibits oculocutaneous albinism and prolonged 
bleeding. At the time, they coined this condition pseudohemophilia considering that 
moderate bleeding deficiency was the main symptom. Since then, 8 proteins in humans 
and 15 proteins in mice have been implicated as causative in HPS pathology. Mice 
mutants have been named according to their coat color. The severity of hemostasis 
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defect is variable among these strains. The whole mount blood specimens from HPS 
patients show complete absence or diminished numbers of dense granules in platelets. 
HPS proteins are components of the BLOC complexes. There are three of these large 
multiprotein tethering complexes that play an important role in trafficking and 
exocytosis of granules. Mutations in any one or multiple of their components may affect 
dense granule biogenesis (Dell'Angelica, Mullins et al. 2000). 
Chediak – Higashi syndrome was known long before it was characterized as 
dense granule SPD (Rendu, Breton-Gorius et al. 1983). CHS is an autosomal recessive 
disorder, responsible for severe bleeding, neurological abnormalities, 
hypopigmentation, immunodeficiency and the presence of giant lysosomes in 
granulocytes and leukocytes (Table 1.1). Several groups mapped the mutations in the 
genes encoding Lysosomal trafficking regulator/ LYST protein which are responsible for 
CHS (Barbosa, Nguyen et al. 1996, Nagle, Karim et al. 1996, Perou, Moore et al. 1996). 
LYST protein is the first identified and an extensively studied member of a large family of 
proteins that contain a BEACH (Beige and Chediak- Higashi) domain. The BEACH domain 
is a conserved domain of about 280 amino acids and is crucial for protein-protein 
interactions. Other important members of this family and their associated disorders 
include neurobeachin (NBEA)- autism , neurobeachin-like 1 (NBEAL1)- glioma, 
neurobeachin-like 2 (NBEAL2)- Gray Platelet Syndrome/ GPS, lipopolysaccharide-
responsive, beige-like anchor protein (LRBA)-autoimmune disorders , WD and FYVE zinc 
finger domain containing protein 3 (WDFY3), WD and FYVE zinc finger domain 
containing protein 4 (WDFY4)- systemic lupus erythematosus/ SLE, neutral 
sphingomyelinase activation-associated factor (NSMAF), and WD repeat domain 81 
(WDR81) – mental retardation  (Cullinane, Schaffer et al. 2013). BEACH containing 
proteins differentially affect platelet granule biogenesis; while LYST is responsible for 
dense granule deficiency in CHS, another member NBEAL 2 is associated with an alpha-
granule deficiency in GPS. The underlying theme of all these pathologies points to the 
role of BEACH- containing proteins’ role in intracellular trafficking and vesicle 
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fission/fusion processes. Although the molecular details of interactions of these scaffold 
proteins are not fully understood. 
In a recent study, Walker et al., showed that serum and glucocorticoid-inducible 
kinase 1\SGK-1 deficient platelets are devoid of dense granules and have diminished 
dense granule cargo levels of serotonin and ATP, while numbers of alpha granules and 
their cargo levels were not affected. These platelets also had an aggregation defect that 
could be overcome with exogenous ADP. SGK-1-/- animals showed delayed and 
diminished thrombosis in the absence of a bleeding defect. Mass spectroscopic analysis 
showed that VAMP-7 and Rab 27B levels were significantly lowered in these animals, 
suggesting a potential association with SGK-1 (Walker, Schmid et al. 2015). Apart from 
SGK-1, another potential protein associated with dense granule biogenesis is SLC35D3. 
Using immunofluorescence, Immunoelectron microscopy and subcellular fractionation 
of megakaryocytoid cells, Meng, and colleagues showed that SLC35D3, a dense granule 
related protein is associated with early endosomes, suggesting that these granules 
originate from an endocytic pathway (Meng, Wu et al. 2015). In addition to human and 
mice, other species affected by CHS are cats (Meyers, Seachord et al. 1981), cattle 
(Meyers, Seachord et al. 1981, Meyers, Seachord et al. 1983), Aleutian minks (Meyers, 
Holmsen et al. 1979), killer whales (Meyers, Holmsen et al. 1979, Meyers, Hopkins et al. 
1982) and pigs (Daniels, Fass et al. 1986). 
B) Alpha-granule biogenesis  
Alpha granules are the most abundant and versatile granule type in platelets. 
According to various proteomic studies, alpha granules contain more than 300 proteins 
(Maynard, Heijnen et al. 2007) and in many ways, are like Weibel Palade bodies in 
endothelial cells. Both contain vWF, P-selectin, and CD63 and play crucial roles in 
hemostasis and inflammation (Heijnen and van der Sluijs 2015). 
Though there are recent advances in proposed mechanisms, alpha-granule 
biogenesis is far from resolved. The current model is based on our understanding that 
alpha granules contain both endocytosed (Fibrinogen, albumin, IgG) as well as de novo 
synthesized cargo (Platelet Factor 4, vWF, β-thromboglobulin) (Blair P et al 2009). This 
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suggests that alpha granules probably originate from the trans-Golgi network/TGN and 
endocytic pathways. After budding from the TGN, the vesicles containing alpha-granule 
cargoes are trafficked to multi-vesicular bodies/MVBs (Heijnen, Debili et al. 1998). 
Subsequent cargo sorting takes place in MVBs and after maturation of various types of 
MVBs, (MVB I, containing only limiting membrane vesicles, MVB II, containing internal 
membrane vesicles along with vesicles containing electron- dense materials), alpha 
granules are formed (Heijnen, Debili et al. 1998). Alternatively, both synthesized and 
endocytosed cargoes could be delivered directly to alpha granules (Blair and 
Flaumenhaft 2009).  
This understanding stems from studies of platelet storage pool deficiencies 
(SPDs), Two major platelet SPDs characterized by either defective or absent alpha 
granules are Gray Platelet Syndrome/ GPS and Arthrogryposis, Renal dysfunction, and 
Cholestasis /ARC syndrome (Table 1.1). GPS is a rare, autosomal recessive disorder 
characterized by macrothrombocytopenia, splenomegaly, myelofibrosis, and large 
platelets that appear gray with Giemsa staining under a light microscope. These 
platelets have an aggregation defect and patients with GPS show a broad range of 
bleeding diathesis (Nurden and Nurden 2011). Three different groups simultaneously 
found that mutations in Neurobeachin Like 2 /NBEAL2 protein cause GPS (Albers, Cvejic 
et al. 2011, Gunay-Aygun, Falik-Zaccai et al. 2011, Kahr, Hinckley et al. 2011). Though 
megakaryocytes and platelets from Nbeal2-/- mice (Deppermann, Cherpokova et al. 
2013) and GPS patients may have rudimentary alpha-granule precursors, they show lack 
of alpha-granule cargoes that are endogenously synthesized (e.g. PF4) or endocytosed 
by megakaryocytes/platelets (e.g. fibrinogen). These granules, however, contain the 
alpha-granule membrane marker P-selectin, suggesting that granules could form but are 
not filled in absence of NBEAL2. 
Originally described in 1973, ARC syndrome is a rare autosomal recessive 
disorder. Patients affected by ARC syndrome manifest congenital joint contractures, 
renal tubular dysfunction, cholestasis, ichthyosis, central nervous system malformation, 
platelet anomalies, and severe failure to thrive. ARC syndrome is caused by mutations in 
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Vacuolar protein sorting 33 homolog B /VPS33B or VPS33B-interacting protein, apical-
basolateral polarity regulator/VIPAR/VPS16B genes (Gissen, Johnson et al. 2004, 
Cullinane, Straatman-Iwanowska et al. 2010). 
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Table 1.1 Summary of major granulopathies affecting dense and alpha granules in platelets 
 
Storage pool 
deficiency 
Affected 
granule 
Clinical features Genes/proteins 
affected 
References 
Hermansky Pudlak 
Syndrome (HPS) 
Dense Severe bleeding, 
oculocutaneous albinism etc. 
BLOC-1/pallid, BLOC-2, 
and BLOC-3. Adaptor 
protein 3 (AP-3/pearl) 
SLC35D3 
(9 genes in humans 
and 15 genes in mice) 
(Falcon-Perez, 
Starcevic et al. 2002, 
Chintala, Tan et al. 
2007, Meng, Wu et al. 
2015) 
 
Chediak-Higashi 
Syndrome(CHS) 
Dense severe bleeding, neurological 
abnormalities, 
hypopigmentation, 
immunodeficiency etc. 
LYST (Barbosa, Nguyen et al. 
1996) 
Gray Platelet 
Syndrome (GPS) 
Alpha Macrothrombocytopenia, 
splenomegaly, myelofibrosis etc. 
NBEAL2 (Albers, Cvejic et al. 
2011, Gunay-Aygun, 
Falik-Zaccai et al. 2011, 
Kahr, Hinckley et al. 
2011) 
Arthrogryposis-
renal dysfunction-
cholestasis (ARC) 
syndrome 
Alpha Ichthyosis, central nervous 
system malformation, platelet 
anomalies, and severe failure to 
thrive etc. 
VPS33B, VPS16B (Gissen, Johnson et al. 
2004, Cullinane, 
Straatman-Iwanowska 
et al. 2010) 
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Platelet receptors and intracellular signaling pathways 
Platelets are decorated with a multitude of surface receptors that sense and 
reciprocate to the intravascular microenvironment. They participate in hemostasis by 
facilitating platelet adhesion and secretion upon vascular injury. Additionally, they also 
contribute to endocytosis and intracellular trafficking upon microbial and immunological 
challenges. A vast, repertoire of these receptors include integrins (αIIbβ3, α2β1, α5β1, 
α6β1, αVβ3), leucine-rich repeated (LRR) receptors (Glycoprotein [GP] Ib/IX/V, Toll-like 
receptors), G-protein coupled seven transmembrane receptors (GPCR) (PAR-1 and PAR-
4 thrombin receptors, P2Y1 and P2Y12 ADP receptors, TPa and TPb TxA2 receptors), 
proteins belonging to the immunoglobulin superfamily (GPVI, FcgRIIA), C-type lectin 
receptors (P-selectin), tyrosine kinase receptors (thrombopoietin receptor, Gas-6, 
ephrins and Eph kinases) and a collection of other receptors (CD63, CD36, P-selectin 
ligand 1, TNF receptor type, etc.)(Rivera, Lozano et al. 2009). 
Formation of a platelet plug at the site of vascular damage is a result of spatially 
and temporally concerted response by various components of the vascular system. The 
main objective of these dynamic events is to stop bleeding, prevent uncontrolled, 
occlusive thrombosis and maintain a platelet plug until wound healing occurs. This 
process could be divided into three stages that describe how platelets respond to injury 
and form a stable plug for hemostasis.  
These stages are as the following: 
Initiation phase 
In this phase, platelets engage with exposed subendothelial adhesive proteins 
and adhere at the site of injury. These get activated, creating a monolayer of activated 
platelets. Upon vascular injury, platelet receptors interact with subendothelial proteins, 
mainly vWF, collagen, thrombospondin, fibronectin, and laminin. These interactions are 
highly dependent on the shear rate. At lower shear, platelet interactions with collagen, 
mediated by GPVI, are predominant while at high shear, platelet interactions with vWF, 
mediated by αIIbβ3, are critical. vWF interaction with another receptor, a major 
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glycoprotein [GP] Ib/IX/V which is critical for the initiation phase. The lack of or defect in 
this receptor leads to Bernard Soulier syndrome (BSS), a congenital bleeding disorder 
characterized by macrothrombocytopenia and inability of these platelets to aggregate. 
In addition to vWF, the GPIb/IX/V complex also has multiple other ligands 
including other adhesive proteins (collagen, thrombospondin-1), alpha-thrombin and 
coagulation factors (kininogen, FXI, FXII). GP1b is indispensable for hemostasis while the 
loss of vWF could be compensated by other GP1b ligands (Bergmeier, Piffath et al. 2006, 
Dubois, Panicot-Dubois et al. 2007). The interaction between GP1b and vWF leads to 
platelet activation manifested as increased [Ca++], thromboxane A2/TxA2 synthesis, 
protein phosphorylation for downstream signaling, ADP release from dense granules 
and finally, activation of αIIbβ3. 
Another critical ligand for platelet adhesion at the site of injury is collagen. 
Collagen is a strong and only stationary agonist. It binds with vWF in flowing blood to 
efficiently carry out platelet adhesion and activation. vWF facilitates initial engagement 
of platelets at the site of injury, while collagen forms stable bonds for firm adhesion 
(mediated through α2β1 receptor) and causes platelet activation (mainly through GPVI). 
This binding of platelets to collagen is facilitated by two platelet surface receptors: GPVI 
and integrin α2β1. 
GPVI is complexed with FcR γ-chain dimers that have an immunoreceptor 
tyrosine-based activation motif/ ITAM as a signal transducing subunit of the receptor. 
Upon activation of GPVI, syk phosphorylated ITAM and downstream signaling results in 
PLCγ2 activation. Diacylglycerol/DAG and inositol 1,4,5-triphosphate/IP3 are released, 
leading to increased intracellular [Ca++] levels that ultimately activate platelets. The lack 
of GPVI or the FcRγ- chain in mice leads to a defective response to collagen and 
impaired thrombosis (Poole, Gibbins et al. 1997, Kato, Kanaji et al. 2003). GPVI is an 
attractive target for antithrombotic therapies. Matsumoto and colleagues showed that 
the Fab fragment of anti-human GPVI antibody, OM4, affected aggregation but had a 
minor effect on bleeding time in cynomolgus monkeys as compared to the effects of 
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anti- αIIbβ3 antibody that significantly augmented the bleeding time (Matsumoto, 
Takizawa et al. 2006). These findings were subsequently validated by Li et al., who 
showed that OM4 inhibits thrombosis without causing bleeding in rats (Li, Lockyer et al. 
2007). Another antibody, JAQ1, has also shown effective long-term protection from 
occlusive thrombosis by downregulating GPVI (Nieswandt, Schulte et al. 2001), however 
studies with similar antibodies against different epitopes by the same group showed 
that targeting the collagen binding site on GPVI may downregulate the receptors 
without affecting platelet activation (Schulte, Rabie et al. 2003). 
The α2β1 integrin is crucial for platelet adhesion and activation. Polymorphisms 
within this gene and receptor density on platelets are associated with the kinetics of 
platelet adhesion on collagen underlining its importance for platelet function (Kritzik, 
Savage et al. 1998, Corral, Gonzalez-Conejero et al. 1999). Mouse models that are 
deficient in either α2 or β1 subunits show minor defects in platelet adhesion and 
aggregation on collagen and have slightly increased bleeding times (Holtkotter, 
Nieswandt et al. 2002, Gruner, Prostredna et al. 2003) which is incongruent with the 
human data where subjects with genetically decreased expression of α2β1 integrin 
display diminished platelet responses to collagen and mild bleeding defect 
(Nieuwenhuis, Akkerman et al. 1985). However, in vivo thrombosis studies in mice 
deficient in α2β1 gave conflicting results. Using fluorescence microscopy on the injured 
carotid artery, Gruner et al., showed that these mice do not have any thrombosis effect 
(Gruner, Prostredna et al. 2003). On the other hand, using photochemically induced 
endothelial injury to the carotid artery, He et al., showed the thrombus formation was 
delayed and decreased in these animals, possibly due to defective collagen interaction 
(He, Pappan et al. 2003, Kuijpers, Pozgajova et al. 2007). Combined deficiency of both 
collagen receptors (α2β1 and GPVI) leads to complete inhibition of thrombus formation 
unlike the partial defects observed in absence of either of these receptors (Sarratt, Chen 
et al. 2005). This suggests that α2β1 and GPVI work synergistically to achieve the 
optimal level of platelet adhesion and activation.  
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Figure 1.2. Platelet secretion affects the vascular microenvironment 
Resting, discoid platelets flow in blood while endothelial cells prevent direct contact 
between platelets and subendothelial adhesive proteins such as vWF and collagen. 
Upon injury, these proteins interact with activate platelets. Platelet activation leads to 
platelet shape change, granule secretion and ultimately, aggregation. Platelet 
aggregation results in thrombus formation.  
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Extension phase 
In this phase, activated platelets recruit and activate more platelets by releasing 
secondary agonists such as ADP. Once a platelet monolayer is formed on exposed vWF 
and collagen in the vascular wall, the subsequent process of recruiting and activating 
more platelets is initiated. The major players in this phase include platelet surface 
integrin αIIbβ3, GPCRs, and secondary agonists from platelet dense granules (ADP, TxA2, 
epinephrine, thrombin, serotonin, calcium etc). that stimulate other platelets. These 
soluble agonists stimulate platelets and form microaggregates. Finally, activation of 
αIIbβ3 leads to conformational changes that facilitate its binding to fibrinogen and vWF. 
These interactions lead to stable contacts among platelets and a platelet plug is formed. 
Integrin αIIbβ3 is the most abundant (40,000-80,000 copies/platelet) integrin on the 
platelet surface and can be activated by inside out or outside in signaling. Platelet 
activation by any agonists leads to PLC activation that increases intracellular calcium 
levels. Subsequent PKC and PI3K activation alter cytoskeletal reorganization and talin, a 
crucial cytoskeletal protein gets activated and binds to a cytoplasmic domain of β3 
subunit affecting the conformation of αIIbβ3 that facilitates fibrinogen binding to the 
receptor. 
GPCRs facilitate the most stable platelet plug formation by propagating signals 
from potent agonists such as thrombin, PAR peptides, and Thromboxane A2. GPCRs are 
seven – transmembrane spanning signaling molecules that activate heterotrimeric 
guanine nucleotide binding proteins. Many downstream effectors get subsequently 
activated including adenylyl cyclase, PLC, and PI3K to finally result in platelet activation. 
GPCRs acts in three ways: 
1. First, through Gqα, they stimulate PLCβ isoforms. This leads to increased 
concentration of cytosolic Ca++ and PKC activation. 
2. Through G12α and G13α, they reorganize the actin cytoskeleton which leads to 
filopodia and lamellipodia formation and platelet shape change. 
3. Through Giα, they inhibit cAMP synthesis by suppressing adenylyl cyclase  
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Thus, GPCRs facilitate platelet plug formation through various pathways. ADP, TxA2, and 
thrombin are the major agonists that activate platelets through GPCR coupled 
receptors. ADP binds to two classes of purinergic GPCRs- P2Y1 (coupled to Gqα) and 
P2Y12 (coupled to Giα) while TxA2 binds to the TxA2 receptor. Thrombin is one of the 
most potent platelet agonists and is also crucial for generating fibrin from precursor 
fibrinogen. It acts through Protease-Activated Receptor/PAR1 and PAR4 in humans and 
PAR3 and PAR4 in mice. 
ADP, released from platelet dense granules as well as RBCs, is an important 
agonist capable of causing the full range of platelet activation. P2Y1 receptors are 
present in a comparatively lower amount (150/platelet (Baurand, Raboisson et al. 2001) 
compared to PAR 1, which is 1000-2000/platelet) (Gachet 2008). Leon et al., showed 
that P2Y1 deficiency leads to defective platelet aggregation and shape change. 
Additionally, P2Y1 participates in collagen-induced platelet activation. This defective 
platelet activation in absence of P2Y1 does not, however, lead to any significant 
bleeding diathesis. Though it mediates the weak response to ADP, it is still a vital 
component for ADP/collagen-induced platelet activation (Leon, Hechler et al. 1999). 
P2Y12 is an extensively studied ADP receptor and an appealing anti-platelet target since 
subjects lacking this receptor have defective ADP induced platelet aggregation 
(Cattaneo 2011). P2Y12 deficient platelets do not aggregate upon ADP stimulation and 
their response to other agonists is also defective. Mice with this deficiency, have a 
severe bleeding deficiency and are protected from arterial thrombosis (Andre, Delaney 
et al. 2003). P2Y12 plays a central role in the amplification of aggregation from various 
agonists in different pathways including thrombin, collagen, TxA2, immune complexes, 
adrenaline, and serotonin. This amplification is achieved by inhibition of cAMP 
production and PI3K and small GTPase Rap 1B activation (Gachet 2008). This pivotal role 
of ADP in platelet activation by multiple agonists makes it an important target. 
Thienopyridine compounds such as clopidogrel and prasugrel as well as competitive 
antagonists of P2Y12 such as AZD6140 and cangrelor are some of the prominent 
antiplatelet drugs. The third receptor for ADP is P2X1, a ligand-gated cation channel that 
  17 
 
is important for a fast calcium entry upon agonist stimulation. This receptor is important 
in high shear conditions and participates in collagen and shear-induced aggregation.  
TxA2, a potent vasoconstrictor and platelet agonist synthesized by activated 
platelets, is generated by cyclooxygenase (COX) and TxA2 synthase enzymes. It acts as a 
secondary agonist by diffusing across the platelet membrane and activating other 
platelets. TxA2 receptor-deficient mice (TP-/-) have increased bleeding time and defective 
responses to TxA2 analogs and collagen (Nieswandt, Aktas et al. 2005). Inhibition of TxA2 
by aspirin has proven to be a valuable treatment for managing high cardiovascular risk 
patients (Eidelman, Hebert et al. 2003), however, it’s efficiency is still controversial at 
high shear conditions (Barstad, Orvim et al. 1996, Valerio, Tran et al. 2016). 
Thrombin is a potent, soluble agonist generated on the surface of activated 
platelets (Offermanns 2006). Thrombin is generated from the prothrombinase complex 
that is comprised of coagulation factor Xa and factor Va that together stimulate factor II 
to generate thrombin. Translocation of phosphatidylserine from the inner to the outer 
leaflet of the platelet plasma membranes provides a procoagulant surface for thrombin 
generation. Thrombin activates platelets through GP1b and other GPCRs-Protease-
activated receptors/PARs. Human platelets have PAR1 and PAR4 while murine platelets 
contain PAR3 and PAR4. Thrombin can stimulate platelets at very low concentration and 
generate the full range of activation (increased intracellular calcium, granule secretion, 
protein phosphorylation, shape change etc.). The role of GP1b in thrombin response is 
illustrated by the patients with Bernard Soulier syndrome. These patients lack GP1b and 
have a defective response to thrombin and increased bleeding time (Lopez, Andrews et 
al. 1998). PAR receptors are activated by a unique mechanism in which thrombin 
cleaves the N terminal sequence exposing a peptide that acts as a tethered ligand. 
Peptides with similar sequences as the uncovered region could be used to stimulate PAR 
receptors. PAR receptors differ in their thrombin response. PAR1 mediates platelet 
activation at low thrombin concentration while PAR4 requires high thrombin 
concentration and calcium mobilization is slower in a PAR4 mediated response. PAR4 
deficient mice have a defective response to thrombin even at high concentrations 
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(Sambrano, Weiss et al. 2001). Both PAR3 KO and PAR4 KO mice are protected against 
thrombosis and show a similar increase in bleeding time (Sambrano, Weiss et al. 2001, 
Weiss, Hamilton et al. 2002). For downstream signaling, PAR1 couples to Gqα, G12/13α, 
and Giα and PAR4 couples to Gqα, and G12/13α. This wide network of G proteins provides 
thrombin a broader access for platelet activation (Rivera, Lozano et al. 2009).  
Epinephrine is a weak agonist that plays a role in potentiating an activation 
signal from other agonists mainly by inhibiting cAMP production. Epinephrine receptor 
α2A deficient mice show a defective response to epinephrine but not to other agonists 
and the tail bleeding time and thrombosis are not affected. These mice are protected 
against pulmonary thromboembolism induced by collagen and epinephrine suggesting 
that epinephrine may play role in the stability of the thrombus (Pozgajova, Sachs et al. 
2006).  
Stabilization phase 
In this phase, the platelet plug is stabilized to prevent premature dissolution to 
facilitate wound healing. Integrin αIIbβ3 plays a central role in the stabilization phase by 
making potent contacts among neighboring platelets. It is a major receptor for 
fibrinogen, vWF, fibronectin, and vitronectin. Deficiency of αIIbβ3 leads to a severe 
bleeding disorder called Glanzmann’s thrombasthenia (Bennett 2005). Platelet 
activation leads to “inside-out” signaling that alters the conformation of αIIbβ3 making 
binding to fibrinogen more accessible. Alternatively, ligand binding (predominantly 
fibrinogen) to αIIbβ3 results in “outside in” signaling that leads to cytoskeletal 
rearrangements, platelet shape change, aggregation and clot retraction. Furthermore, 
activated platelets also provide a procoagulant surface for prothrombinase complex 
where thrombin is generated and proceeds to cleave fibrinogen to form fibrin fibers. 
Fibrin maintains the integrity of thrombus till blood loss is ceased. Apart from integrin 
αIIbβ3, many other molecules promote stability of the thrombus. These molecules 
include junctional adhesion molecules (JAM-A and JAM-C), Ephrin family of receipt 
tyrosine kinases (EphA4, EphB1, and ephrin B), and CD 40 Ligand (Rivera, Lozano et al. 
2009). 
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Negative regulation of platelet activation and thrombus growth 
Thrombus growth is a dynamic process with multiple factors working 
concurrently to facilitate thrombus formation to stop blood loss. This process, however, 
must be controlled to prevent occlusive thrombosis that prevents blood flow to tissues 
downstream. Many mechanisms exist to control this process. First, nitric oxide and 
prostaglandin I2 /PGI2 are secreted by endothelial cells that inhibit adenylyl cyclase and 
increase cAMP levels to prevent platelet activation (Radomski, Palmer et al. 1987). Nitric 
oxide activates guanylyl cyclase and inhibits PI3K and cyclooxygenase-1, preventing 
platelet activation, adhesion, and aggregation. Platelets are also an important source of 
NO and this platelet pool is a deciding factor in the recruitment of platelets to the 
platelet-rich thrombus (Loscalzo 2001). Second, a nucleosidase is secreted that cleaves 
ATP and ADP to AMP inhibiting platelet activation by reducing the intracellular 
nucleoside stock. Additionally, some surface receptors such as Platelet endothelial cell 
adhesion molecule-1 (PECAM-1), a glycoprotein, expressed on platelets and endothelial 
cells play an inhibitory role in platelet aggregation (Falati, Patil et al. 2006). 
The degree of platelet activation varies depending on the nature of stimulation - 
strong vs weak agonist (thrombin/collagen vs epinephrine), duration of activation (short 
vs long) and quantity/dose of agonist (low vs high- minor vs major vascular damage) and 
alters the  rate and extent of platelet secretion (Hechler, Nonne et al. 2010). This is 
manifested in diverse platelet morphologies. In resting conditions, platelets are discoid. 
Upon activation, they become spherical and form cellular projections, in the form of 
filopodia and lamellipodia. In early stages of activation, platelets undergo cytoskeletal 
changes that result in shape change but they do not release any cargo. Dense granule 
release is responsive to weaker stimulation since these granules are docked before 
stimulation (Chicka, Ren et al. 2016), while alpha granule release needs a stronger 
stimulation. At a higher agonist concentration, platelets release all their cargoes 
(Jonnalagadda, Izu et al. 2012).  
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Subsection Two:  Hemostasis and thrombosis 
Hemostasis is a process by which the vascular system maintains blood in a fluid 
state under physiological conditions. Upon vascular injury, it responds rapidly to stop 
blood loss by forming a clot/ thrombus. Thrombosis is a process of unrestricted 
thrombus formation in the absence of natural anticoagulant mechanisms or when these 
mechanisms fail to control thrombosis due to the severity of the injury. Hemostasis and 
thrombosis are mediated by dynamic interactions among vascular cells, extracellular 
matrix components, platelets, and the coagulation system and the synchronization 
among all these components is fundamental for achieving hemostatic balance. 
Coagulation cascade 
The coagulation cascade is traditionally described as an extrinsic pathway (tissue 
factor-initiated) and intrinsic pathway which activates a common downstream pathway 
which ultimately leads to fibrin formation delivering the necessary “glue” to aggregated 
platelets providing a mechanical support to a growing thrombus. According to a widely 
used current model, coagulation is divided into three phases: 
1. Initiation phase 
2. Amplification phase 
3. Propagation phase 
1. Initiation phase-  
The initiation phase is also referred to as the extrinsic pathway (Figure 1.3) and 
starts when a vascular injury occurs. This phase is marked by the generation of low 
amounts of active coagulation factors. Disruption of the vasculature exposes a critical 
coagulation factor, Tissue factor (TF), which resides on endothelium and on 
extravascular tissues like fibroblasts and smooth muscle cells (Versteeg, Heemskerk et 
al. 2013). TF binds and activates factor VII(FVII) to FVIIa by proteolysis. This TF\FVIIa 
complex then cleaves FIX and FX into FIXa and FXa respectively. FXa associates with FVa 
to form a prothrombinase complex that cleaves prothrombin to thrombin, a strong 
platelet agonist. 
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2. Amplification phase-  
In this phase, the levels of active coagulation factors are significantly increased. 
Thrombin activates platelets, converts FV to FVa, and FVIII to FVIIIa. FVIIIa is a cofactor 
for FIXa generation that ultimately leads to FXa generation, thus thrombin amplifies 
prothrombinase activity by providing positive feedback. Additionally, thrombin also 
converts FXI into FXIa. 
3. Propagation Phase- 
 In this phase, coagulation factors bind to procoagulant membranes of activated 
platelets and fibrin clots are formed. 
Role of platelets in coagulation 
Platelet activation and blood coagulation are mutually dependent processes in 
hemostasis and thrombosis (Heemskerk, Bevers et al. 2002). Platelets contain some (i.e. 
FV) and interact with multiple coagulation factors. Thrombin, generated by 
prothrombinase complex activates platelets leading to platelet granule secretion and 
aggregation. Increased cytosolic calcium levels in platelets also lead to exposure of 
phosphatidylserine (PS) on their outer membrane providing a procoagulant surface for 
the assembly of coagulation factors. PS exposure mainly facilitates the assembly and 
activation of tenase (TF-FVIIa) and prothrombinase (FVa-FXa) complexes, leading to 
thrombin and fibrin generation. 
PS exposure in platelets 
The plasma membrane has asymmetric lipid composition. The outer layer is 
composed of phosphatidylcholine/PC and sphingolipids while the inner/cytosolic leaflet 
contains phosphatidylethanolamine/PE, phosphatidylinositol/PI, phosphoinositides and 
PS. This gradient of phospholipids where neutral lipids are on the outer leaflet and 
mostly anionic lipids on the inner leaflet is crucial for membrane protein interactions 
with the membrane and signaling. PS exposure on the outer leaflet is an apoptotic signal 
for clearance of dying cells whereas PS exposure on RBCs and platelets is critical for 
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thrombosis. The absence of PS exposure leads to a rare bleeding disorder known as 
Scott syndrome.  
First described in 1979 (Weiss, Vicic et al. 1979), Scott syndrome is characterized 
as a bleeding disorder caused due to lack of PS exposure rendering feeble thrombosis 
(Toti, Satta et al. 1996). These platelets show normal morphology and functions, 
including secretion, aggregation, metabolism, granule content and adhesion to 
subendothelium. Moreover, coagulation factor levels are not altered. Using annexin V 
antibody, the authors reported that PS exposure was affected in these platelets that 
interfered with fibrin formation and ultimately thrombosis (Toti, Satta et al. 1996).  
Three classes of proteins are important for the formation, maintenance, and 
dissolution of this membrane asymmetry: flippases, floppases, and scramblases. 
Flippases catalyze the movement of phospholipids from outer to inner leaflet while 
floppases are responsible for the same movement in reverse directions. Both flippaes 
and floppases function in ATP dependent manner, unlike scramblases which are ATP-
independent and randomly distribute lipids in the inner or outer leaflet (Hankins, 
Baldridge et al. 2015). Following agonist stimulation, cytosolic calcium levels are 
increased in platelets leading to inhibition of flippases and stimulating scramblase 
activity (Lhermusier, Chap et al. 2011). Multiple reports suggested that store-operated 
calcium entry (SOCE) machinery including the Orai 1 channel and the STIM1 calcium 
sensors are important for PS exposure; although non-SOCE mechanisms may also 
participate in PS exposure (Gilio, van Kruchten et al. 2010). Calpain activity (Siljander, 
Farndale et al. 2001) and cholesterol-rich rafts are also important for PS exposure 
(Kunzelmann-Marche, Freyssinet et al. 2002). 
Since PS exposure has dual roles as an apoptotic signal and a component of the 
procoagulant surface, it was unclear if these processes are related to each other. In an 
elegant study, Schoenwaelder and colleagues showed that PS exposure inducing an 
apoptotic signal is different from the one aiding in the formation of the procoagulant 
surface (Schoenwaelder, Yuan et al. 2009). Inhibition of one pathway by 
pharmacological or signaling inhibitors does not have any impact on the other pathway. 
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These findings are consistent with normal PS exposure in apoptotic lymphocytes 
whereas PS exposure in calcium-stimulated platelets is absent (Williamson, Christie et 
al. 2001). Suzuki and coworkers showed that TMEM16F also known as anoctamin 6 is a 
transmembrane protein, crucial for calcium-dependent phospholipid scrambling activity 
and is muted in Scott syndrome (Suzuki, Umeda et al. 2010). Subsequent studies 
identified two new mutations in TMEM16F in another Scott syndrome patient (Castoldi, 
Collins et al. 2011). 
Despite this insight, many questions are still unanswered. What is the trafficking 
route of flippases/flippases and scramblases that play roles in PS exposure? 
Phospholipid synthesis occurs in ER. In addition to the vesicle budding and fusion, other 
pathways also contribute to their transport to their respective destination (Kaplan and 
Simoni 1985) (Vance, Aasman et al. 1991). Some reports suggest a role of lipid transfer 
proteins (LTPs) in PS trafficking to the plasma membrane/PM in S. cerevisiae (Maeda, 
Anand et al. 2013), but it is not clear if this process is unidirectional and how the PS 
concentration in PM is maintained. Also, is PS trafficking in platelets LTP dependent? 
Finally, is it possible that these enzymes may get transferred from megakaryocytes to 
platelets, possibly packaged in granules or some other intracellular organelle such as 
endosomes? Does platelet granule secretion affect the release of PS exposure? PS 
exposure is affected in Nbeal2-/- animals (Deppermann, Cherpokova et al. 2013) 
suggesting that alpha granules play a role in PS exposure leading to procoagulant nature 
of platelets. However, it remains to be seen if dense granules are also important for PS 
exposure. 
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Figure 1 3. Intrinsic and extrinsic coagulation pathways of coagulation 
The intrinsic pathway is a sequence of proteolytic events that lead to activation of FIX. 
Tissue factor exposure upon vascular injury initiates the extrinsic pathway. Both 
pathways ultimately lead to the assembly of prothrombinase complex (FX and FV) that 
results in cleavage of fibrinogen into fibrin forming a blood clot. 
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Thrombus architecture 
Upon vascular injury, exposure to adhesive proteins in the endothelial cortex and 
to soluble agonists leads to platelet activation as described above and ultimately 
platelet shape change, granule secretion, and aggregation. Several in vivo studies using 
genetic and pharmacologic approaches have demonstrated that platelet activation 
during thrombus formation is a heterogeneous process where the most activated 
platelets form a core/central part of the thrombus while less activated platelets form 
the outer shell (van Gestel, Heemskerk et al. 2002) (Stalker, Traxler et al. 2013) (Hechler, 
Nonne et al. 2010) (Hayashi, Mogami et al. 2008). Multiple distinct pathways of 
activation are synchronized in a temporal and spatial manner to achieve an optimal 
response to form a stable thrombus. A myriad of platelet agonists is present at the site 
of vascular injury including collagen, thrombin, ADP, TxA2, serotonin, and calcium among 
others which vary in their potency and concentration (Hechler, Nonne et al. 2010). 
Strong, potent platelet stimulation from all these agonists will result in a robust release 
of platelet granule cargo as a bolus. Considering the shear stress of blood flow, the 
cargo molecules may wash away downstream of the flow and will not be able to engage 
at the site of injury. Similarly, weak stimulation of platelets may delay thrombus 
formation altogether leading to severe bleeding. Hence the balance between unwanted 
thrombosis and required hemostasis is crucial and should be met by an optimal 
structure of the thrombus. 
Using a systems approach, Brass et al., demonstrated how thrombus structure is 
influenced by various factors including the distribution of platelet agonists, the porosity 
of the region, permeability, the ease of solute transport within the platelet plug and 
platelet density (Stalker, Welsh et al. 2014, Tomaiuolo, Stalker et al. 2014). Using a novel 
thrombin biosensor and a thrombus porosity probe, the authors reported that 
molecular transport is slow in the shell region and even slower in the core which 
overlaps with high packing in the core region (Welsh, Stalker et al. 2014). 
Sema4D KO mice are deficient in collagen-mediated platelet activation 
(Wannemacher, Zhu et al. 2010). Using these mice, the authors showed that platelet 
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accumulation at the site of injury and gradual reduction in gaps among platelets impede 
agonist transport in the region leading to robust activation on platelets in the core and 
progressively weaker activation in the shell region (Figure 1.4). They also showed that 
thrombin is a central agonist responsible for core formation while ADP plays a crucial 
role in shell formation (Stalker, Traxler et al. 2013). These studies and multiple other 
reports clearly demonstrate that platelet activation and granule secretion shapes 
thrombus composition. Hyperactive platelets lead to occlusive thrombosis while 
hypoactive/secretion deficient platelets contribute to bleeding.  
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Figure 1 4. Platelet activation influences thrombus architecture 
Thrombus composition is influenced by the level of platelet activation. Platelets exposed 
to subendothelial adhesive proteins get activated and forms a core region while less 
activated platelets form an shell region.  
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Platelets influence vascular microenvironment 
How do platelets influence vascular microenvironment? The content of the 
platelet release and how its composition is controlled have been subjects of great 
interest. Are platelets able to release only subsets of their cargo or is the process 
stochastic? Both unbiased proteomics and directed antibody array systems have been 
used to monitor the release of multiple cargoes simultaneously. Several groups suggest 
that specific classes of cargo (e.g., pro-angiogenic and anti-angiogenic factors) can  be 
released in response to specific agonists (Ma, Perini et al. 2005, Italiano, Richardson et 
al. 2008, Chatterjee, Huang et al. 2011). However, other studies detected no thematic 
patterns in cargo release. Jonnalagadda et al., using a custom microELISA array and 
four agonists (thrombin, convulxin, PAR1 and PAR4), showed that agonist potency 
influences the kinetics and extent of secretion, but there were no “functionally 
thematic” patterns in the release process (Jonnalagadda, Izu et al. 2012). Broader 
proteomic studies confirmed the lack of thematic patterns in the release of granule 
cargo (Wijten, van Holten et al. 2013, van Holten, Bleijerveld et al. 2014); however, 
there are distinct kinetic patterns with cargo release occurring in waves. These findings 
suggest that platelets can use distinct release rates to temporally affect their 
microenvironment. The kinetics of release may be governed by the degree of 
stimulation as discussed earlier, the chemical properties of the cargo, the locale where 
the cargo is packaged in a granule and/or the machinery used (Sehgal and Storrie 
2007, Kamykowski, Carlton et al. 2011, Jonnalagadda, Izu et al. 2012). A newly 
emerging perspective is the presence of a granule scaffold that acts as a platform to 
contain densely packed granule cargo inside the granule. It may also facilitate the 
release of these cargoes once fusion occurs, releasing contents closer to the fusion 
pore first. It remains to be seen if serglycin shown to be present in alpha granules 
(Woulfe, Lilliendahl et al. 2008) is important for controlling the rate of alpha-granule 
cargo release. 
Since most of these past studies were done in suspension, it is unclear if there 
are also spatial constraints on platelet secretion. Early electron microscopy studies 
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suggested that the ventral platelet surface is different from the distal surface, 
consistent with some degree of polarity (White and Krumwiede 1994). Furthermore, a 
recent study reported that platelets actively migrate to collect bacteria (Gaertner, 
Ahmad et al. 2017) suggesting that at least some degree of polarity must be present in 
platelets guiding their movement in the vasculature. 
Subsection Three: Mechanisms of secretion 
Secretion or exocytosis is an event of fusion between a granule/vesicle to the 
plasma membrane to release cargo content. This process can be variable in different cell 
types. Types of fusion events include simple fusion (granule fuses to plasma membrane), 
compound fusion (granule fuses to another granule before or after fusing to plasma 
membrane), piecemeal degranulation (selective vesicular transport of cargo from the 
cytoplasmic secretory granules to the cell surface), and total granule extrusion/cytolysis 
(release of intact granules that coincides with the cell death). 
Simple fusion is the most common fusion event. Compound fusion events are 
observed in mast cells (Hide, Bennett et al. 1993), eosinophils (Scepek, Moqbel et al. 
1994), neutrophils (Lollike, Lindau et al. 2002), and platelets (Morgenstern 1995). 
Piecemeal degranulation/PMD has been identified as the predominant mode of 
secretion from eosinophils (Melo and Weller 2010), and to some extent, by mast cells 
(Crivellato, Candussio et al. 2002) while cytolysis is a mode of fusion mainly used by 
tissue eosinophils, secondary to PMD (Erjefalt, Greiff et al. 1999). 
Apart from the type of fusion, these various secretion events also differ in their 
SNARE usage. v- and t- SNARE expression alters according to tissue type as does the 
SNARE complex composition. While VAMP-2/syntaxin-1/ -SNAP-25 complex is important 
for chromaffin granule release (Fitch-Tewfik and Flaumenhaft 2013), VAMP-8/syntaxin- 
11/SNAP23 complex is crucial for platelet granule release (Joshi and Whiteheart 2017).  
Mechanism of platelet secretion 
Platelet secretion is a textbook example of regulated secretion since there are 
stores of cargoes in granules that are released upon stimulation with an agonist (often 
called a secretagogue). Platelets respond to many agonists; including some, such as 
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thrombin and convulxin, considered strong and cause robust release while others, e.g., 
ADP and epinephrine are weak secretagogues. In physiological conditions, these 
various agonists stimulate platelets at various stages and at various concentrations to 
shape thrombus architecture.  
Secretion of dense granules is generally monitored by measuring ATP or serotonin 
release. Alpha-granule exocytosis is monitored by measuring the release of soluble 
cargo proteins e.g., PF4, thromboglobulin, vWF, or the surface exposure of P-selectin, an 
abundant alpha granule membrane protein. Hydrolytic enzymes, such as β-
hexosaminidase, are used as metrics of lysosome release. In many studies, single time 
points or agonist doses are used; however, this obscures the complexity of the platelet 
exocytosis process. More detailed studies demonstrate that the rates and extents of 
platelet exocytosis are directly related to stimulation strength which could be from 
strong vs weak agonist or shorter vs longer stimulation time (Jonnalagadda, Izu et al. 
2012). Dense granule release is the fastest, most sensitive process; lysosome release is 
the slowest and requires greater stimulation. The alpha-granule release is kinetically the 
most diverse. Together, these three exocytic processes form the platelet releasate, 
which has been shown to contain hundreds of bioactive components (Coppinger, 
Cagney et al. 2004, Maynard, Heijnen et al. 2007, van Holten, Bleijerveld et al. 2014). It 
is this releasate that affects the microenvironment around activated platelets and 
contributes to platelet function. 
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Figure 1.5. Pathway of SNARE-mediated platelet granule release 
Platelet exocytosis is a pathway of protein-protein interactions leading from 1) granule 
docking, 2) SNARE engagement to 3) membrane fusion and 4) cargo release. The 
interactions and their proposed order of occurrence are depicted in the schematic. The 
machinery, which could be on the granules, includes v-SNAREs (Vesicle-Associated 
Membrane Protein/VAMPs); Munc13-4 and synaptotagmin-like protein (SLP); small 
GTPases Rab and Ral; and the Exocyst complex. The machinery on the plasma 
membrane includes t- SNARE heterodimer of syntaxin-11 and SNAP23; the Syntaxin-
chaperone Munc18b; and the t-SNARE regulator STXBP5/Tomosyn 1. Also depicted are 
domains in each protein, which contribute to protein function and thus platelet 
exocytosis: blue lines, C2 domains in Munc13-4 and SLP; brown line, Munc homology 
domain in Munc13-4; red lines, SLP homology domain in SLP; rounded rectangles, 
SNARE domain. 
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Granule-plasma membrane fusion 
The penultimate step of exocytosis is the fusion of cargo- containing granules 
with the plasma membranes/PM. Platelet granules also fuse with each other, in a 
process called compound fusion, which may or may not precede fusion with the PM 
(Morgenstern 1995). Membrane fusion is mediated by proteins called Soluble N-
ethylmaleimide-sensitive factor Attachment Protein Receptor (SNARE) proteins (Figure 
1.4). This process is highly conserved in all eukaryotes and the family of SNARE proteins 
is quite large (Kloepper, Kienle et al. 2007). SNAREs are classified into two groups based 
on their relative locations: v- for vesicle/granule localized and t- for target membrane-
localized SNAREs. They are also classified based on the amino acid at the center of their 
SNARE domains, either R (Arg) or Q (Glu). Vesicle-Associated Membrane Proteins 
(VAMPs) constitute a large group of the known v-SNAREs (R-SNAREs). t- SNAREs (Q-
SNAREs) consist of two classes of proteins – Syntaxins and Synaptosome Associated 
Proteins/SNAP-23/25 proteins (Fasshauer, Sutton et al. 1998). All SNAREs contain one or 
two amphipathic, heptad- repeat-containing, SNARE domains of ~60 amino acids; which 
are typically adjacent to a C-terminal tail-anchored membrane segment. Cognate v- and 
t- SNAREs interact, through these domains, to form a stable transmembrane complex 
that promotes membrane fusion (Jahn and Scheller 2006). Four SNARE domains, one 
each from v- SNARE (R-SNARE) and syntaxin (Qa-SNARE) and two from SNAP23/25 (Qbc 
SNARE), form a coiled-coil structure that buries the hydrophobic residues and draws the 
two membranes together for fusion. 
v-SNAREs in platelets 
Though there are nine VAMPs found in the human genome (VAMP-1-8 excluding 
VAMP-6, Sec22, and Ykt6p) (Bock, Matern et al. 2001), only six of them are expressed in 
platelets (Graham, Ren et al. 2009, Burkhart, Schumbrutzki et al. 2012, Joshi and 
Whiteheart 2017). VAMP-2, VAMP-3, VAMP-7, and VAMP-8 are the major ones and 
VAMP-4 and VAMP-5 have been found only in trace amounts. VAMPs are divided into 
two groups based on their structure. Brevin VAMPs are smaller with a short cytoplasmic 
domain, a transmembrane domain, and an N terminal SNARE domain. This class includes 
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VAMP-2, VAMP-3, and VAMP-8. The second group is called longins, since the members 
of this group contain a unique longin domain on the N terminus, downstream of a 
SNARE domain. VAMP-7, Sec22, Ykt6 and the yeast protein Nyv1p are contained within 
this group (Chaineau, Danglot et al. 2009). 
Synaptobrevin/VAMP-2/V-2 
First identified in synaptic vesicles and named as a homolog of VAMP-1 (Elferink 
et al, 1989), VAMP-2 is expressed in the central nervous system/CNS and in peripheral 
neurons. V-2 -/- animals die after birth though neuronal development is normal and they 
show defective secretion upon Ca++ stimulation in the neuronal synapse (Schoch, Deak 
et al. 2001). These findings support previous reports from Schiavo and colleagues 
suggesting that upon tetanus toxin treatment, which cleaves VAMP-1, -2, and -3, 
synaptic transmission is severely affected (Schiavo, Benfenati et al. 1992). Since VAMP-1 
is present in trace amounts and VAMP-3 is not detectable in neurons, VAMP-2 must be 
essential for synaptic fusion events. Apart from the nervous system, VAMP-2 is also 
expressed in adipocytes, skeletal muscles and in hematopoietic lineage cells such as 
mast cells, neutrophils and eosinophils (Stow, Manderson et al. 2006). VAMP-2 is 
important for gelatinase-containing granule secretion from neutrophils and secretory 
vesicles from eosinophils. It also plays a role in insulin-mediated GLUT4 translocation in 
cultured 3T3-L1 adipocytes, and in L6 muscle cell line (Martin, Shewan et al. 1998, 
Randhawa, Bilan et al. 2000). 
Cellubrevin/VAMP-3/V-3-  
VAMP-3 is a homolog of VAMP-2 and is expressed in a wide variety of tissues. In 
fact, its ubiquitous expression led to naming this protein “cellubrevin” (McMahon et al, 
1993). VAMP-3 is expressed in neuroendocrine cells (Chilcote, Galli et al. 1995), glial 
cells (Bezzi, Gundersen et al. 2004), macrophages, heart, adipose tissue, skeletal 
muscles, brain, liver, testis, kidneys, lungs, mast cells, chromaffin granule, and 
pancreatic beta cells (Yang, Mora et al. 2001). Like VAMP-2, VAMP-3 is also a substrate 
for proteolytic cleavage by tetanus toxin light chain (McMahon, Ushkaryov et al. 1993, 
Galli, Chilcote et al. 1994). VAMP-3 has been implicated in many trafficking events. It is 
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important for guanosine-59-O-(3-thiotriphosphate) (GTPγS)-stimulated GLUT4 
translocation (Millar, Shewan et al. 1999), phagosome formation (Bajno, Peng et al. 
2000), phagocytosis (Hackam, Rotstein et al. 1998, Murray, Kay et al. 2005), and 
transferrin recycling through endosomes (Galli, Chilcote et al. 1994, Daro, van der Sluijs 
et al. 1996). VAMP-3 contributes to apical transport of H+-ATPase (Breton, Nsumu et al. 
2000). It is also important for migration of epithelial cells and recycling of β1 integrins 
(Proux-Gillardeaux, Gavard et al. 2005). 
Tetanus toxin insensitive VAMP / TI-VAMP/VAMP-7 
VAMP-7 is structurally distinct from other, shorter VAMP isoforms (VAMP-2, -3, 
and -8). It contains a characteristic domain at its N terminus, called a Longin domain. 
The longin domain is important for regulation of SNARE complex formation and 
targeting VAMP-7 to late endosomes through interaction with an adaptor protein, AP-3 
(Martinez-Arca, Rudge et al. 2003). Recently, it was shown to interact with cytoskeleton 
regulators, specifically with VPS9 and ankyrin repeat containing protein (VARP) (Schafer, 
Hesketh et al. 2012, Koseoglu, Peters et al. 2015). 
Galli et al., first identified this VAMP isoform in epithelial cells. They found that 
VAMP-7 contributes to apical membrane exocytosis and it is protected from the tetanus 
toxin light chain that cleaves VAMP-1, -2 and -3 (Galli, Zahraoui et al. 1998). Apart from 
epithelial cells, VAMP-7 is expressed in neurons, neuroendocrine cells, heart, kidney, 
liver, spleen, and thymus (Advani, Bae et al. 1998). VAMP-7 has been implicated in 
inhibition of neurite outgrowth (Martinez-Arca, Alberts et al. 2000) and in intracellular 
trafficking from endosomes to lysosomes (Advani, Yang et al. 1999). VAMP-7 contributes 
to lysosomal secretion in Normal Rat Kidney Epithelial/NRK cells (Rao, Huynh et al. 
2004), FcR stimulated exocytosis and phagocytosis in macrophages (Braun, Fraisier et al. 
2004), and Glut4 trafficking in adipocytes (Williams and Pessin 2008). A recent report by 
Molino, et al., show that the transport of endogenous and exogenous GPI anchored 
proteins was altered in VAMP-7 deficient fibroblasts. The authors suggested that VAMP-
7 contributes to Golgi homeostasis by facilitating trafficking of GPI anchored proteins to 
the cell surface (Molino, Nola et al. 2015). 
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Endobrevin\VAMP-8\V-8- 
VAMP-8 was first identified by Wong, et al., as an endosomal v- SNARE in 
cultured cells and in rat liver and thus named endobrevin. Its presence in HeLa cells, 
MDCK cells, and normal rat kidney cells/NRK was reported (Wong, Zhang et al. 1998). 
VAMP-8 is broadly expressed in all membranes connected with the endosomal system 
including the plasma membrane, clathrin-coated pits, late endosomes, and membranes 
of the trans-Golgi network (Antonin, Holroyd et al. 2000). It mediates fusion of early and 
late endosomes (Antonin, Holroyd et al. 2000). VAMP-8 forms a complex with syntaxin-
7, syntaxin-8, and vti1b, and aids in the homotypic fusion of late endosomes or 
heterotypic fusion with lysosomes (Antonin, Holroyd et al. 2000). Williams, et al., 
showed that in adipocytes, siRNA mediated VAMP-8 knockdown affected GLUT4 
endocytosis from plasma membranes (Williams and Pessin 2008). Using bone marrow-
derived mast cells (BMCCs) from V-8-/- mice, Tiwari, et al., showed that VAMP-8 plays a 
role in β-hexosaminidase and histamine release from mast cells. These animals, 
however, showed no defect in secretion of cytokines such as Tumor necrosis factor/TNF-
α, IL-6, and Macrophage inflammatory protein/MIP-1α. This indicates that VAMP-8 
deficiency affects Fc€RI induced degranulation but not cytokine and chemokine 
secretion (Tiwari, Wang et al. 2008). 
Though important for endosomal trafficking, VAMP-8 is dispensable for 
endocytosis. Using global VAMP-8 deficient mice, Wang et al., showed that cultured 
embryonic V-8 -/- fibroblasts or primary hepatocytes do not have any endocytic defect. 
Furthermore, receptor-mediated endocytosis, intracellular trafficking of cathepsin D 
from TGN to lysosomes, degradation of low-density lipoproteins/LDL and recycling of 
the transferrin receptors all were normal (Wang, Ng et al. 2004). Wang et al., also 
reported that VAMP-8 is enriched in zymogen granule membranes and is important for 
their secretion from pancreatic acinar cells. In fact, VAMP-8 deficient pancreatic acinar 
cells harbored three times more zymogen granules than the control cells indicating 
accumulation of granules due to failure to secrete. Furthermore, V-8-/- pancreas failed to 
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secrete digestive enzymes upon cholecystokinin stimulation indicating VAMP-8 is 
required for enzyme secretion from the exocrine pancreas.  
Another elegant study by the same group further illuminated VAMP-8’s broad 
role in encompassing regulated exocytosis of the entire exocrine system (Wang, Shi et 
al. 2007). In this report, the authors characterized the role of VAMP-8 in secretion from 
exocrine tissues. They found that VAMP-8 is widely expressed in an exocrine system 
including salivary glands, lacrimal glands, sweat glands, sebaceous glands, mammary 
glands and the prostate. Further evaluation indicated that VAMP-8 mediated secretion 
is vital in salivary and lacrimal glands. VAMP-8 is also expressed in kidneys and has been 
attributed to playing a role in the transport of a water channel aquaporin 2, to the 
plasma membrane (Wang, Ng et al. 2010).  
Since these early reports, major in vitro studies have implicated VAMP-8 as a 
critical player in the terminal step of cytokinesis in mammalian cells along with syntaxin-
2 (Low, Li et al. 2003) and also in the release of hexosaminidase from rat basophilic 
leukemia cells (Lippert, Ferrari et al. 2007). 
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Table 1.2 Secretory machinery in platelets 
Protein Gene Aliases  
(in Homo sapiens) 
Abundance in 
Mice 
Abundance in 
Humans 
Functional References 
v- SNAREs (R-SNAREs)  
VAMP-2 VAMP2 SYB2, VAMP-2 7,600 † 
1,012 *  
<800 † (Ren, Barber et al. 2007) 
VAMP-3 VAMP3 CEB 2,200 † 
35,813 *  
4,600 † 
4,200 ǂ 
(Flaumenhaft, Croce et al. 
1999, Feng, Crane et al. 2002, 
Polgar, Chung et al. 2002, 
Schraw, Rutledge et al. 2003) 
VAMP-4 VAMP4 VAMP-4, VAMP24 ND ND   
VAMP-5 VAMP5   6,775 * 740 ǂ   
VAMP-7 VAMP7 SYBL1, TIVAMP, VAMP-7, TI-VAMP 2,700 † 3,800 † 
8,100 ǂ 
(Koseoglu, Peters et al. 2015) 
VAMP-8 VAMP8 EDB, VAMP-8 8,400 † 
37,751 * 
6,600 † 
7,100 ǂ 
(Ren, Barber et al. 2007, 
Graham, Ren et al. 2009) 
t- SNARES (Q-SNAREs)    
Syntaxin 2 STX2 EPM, EPIM, STX2A, STX2B, STX2C 1,800 § 
1,738 * 
1,600 § 
4,100 ǂ 
(Chen, Bernstein et al. 2000, 
Chen, Lemons et al. 2000) 
Syntaxin 4 STX4  STX4A, p35-2 1,600 § 
9,892 * 
9,600 § 
3,800 ǂ 
(Lemons, Chen et al. 1997, 
Chen, Bernstein et al. 2000, 
Chen, Lemons et al. 2000, 
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Lemons, Chen et al. 2000) 
(Flaumenhaft, Croce et al. 
1999) 
Syntaxin 6 STX6  522 * 1,400 ǂ  
Syntaxin 7 STX7  3,700 § 
10,468 * 
3,900 § 
7,100 ǂ 
 
Syntaxin 8 STX8 CARB 1,077 * <500 ǂ }(Golebiewska, Harper et al. 
2015) 
Syntaxin 11 STX11 FHL4, HLH4, HPLH4 47,000 § 
12,190 * 
52,000 § 
7,500 ǂ 
(Ye, Karim et al. 2012) 
SNAP-23 SNAP23 SNAP-23, SNAP23A, SNAP23B, HsT17016 5,400 § 
27,531 * 
19,000 § 
11,400 ǂ 
(Lemons, Chen et al. 1997, 
Flaumenhaft, Croce et al. 
1999, Chen, Lemons et al. 
2000, Lemons, Chen et al. 
2000) 
SNAP-25 SNAP25 SUP, RIC4, SEC9, SNAP, CMS18, RIC-4, 
SNAP-2, bA416N4.2, dJ1068F16.2 
ND ND   
SNAP-29 SNAP29 CEDNIK, SNAP-29 13,969 * 3,400 ǂ (Williams, Savage et al. 2016) 
SNARE REGULATORS 
Munc18a STXBP1 P67  NSEC1, UNC18, RBSEC1, MUNC18-1 984 * 1,600 ǂ (Schraw, Lemons et al. 2003) 
Munc18 b STXBP2 FHL5, UNC18B, Hunc18b, UNC18-2, 
pp10122, MUNC18-2 
18,722 * 15,800 ǂ (Al Hawas, Ren et al. 2012) 
Munc18c STXBP3 PSP, MUNC18C, UNC-18C, MUNC18-3 7,626 * 2,900 ǂ (Reed, Houng et al. 1999) 
α-Synuclein SNCA PD1, NACP, PARK1, PARK4 42,331* 38,100 ǂ unpublished 
STXBP5 / STXBP5 LGL3, LLGL3, Nbla04300 6,910* 3,300 ǂ (Ye, Huang et al. 2014, Zhu, 
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Tomosyn 1 Yamakuchi et al. 2014) 
SLP4 / 
Granuphilin 
SYTL4 SLP4 18,116 * 9,200 ǂ (Hampson, O'Connor et al. 
2013) 
α-SNAP NAPA SNAPA ND 8,900 ǂ unpublished 
NSF NSF SKD2 7,162 *   (Polgar and Reed 1999)and 
unpublished 
γ-SNAP NAPG GAMMASNAP ND 3,500 ǂ  
IKK-α CHUK IKK1, IKKA, IKBKA, TCF16, NFKBIKA, IKK-
alpha 
516 * 1,800 ǂ  
IKK-β IKBKB IKK2, IKKB, IMD15, NFKBIKB, IKK-beta 603 * 1,300 ǂ (Karim, Zhang et al. 2013) 
IKK-γ IKBKG IP, IP1, IP2, FIP3, IKKG, IPD2, NEMO, FIP-
3, Fip3p, IMD33, AMCBX1, IKKAP1, 
ZC2HC9, IKK-gamma 
ND ND  
TETHERING FACTORS 
Munc13-4 UNC13D FHL3, HLH3, HPLH3, Munc13-4 320, 9,249 * ND (Ren, Wimmer et al. 2010) 
Rab 27b RAB27B C25KG 55,593 * 35,900 ǂ (Tolmachova, Abrink et al. 
2007) 
SLP1 SYTL1 JFC1, SLP1 ND ND Neumuller, 2009 #75} 
EXOCYST COMPONENTS 
Sec3 EXOC1 SEC3, SEC3P, BM-102, SEC3L1 1,525 * 1000 ǂ  
Sec5 EXOC2 SEC5, Sec5p, SEC5L1 ND 1800 ǂ  (Kawato, Shirakawa et al. 
2008) 
Sec6 EXOC3 SEC6, Sec6p, SEC6L1 1,081 * 1600 ǂ  
Sec8 EXOC4 SEC8, Sec8p, SEC8L1 ND 1900 ǂ  
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Sec10 EXOC5 SEC10, HSEC10, SEC10P, PRO1912, 
SEC10L1 
1,331 * 1300 ǂ  
Sec15 EXOC6 SEC15, EXOC6A, SEC15L, Sec15p, 
SEC15L1, SEC15L3 
1,061 * 710 ǂ  
Exo70 EXOC7 EX070, EXO70, EXOC1, 2-5-3p, Exo70p, 
YJL085W 
ND 1400 ǂ  
Exo84 EXOC8 EXO84, SEC84, Exo84p 1,325 * 1100 ǂ  
Ral A RALA RAL 2,755*  3400 ǂ (Kawato, Shirakawa et al. 
2008) 
Ral B RALB - 12,165 * 6,800 ǂ  
*Determined by Stable Isotope Labeling in Cell Culture- Protein Epitope Signature Tag (SILAC- PrEST) method 
† Determined by quantitative western blotting (Graham et al) 
§ Determined by quantitative western blotting (Ye and Whiteheart unpublished) 
‡ Determined by spectral counting 
ND Not Determined 
All numbers are rounded to nearest hundredth. 
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VAMPs/v-SNAREs in platelets 
Quantitative western blotting and proteomic analysis (Graham, Ren et al. 2009, 
Burkhart, Schumbrutzki et al. 2012) have shown that platelets contain multiple v-SNARE 
isoforms (e.g., VAMP-2, -3, -4, -5, -7, and -8; Table 1.2). VAMP-8 and -7 are most 
abundant in human platelets while VAMP-8, -2, and -7 are most abundant in mouse 
platelets. Although previous studies using permeabilized platelets showed a role for 
VAMPs, the assignment of specific isoforms was equivocal (Flaumenhaft, Croce et al. 
1999, Feng, Crane et al. 2002, Polgar, Chung et al. 2002, Schraw, Rutledge et al. 2003). 
More definitive studies of platelets from knockout (KO) mice demonstrated roles for 
VAMP-8 and -7; however, in neither case does a single VAMP account for all the release 
(Ren, Barber et al. 2007, Koseoglu, Peters et al. 2015). Deletion of VAMP-3 or reduction 
of VAMP-2 had no effect when VAMP-8 and -7 were present (Ren, Barber et al. 2007). 
Interestingly, permeabilized V-8-/- mouse platelets did show diminished secretion upon 
treatment with a tetanus toxin light chain fragment, which specifically cleaves VAMP-2 
and -3 (Schiavo, Matteoli et al. 2000). VAMP-7 is resistant to the toxin peptidase (Galli, 
Zahraoui et al. 1998). The roles of VAMP-4 and -5 have not been addressed, but their 
levels are low compared to the other platelet VAMPs (Table 1.2). These data imply 
unique and dominant roles for VAMP-7 and -8 in platelet secretion and suggest that, at 
least in mice, VAMP-2 and -3 contribute to the process. This type of compensation or 
“ranked redundancy” in isoform usage has been reported in chromaffin cells 
(Borisovska, Zhao et al. 2005) and in mast cells (Sander, Frank et al. 2008, Tiwari, Wang 
et al. 2009) and may be related to some intrinsic property of each VAMP or to the 
amounts of each isoform. This distinction is not clear at present. Phenotypically, the loss 
of VAMP-8 causes defective thrombosis. Global deletion of VAMP-8 resulted in delayed 
and diminished thrombus formation (Graham, Ren et al. 2009). However, V-8-/- mice 
failed to show any bleeding diathesis. Interestingly, loss of VAMP-7 caused no defect in 
platelet accumulation at the site of laser injury nor in the tail-bleeding assay, though the 
alpha-granule release is affected in the growing thrombus (Koseoglu, Peters et al. 2015). 
These data support the primacy of VAMP-8-mediated secretion in hemostasis and 
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suggest that VAMP-7 and -8 contribute distinctly to platelet function. Consistent with 
the primacy of its usage, the gene encoding VAMP-8 has been linked, by Genome-Wide 
Association Studies (GWAS), to early-onset myocardial infarction, which is indicative of 
hyper-reactive or perhaps “hyper-secretory” platelets (Shiffman, Rowland et al. 2006, 
Shiffman, O'Meara et al. 2008). 
Additional genetic studies identified a microRNA (microRNA-96) that controls 
VAMP-8 expression and correlates with increased platelet response to epinephrine 
(Kondkar, Bray et al. 2010). This microRNA affected VAMP-8 levels in a tissue culture 
system, but the effects on secretion were not tested. From the mouse models and the 
implications of the human genetic data, it seems possible that VAMP-8 levels directly 
affect platelet secretion efficacy. 
VAMP-7 positive structures localize to the periphery of spreading platelets, while 
VAMP-8 and -3 positive granules concentrate in the central granulomere (Peters, 
Michelson et al. 2012). These data imply that VAMP-7 mediates secretion at the 
periphery where it is needed for platelet spreading. VAMP-8 (and perhaps VAMP-2 or -
3) mediates fusion in the centralized granulomere, which is needed for thrombus 
growth. However, while the platelet granulomere is readily visible in platelets bound to 
rigid surfaces (i.e., glass coverslips and electron microscopy (Allen, Zacharski et al. 
1979)), it is yet to be defined in a growing thrombus. VAMP-8’s role in platelet spreading 
has not been directly tested. Similar studies in neutrophils (Mollinedo, Calafat et al. 
2006), and mast cells (Puri and Roche 2008) also show a polarization of VAMP isoform-
positive structures during the exocytosis process. 
The spatial differences between VAMP-7 and -8 positive granules suggest the 
potential for differential cargo release mediated by the two isoforms. At present, it is 
unclear if the two VAMPs associate specifically with distinct cargo or mediate 
differential release in response to different secretagogues. However, the existing data 
offer intriguing hints about the spatial nature of platelet exocytosis. Future experiments 
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using microfluidics and/or enhanced-resolution imaging, in vivo, will be needed to 
resolve these questions. 
t-SNAREs in platelets  
Platelets contain syntaxin-2, -4, -6, -7, -8, -11 -12, -16, -17, and -18 and SNAP23, 
25 and 29 (Table 1.2; (Ren, Ye et al. 2008, Burkhart, Schumbrutzki et al. 2012, Zeiler, 
Moser et al. 2014, Joshi and Whiteheart 2017). SNAP23 is thought to be the functionally 
relevant Qbc t-SNARE, based on studies using permeabilized platelets with inhibitory 
antibodies and peptides (Flaumenhaft, Croce et al. 1999, Chen, Bernstein et al. 2000, 
Chen, Lemons et al. 2000, Lemons, Chen et al. 2000). SNAP25 is much less abundant and 
platelets from SNAP29 KO mice show no significant secretion defect (Williams, Savage et 
al. 2016). The Qa t-SNAREs, syntaxin-2 and -4, were previously reported to be important 
(Flaumenhaft, Croce et al. 1999, Chen, Bernstein et al. 2000, Chen, Lemons et al. 2000, 
Lemons, Chen et al. 2000). However, these findings were not consistent with data from 
KO mice (Ye 2012, Ye, Karim et al. 2012). Secretion from syntaxin-2/4 double KO 
platelets is unaffected though endocytosis is defective (Ye 2012). Analysis of platelets 
from a Familial Hemophagocytic Lymphohistiocytosis type 4 (FHL-4) patient, lacking 
syntaxin-11, indicate its role in secretion from all three granules. Consistently, syntaxin-
11 forms complexes with SNAP23 and VAMP-8. To explain previous data, Ye et al., 
showed that the original anti-syntaxin-2 antibodies, which inhibited release from 
permeabilized platelets, cross-reacted with syntaxin-11 (Ye, Karim et al. 2012). Recently, 
another report demonstrated that syntaxin-8 influences dense granule but not alpha 
granule or lysosome release (Golebiewska, Harper et al. 2015). The authors showed that 
syntaxin-8 interacts with syntaxin-11 but not with SNAP23. This shows that syntaxin-8’s 
Qb SNARE motif forms different complexes with the Qa motif of syntaxin-11 than the 
complexes formed with SNAP23’s Qbc motifs. 
SNARE heterogeneity in exocytosis 
A role of SNARE isoforms in trafficking and exocytosis of various intracellular 
vesicles has been a subject of intense investigation. Multiple studies indicate that SNARE 
isoforms may have overlapping functions in trafficking and exocytosis depending on the 
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cell type. First started with studies in Saccharomyces cerevisiae, these investigations 
soon were implemented in other model systems. 
Early studies in Drosophila neurons showed compensatory mechanisms among 
SNAREs. Bhattacharya et al., elegantly showed that members of VAMP family 
compensate for each other (Bhattacharya, Stewart et al. 2002). Drosophila has two 
distinct VAMP family members: ubiquitously expressed synaptobrevin/syn and neuronal 
synaptobrevin (n-syb) which is expressed exclusively in the CNS. While syb is important 
for cell viability, n-syb is required for synaptic vesicle secretion. Deletion of syb leads to 
developmental defects while the loss of n-syb reduces spontaneous vesicle fusion and 
completely blocks action potential-evoked vesicle exocytosis. Interestingly, the 
expression of the n-syb in syb-/- and syb in n-syb-/- mutants effectively rescue these 
phenotypes. In fact, rat n-syb and cellubrevin/VAMP-3 also can compensate for the loss 
of syb. This indicates that despite different cellular locations, these VAMP isoforms 
could efficiently compensate for each other (Bhattacharya, Stewart et al. 2002). Another 
study in Drosophila suggested that the loss of the t-SNARE SNAP25 could be 
compensated for by another SNAP isoform, SNAP24, to facilitate synaptic transmission 
in Drosophila larval neuromuscular junction (Vilinsky, Stewart et al. 2002). 
This concept of functionally interchangeable SNARE isoforms is heavily 
supported by vigorous studies in yeast. In yeast, two syntaxin homologs, Vam3p and 
Pep12p function as vacuolar and endosomal t- SNAREs respectively. Mutations in 
Vam3p affect vesicle fusion with vacuoles while mutations in the Pep12p manifest as 
defective vesicle trafficking from the late Golgi to the endosome. When overexpressed, 
both Pep12p and Vam3p can compensate for each other’s loss and rescue the relevant 
phenotype (Darsow, Rieder et al. 1997, Gotte and Gallwitz 1997). Likewise, Liu et al., 
showed that a similar relationship exists between yeast Sec22p and Ykt6p. Sec22p is 
crucial for fusion of ER-derived vesicles with Golgi membranes and Ykt6p is important at 
late stages of the secretory pathway. Upon deletion of Sec22p, Ykt6p is up-regulated 
and compensates for the loss of Sec22p by facilitating ER- Golgi secretory pathway (Liu 
and Barlowe 2002). 
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In a seminal study in chromaffin cells, Borisovska and colleagues showed that 
synaptobrevin II/VAMP-2 is the major v- SNARE critical for catecholamine release from 
chromaffin cells. However, its loss could be efficiently compensated for by VAMP-3. 
Similarly, VAMP-2 could compensate in the absence of VAMP-3. The catecholamine 
secretion was completely abolished in V-2/3-/- animals indicating that other residual 
VAMP isoforms could not efficiently override the effect of V-2/3 loss (Borisovska, Zhao 
et al. 2005). 
This pattern of functional redundancy in SNAREs is also observed in neutrophils. 
The secretion of various types of cytoplasmic granules in human neutrophils is mediated 
by distinct combinatorial SNARE complexes. Specific and tertiary granules which are 
readily exocytosed upon stimulation are under the control of VAMP-1, VAMP-2, 
syntaxin-4, and SNAP23, while the release from azurophilic granules was mediated by 
VAMP-1, VAMP-7, and syntaxin-4. This suggests that differential mobilization of a 
distinct type of granule is facilitated by the quantitative and qualitative difference in 
combinatorial SNARE complexes formation. This diversity in SNARE complexes aids the 
rate and the degree of secretion (Mollinedo, Calafat et al. 2006). 
In myoblasts, VAMP-2 but not VAMP-3 has been shown to mediate insulin-
stimulated Glucose Transporter/GLUT4 translocation to the plasma membrane 
(Randhawa, Bilan et al. 2000). In adipocytes, GLUT4 is found in two pools of vesicles- 
endocytic pool (including trans-Golgi network) and non-endocytic pool that consists of 
special vesicles called GLUT4 storage vesicles (GSVs). Millar and colleagues showed that 
these different pools of vesicles release GLUT4 in agonist-dependent and VAMP 
isoform-dependent manner. VAMP-3 facilitates GLUT4 translocation from the 
endosomal pool in a guanosine-59-O-(3-thiotriphosphate) (GTPγS) dependent manner 
while VAMP-2 is important for insulin-stimulated GLUT4 translocation. VAMP-3 is also 
associated with both insulin and GTPγS stimulated GLUT1 translocation contrary to 
VAMP-2 which does not have any impact on GLUT1 translocation (Millar, Shewan et al. 
1999).  
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In human mast cells, VAMP-7 and VAMP-8 translocate to the plasma membrane 
upon IgE stimulation and play central roles in the release of histamine granules while 
VAMP-2 and VAMP-3 are dispensable (Sander, Frank et al. 2008). The role of VAMP-8 in 
mast cell degranulation was further supported by another study. Using bone marrow-
derived mast cells (BMCC) from VAMP-8-/- mice, Tiwari et al., showed that VAMP-8 is 
crucial for mast cell degranulation but not for cytokine/chemokine release. However, 
there is some residual secretion in absence of VAMPs suggesting a compensatory 
mechanism. Co-immunoprecipitation studies indicated an increased presence of VAMP-
2/SNAP23 complexes in VAMP-8 deficient platelets suggesting a compensatory role for 
VAMP-2 (Tiwari, Wang et al. 2008). However, the lack of direct evidence fails to support 
this possibility. 
The data gleaned from all these studies could be interpreted as- 
1. Various SNARE isoforms, both v- and t- SNAREs play redundant roles in secretion 
and trafficking.  
2. Despite their different intracellular locations and dissimilar structures, they can 
compensate for each other in vitro and in vivo, albeit sometimes less efficiently. 
3. Though they are thought to be important for vesicle fusion specificity, they 
might not be the only contributing factors. 
However, it is not yet clear if this redundancy in the roles of SNAREs could be 
due to the quantity at which they are expressed in these tissues or if it is because of 
their structural attributes. 
Recently, using V-2-/-, V-3-/- and V-2/3-/-  model systems, Schwarz, et al., showed 
that though both VAMP-2 and VAMP-3 are expressed in cultured hippocampal 
astrocytes, their expression is limited to distinct subcellular organelles. VAMP-2 is 
preferentially found at the cells’ periphery while VAMP-3 is scattered throughout the 
cytoplasm. VAMP-2 is located on glutamatergic vesicles and is responsible for their 
release while VAMP-3 is associated with endogenous large dense core vesicles/LDCV 
and contributes to the release of marker protein neuropeptide Y/ NPY from them 
(Schwarz, Zhao et al. 2017). NPY secretion was unaltered in V-2-/- astrocytes but was 
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completely abolished in V-3-/- and V-2/3-/- astrocytes. Conversely, glutamate release was 
affected in V-2-/- and V-2/3-/- astrocytes. Further investigation showed that neuronal 
glutamatergic signaling was influenced by both VAMP dependent pathways. This report 
points to a possibility that VAMP isoforms may facilitate opposing pathways to regulate 
a process. 
Subsection Four: Intracellular trafficking in platelets 
Intracellular trafficking of vesicles carrying proteins, lipids and various cargo is 
critical for the growth, function, and survival of cells. This process is crucial for cells to 
sense (through endocytosis) and react (through exocytosis) to their environment. 
Platelets contain clathrin-coated vesicles (King and Reed 2002) and endocytose IgG, 
albumin and fibrinogen (Handagama, Shuman et al. 1989) mainly through integrin 
αIIbβ3 receptors. In fact, Klinger et al., showed that fibrinogen, vWF and fibronectin co-
localize with clathrin-coated vesicles (Klinger and Kluter 1995). Platelets also endocytose 
and recycle purinergic receptors P2Y1 and P2Y12 (Cunningham, Nisar et al. 2013). 
Behnke showed that fibrinogen (alpha granule marker) is endocytosed through a 
clathrin-dependent pathway while acid phosphatase (lysosomal marker) is endocytosed 
through clathrin-independent pathway indicating that human platelets can implement 
both of these pathways (Behnke 1992).  
Clathrin-dependent endocytosis- 
Platelets contain dynamin, disabled, and dynamin-related protein which are 
components of the clathrin-dependent endocytosis machinery. Dynamin 2 is the 
predominant form present in murine platelets and mutations in dynamin 2 are 
associated with Charcot- Marie- Tooth disease (Zuchner, Noureddine et al. 2005). 
Bender et al., used a platelet-specific KO mouse model to study its role in 
hematopoiesis. These animals have severe thrombocytopenia, macrothrombocytopenia, 
and increased abundance of clathrin-coated vesicles (Bender, Giannini et al. 2015). 
Koseoglu et al., showed that dynamin-related protein-1 regulates fusion pore stability 
during platelet granule secretion (Koseoglu, Dilks et al. 2013). 
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Clathrin-independent endocytosis-  
This mode of endocytosis is further divided into dynamin-dependent (caveolae 
and/or Rho families of GTPases) and dynamin-independent (Cdc42 and ADP-ribosylation 
factor (Arf) families of small GTPases). Using a megakaryocyte-specific RhoA deficient 
mouse model, Pleines et al., showed that RhoA deficiency leads to 
macrothrombocytopenia and granule secretion defects. RhoA is crucial for integrin-
mediated clot retraction but not for platelet spreading on fibrinogen. These animals had 
a severe hemostatic deficiency but also were protected from arterial thrombosis 
indicating that RhoA is an essential component of platelet function (Pleines, Hagedorn 
et al. 2012). 
Platelets contain multiple ADP ribosylation factor/Arf isoforms-Arf1, Arf3, and 
Arf6 (Burkhart, Schumbrutzki et al. 2012). Using a platelet-specific Arf6 KO mouse model 
Huang et al., showed that fibrinogen uptake was significantly decreased in these 
platelets in both in vitro and in vivo analysis. Arf6 deficiency led to increased spreading 
and faster clot retraction suggesting its role in endocytic trafficking. Arf6 deficiency does 
not affect platelet secretion, tail bleeding time or thrombosis indicating that it is 
dispensable for platelet exocytosis. This feature makes these mice an important tool to 
study endocytosis without affecting exocytosis (Huang, Joshi et al. 2016).  
SNAREs in intracellular trafficking in platelets- 
The role of SNAREs in vesicular trafficking was first uncovered in yeast studies 
(Nichols and Pelham 1998). Since then, monumental work has shown that multiple 
members of SNARE family facilitate almost every stage of endocytosis, trafficking and 
homotypic and heterotypic fusion events inside diverse types of cells including plants 
(Fujiwara, Uemura et al. 2014), Drosophila (Morelli, Ginefra et al. 2014), and 
macrophages (Murray, Kay et al. 2005, Murray and Stow 2014). 
In platelets, however, the picture is not yet clear. As discussed above, VAMP-8 
has been shown to play a role in homotypic early or late endosome fusion events while 
VAMP-7 is vital for heterotypic endosome to lysosome fusion events. However, animals 
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deficient in VAMP-8 (Ren, Barber et al. 2007), VAMP-7, (Koseoglu, Peters et al. 2015), 
syntaxin-8 (Golebiewska, Harper et al. 2015) or munc 13-4 (Ren, Wimmer et al. 2010) 
did not exhibit any accumulation of transport vesicles or cargo deficiency. Similarly, 
extensive studies that investigated the roles of t- SNAREs and SNARE regulators did not 
find any significant cargo level defects (Al Hawas, Ren et al. 2012, Ye, Karim et al. 2012, 
Karim, Zhang et al. 2013). This suggests that either these proteins may play a role in 
trafficking but are compensated for by other isoforms. Recently, our lab showed that 
VAMP-3 plays a major role in endocytosis of fibrinogen and this is crucial for an 
immunogenic response from platelets (Banerjee, Joshi et al. 2017). 
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Table 1.3 Summary of various molecules crucial for platelet secretion 
Protein/ 
strain 
Dense 
(%)  
ATP 
Release (%) 
Aggregation 
(%) 
Alpha  
(%) 
Lysosome 
(%) 
Bleeding  Thrombosis Reference 
WT 100 100 100 100 100 no No  
V-3 100 100 100 100 100 no No (Schraw, Rutledge et al. 
2003) 
V-7 70 50 30-40 55 NA no No (Koseoglu, Peters et al. 2015  
V-8 Het 100 100 100 100 100 no No (Ren, Barber et al. 2007) 
V-8 70 50 80? 30 35 no Delayed (Ren, Barber et al. 2007) 
V-2/3 100 90 100 100 90 no No Joshi et al. (unpublished)  
V-8 het2/3 100 90 100 100 90 no No Joshi et al. (unpublished) 
V-2/3/8 40 30 80 15 20 +++ +++ Joshi et al. (unpublished) 
Syntaxin 2/4 100 NA 100 100 100 no no (Ye, Karim et al. 2012) 
Syntaxin 11 0 0 10-60 0 40 +++ NA (Ye, Karim et al. 2012) 
Syntaxin 8 50 50 70 100 100 no Embolism 
increased 
(Golebiewska, Harper et al. 
2015) 
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Protein/ 
strain 
Dense 
(%)  
ATP 
Release (%) 
Aggregation 
(%) 
Alpha  
(%) 
Lysosome 
(%) 
Bleeding  Thrombosis Reference 
SNAP 29 NA 100 100 90 NA NA NA (Williams, Savage et al. 
2016) 
Munc 18b 
 
0 0 NA 0 50 variable NA (Al Hawas, Ren et al. 2012) 
Munc 13-4 0 0 50 25 25 +++ NA (Ren, Wimmer et al. 2010) 
Tomosyn 90 60 50 50 60 +++ +++ (Ye, Huang et al. 2014) 
serglycin 25 NA 50 100 NA NA +++ (Woulfe, Lilliendahl et al. 
2008) 
Alpha-synuclein 90 NA NA 80 90 No NA Whiteheart, unpublished 
Rab 27A 100 NA NA 100 NA No NA (Tolmachova, Abrink et al. 
2007) 
Rab 27B 76 NA 60 100 NA +++ NA (Tolmachova, Abrink et al. 
2007) 
Rab 27A/B 46 NA 60 100 NA +++ NA (Tolmachova, Abrink et al. 
2007) 
IKK-β 25 NA NA 30 30 +++ defect (Karim, Zhang et al. 2013) 
Cal DAG 20 NA 10 20 NA +++ +++ (Piatt, Paul et al. 2016) 
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Protein/ 
strain 
Dense 
(%)  
ATP 
Release (%) 
Aggregation 
(%) 
Alpha  
(%) 
Lysosome 
(%) 
Bleeding  Thrombosis Reference 
ROCK2 NA NA 30 60-90 NA +++ +++ (Sladojevic, Oh et al. 2017) 
HPS (pearl, pallid  
and light ear) 
0 0 0 25-30 20 NA +++ (Meng, Wu et al. 2015) 
NBEAL2 100 100 50 50 NA +++ +++ (Deppermann, Cherpokova 
et al. 2013) 
NBEAL2 NA NA 70-80 30 NA NA NA (Kahr, Hinckley et al. 2011) 
VPS33A NA 20 30 NA NA NA NA Suzuki et al, 2003 
VPS33B NA 50 50 NA NA +++ +++ (Xiang, Zhang et al. 2015) 
VPS33B NA 70 100 60 NA +++ +++ (Bem, Smith et al. 2015) 
SERT NA 50 50 NA NA NA NA (Carneiro, Cook et al. 2008) 
SGK-1  50 50 70 NA NA normal +++ (Walker, Schmid et al. 
2015) 
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Subsection Five: SNARE regulatory proteins 
SNAREs are essential for membrane fusion, but their associations to form 
membrane-fusing complexes are controlled temporally and spatially by several types of 
regulatory proteins and by post-translational modifications of the SNAREs themselves 
(Figure 1.4 and Table 1.2). Some SNARE regulators are chaperones (e.g., the Sec/Munc 
proteins), while others promote the apposition of fusing membranes, indirectly (or 
directly) affecting SNARE association (e.g., Munc13, Rabs, STXBP5/Tomosyn 1, 
SLP4/granuphilin, etc.). These so-called docking factors also affect where fusion occurs. 
Munc18b 
The Sec1/Munc18 (SM) family of cytosolic proteins is crucial for membrane 
trafficking and exocytosis. In mammals, the seven SM proteins act as syntaxin 
chaperones, targeting and directing the t-SNARES to form specific SNARE complexes 
(Archbold, Whitten et al. 2014, Rehman, Archbold et al. 2014). Platelets contain VPS33a 
and 33b, which are involved in dense and alpha-granule biogenesis, respectively 
(Huizing, Didier et al. 2001, Bem, Smith et al. 2015). Recently, Xiang et al., reported that 
VPS33b binds with the integrin β subunit and this can potentially regulate αIIbβ3 
mediated fibrinogen endocytosis, platelet activation, spreading, clot retraction, platelet 
aggregation and in vivo hemostasis and thrombosis (Xiang, Zhang et al. 2015). Platelets 
also contain Munc18a, Munc18b, and Munc18c (STXBP1, 2, 3); however, Munc18b is 
significantly more abundant (Table 1.2 and (Al Hawas, Ren et al. 2012). Previous studies 
suggested that Munc18c contributes to platelet secretion by interacting with syntaxin-4 
(Houng, Polgar et al. 2003); however, platelets from Munc18c+/- mice have normal 
secretion indicating that partial loss (~30%) of this isoform is insufficient to depress 
secretion (Schraw, Crawford et al. 2004). Recent studies of FHL type 5 patients, which 
have defects in the gene encoding Munc18b, show that Munc18b is critical for platelet 
secretion from all three granule types (Al Hawas, Ren et al. 2012) (Table 1.3). Consistent 
with Munc18b’s role as a chaperone, deficient platelets showed a decrease in syntaxin-
11; no other syntaxins were affected. Platelets from biallelic patients have robust 
secretion defects and heterozygous patients have intermediate deficits. Such 
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haploinsufficiency suggests that Munc18b is limiting for the secretion process in 
platelets. Consistently, semi-quantitative western blotting data suggest that syntaxin-11 
and SNAP23 are in molar excess over Munc18b in human platelets (Al Hawas, Ren et al. 
2012, Ye, Karim et al. 2012). Several reports suggest that the Munc18s are 
phosphorylated in platelets and that phosphorylation affects Munc18/syntaxin 
interactions (Reed, Houng et al. 1999, Houng, Polgar et al. 2003, Schraw, Lemons et al. 
2003). However, many of the studies focused on Munc18c, whose role in secretion is 
uncertain. Detailed studies of Munc18b phosphorylation in platelets have not been 
done. 
STXBP5/Tomosyn 1 
Another t-SNARE regulator is Syntaxin Binding Protein 5 (STXBP5), also known as 
Tomosyn 1, meaning friend (tomo) of syntaxin (Fujita, Shirataki et al. 1998). In neurons, 
STXBP5 is a negative regulator of exocytosis. STXBP5 contains WD-40 repeats, which are 
thought to interact with the cytoskeleton (Ashery, Bielopolski et al. 2009). C-terminal of 
these repeats is a variable linker region with multiple predicted phosphorylation sites. 
Adjacent to the linker is a v-SNARE-like domain that interacts with t-SNARE 
heterodimers (e.g., syntaxin-11/SNAP23) and is thought be a regulatory “place-holder”. 
Consistently in platelets, STXBP5 antibody only precipitated t-SNAREs but no VAMPs (Ye, 
Huang et al. 2014). Surprisingly, platelet secretion is significantly diminished in platelets 
lacking STXBP5 (Table 1.3). Mice lacking STXBP5 showed a robust bleeding diathesis that 
exceeded expectations based on their secretion defect. The bleeding was due to 
defective platelet secretion based on bone marrow transplantation studies. 
A recent GWAS linked polymorphisms in the STXBP5 gene to increased plasma 
vWF and thus to an increased risk of cardiovascular diseases (Smith, Rice et al. 2011) 
(van Loon, Leebeek et al. 2010), which conflicts with the phenotype of the KO mice. 
Lowenstein and colleagues resolved this inconsistency by showing that STXBP5 
negatively regulates Weibel Palade Body release from endothelial cells. Consistently, the 
KO mice had increased plasma vWF (Zhu, Yamakuchi et al. 2014). Interestingly, 
rs1039084, a non-synonymous single nucleotide polymorphism (SNP) in the STXBP5 
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gene, correlated with increased bleeding (van Loon, Sanders et al. 2012). Taken 
together, these data suggest that STXBP5 is a critical regulator of vascular health and 
plays distinct roles in both endothelial cells and platelets. 
Tethering and docking factors 
The factors discussed above directly control SNAREs; however, there are other 
factors that control secretion by affecting docking/tethering of granules to exocytosis 
sites. Many of these regulators are recruited from the cytosol through interactions with 
lipids and/or membrane proteins to promote SNARE engagement and enhance 
membrane fusion. The relevance of granule docking in platelets is understudied; 
however, dense granules do appear “docked” in resting platelets, which may account 
for their rapid release (Chicka, Ren et al. 2016).  
Rab27 
Rab27a/b are small GTPases that direct granule docking and tethering in many 
secretory systems (Fukuda 2013). In a seminal study using Rab27a−/- (ashen), Rab27b−/- 
and Rab27a/b−/- mice, Seabra and colleagues (Tolmachova, Abrink et al. 2007) showed 
that only mice homozygous for Rab27b loss had a significant bleeding diathesis. Loss of 
Rab27a alone affected pigmentation but not bleeding. Detailed studies showed that 
Rab27b was important for dense granule release, but its loss had no effect on P-selectin 
exposure (alpha-granule release) (Table 1.3). Rab27b did appear to contribute to dense 
granule biogenesis since endogenous serotonin levels were lower in Rab27b−/- platelets, 
irrespective of Rab27a’s presence. Since platelets contain both Rab27a and b, it appears 
that some level of compensation does occur, but it is not complete. Given the 
interactions between Rab27 and other elements discussed below (i.e. SLPs and Munc13-
4), this small GTPase is a key to dense granule release in platelets. 
Munc13-4 
Munc13 proteins are a family of multi-domain proteins, not to be confused with 
the Munc18 proteins. Munc13s contain a characteristic Munc Homology Domain (MUN) 
domain and, at least, two calcium/ lipid-binding C2 domains. Some also contain 
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calmodulin and diacylglycerol (DAG) binding sites (Rizo and Xu 2015). Munc13s have 
been described as “priming factors” which promote trans-SNARE complex formation 
(James and Martin 2013, Rizo and Xu 2015). We classify Munc13-4 together with 
tethering factors due to its effects on platelets and in vitro assays, discussed below. 
Munc13-4 is a known Rab27 effector (Fukuda 2013). In vitro studies with liposomes 
show that Munc13-4 bridges, but does not fuse, membranes in a calcium-dependent 
manner (Chicka, Ren et al. 2016). This clustering requires both C2 domains. Secretion is 
dramatically abolished in Munc13-4−/- platelets. Consistently, Munc13-4−/- mice have a 
significant bleeding diathesis (Ren, Wimmer et al. 2010). Quantitative analysis suggests 
that Munc13-4 may be limiting (Table I.2), which was confirmed by titration 
experiments using permeabilized Munc13-4−/- platelets and in Munc13-4+/- mice which 
had an intermediate phenotype. Loss of Munc13-4 also increased the in-situ mobility of 
dense granules, which is consistent with its role as a docking/tethering factor (Ren, 
Wimmer et al. 2010). Parenthetically, these results imply that dense granules are pre-
docked in resting platelets, perhaps accounting for their rapid release rates. 
Although Munc13-4 clearly plays a role in dense granule release, its role in α-
granule and lysosome release is less certain. Ren et al., (Ren, Wimmer et al. 2010) 
showed that the alpha granule and lysosome release defects in Munc13-4−/- platelets are 
less apparent at higher secretagogue concentrations. Poole and colleagues showed that 
ADP addition overrides much of the α-granule secretion defect (Harper, van den Bosch 
et al. 2015). These data underline the fact that dense granule secretion deficiency 
precipitates defects in α-granule and lysosome release; a point that has been noted by 
others (Meng, Wu et al. 2015, Sharda, Kim et al. 2015). Thus, the autocrine signaling 
from released ADP plays a critical role in modulating α-granule and lysosome release. 
As in platelets, Munc 13-4 also plays a role in mast cell degranulation (Rodarte, 
Ramos et al. 2017). Using global and mast cell-specific KO murine models, Rodarte et al 
showed that Munc 13-4 is a crucial component of mast cell exocytosis that facilitates 
compound fusion. Although another isoform Munc 13-2 is present and in some degree 
could compensate for Munc 13-4, it cannot compensate for all its functions. 
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Synaptotagmin-like proteins 
Rab effectors such as synaptotagmin-like-proteins (SLPs) are present in platelets 
and appear to have both stimulatory and inhibitory roles (Fukuda 2013). Using a yeast 
two-hybrid assay, Smolenski and colleagues showed that SLP1 forms a trimeric complex 
with Rap1, a Ras-like GTPase, and the Rap GTPase activating factor RAP1GAP2. SLP1 had 
a negative effect on dense granule release from permeabilized platelets while 
RAP1GAP2 addition increased release (Neumuller, Hoffmeister et al. 2009). The same 
group showed that SLP4/granuphilin interacts with Rab8 in human platelets and its 
addition to permeabilized platelets enhanced dense granule release (Hampson, 
O'Connor et al. 2013). This enhancement required SLP4 binding to Rab8. SLP4 is also a 
Rab27 effector (Fukuda 2013) and interacts with Munc18/Syntaxin complexes in 
platelets  (Ye, Huang et al. 2014). SLP proteins contain calcium/lipid-binding, C2 domains 
and thus could serve as calcium sensors. Despite these data, a clear mechanistic 
understanding of their function is still lacking. 
Sorting complexes 
Tethering/Sorting complexes appear to be important for granule biogenesis 
(Masliah-Planchon, Darnige et al. 2013); however, it is unclear how such complexes 
influence exocytosis. One potential example, the Exocyst, is thought to be important for 
polarized secretion  (Liu and Guo 2012). Exocyst is a conserved octameric complex that 
directly interacts with SNAREs and SM proteins (Wu and Guo 2015). Platelet proteomics 
studies show that the Exocyst subunits are expressed in stoichiometric amounts (Table 
1.2; (Burkhart, Schumbrutzki et al. 2012)). The Exocyst is targeted to mammalian cell 
membranes via an interaction with a prenylated, ras-like GTPase called Ral (Gentry, 
Martin et al. 2014). Ral is expressed in platelets and is activated to its GTP-bound state 
following thrombin-treatment (Wolthuis, Franke et al. 1998). There are two Ral 
isoforms, A and B; both are present in platelets. Horiuchi and colleagues showed that by 
blocking Ral- GTP binding to the Sec5/Exoc2 subunit, they could inhibit GppNHp-induced 
dense granule release from permeabilized platelets (Kawato, Shirakawa et al. 2008). 
Consistently Ral and Exocyst interact in thrombin-stimulated platelets. Despite these 
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insights, there are many unanswered questions about the roles of Ral and Exocyst. Does 
the presence of Exocyst imply some polarization of platelet secretion? Ral A and B have 
distinct functions in other systems (Shirakawa and Horiuchi 2015). Will that be true in 
platelets as well? Given the development of Ral inhibitors as anti-cancer drugs (Yan, Liu 
et al. 2014), it seems important that the roles of this protein and the Exocyst be 
determined to appreciate how these drugs might affect platelet function. 
NSF and SNAPs 
The first membrane trafficking proteins purified were the AAA+ ATPase, N-
ethylmaleimide Sensitive Factor (NSF) and its adaptors, the Soluble NSF Attachment 
Proteins (SNAPs) (Block, Glick et al. 1988, Clary, Griff et al. 1990). These proteins 
disassemble spent SNARE complexes, post-fusion, and thus are critical for SNARE 
recycling (Zhao, Smith et al. 2012). Lemons et al., (Lemons, Chen et al. 1997) first 
reported their presence in platelets and Polgar et al., (Polgar and Reed 1999) showed 
that inhibitory peptides that blocked NSF activity also blocked release from 
permeabilized platelets. Consistently, nitrosylation reversibly inhibits platelet NSF, 
accounting for a portion of the inhibitory effect of NO on platelet exocytosis (Morrell, 
Matsushita et al. 2005). Initially, NSF’s role was contentious since platelet exocytosis 
was thought to be a “one-shot” event; thus, there was no need to recycle spent SNAREs. 
Subsequent studies suggest that platelets have multiple, membrane fusion/ trafficking 
processes (i.e. endocytosis, autophagy, etc. (Ouseph, Huang et al. 2015, Huang, Joshi et 
al. 2016) explaining the presence of NSF and SNAPs. However, their role in recycling 
SNAREs for exocytosis is still puzzling. 
Actin cytoskeleton in platelet secretion 
Upon agonist stimulation, platelets change shape before undergoing secretion. 
These instigated investigations into the role of the platelet cytoskeleton in secretion. 
Resting platelets contain about 40% filamentous actin/F actin which dramatically 
increases up to 80% upon stimulation. Multiple reports suggested that the inhibition of 
actin polymerization by latrunculin A or cytochalasins (Cox 1988, Flaumenhaft, Dilks et 
al. 2005) or cleavage of F-actin by scinderin leads to increased dense granule (Marcu, 
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Zhang et al. 1996) and alpha-granule release (Flaumenhaft, Dilks et al. 2005) suggesting 
inhibitory role of actin polymerization in platelet granule secretion. Contrary to these 
findings, Woronowicz et al., showed that inhibition of actin polymerization prevents 
alpha-granule release (Woronowicz, Dilks et al. 2010). t- SNARE SNAP23 associates with 
the actin cytoskeleton in resting and activated states, however, it is not clear how this 
association plays a role in secretion. 
Post-translational modifications of the secretory machinery 
There have been several reports of phosphorylation of platelet secretory 
machinery components (e.g., syntaxin-4, Munc18, STXBP5, etc.), although few have 
definitively linked modifications to exocytosis control (Houng, Polgar et al. 2003, Polgar, 
Lane et al. 2003, Schraw, Lemons et al. 2003). One example where phosphorylation 
clearly affects function is the phosphorylation of SNAP23 by IκB kinase (IKK). Originally 
seen in mast cells, IKK phosphorylates specific serines (Ser95) on SNAP23, which affects 
SNARE complex dynamics (Cabaniols, Ravichandran et al. 1999, Hepp, Puri et al. 2005, 
Puri and Roche 2008, Suzuki and Verma 2008, Karim, Zhang et al. 2013). 
Consistently, platelet-specific deletion of IKKβ or treatment with IKK inhibitors 
blocks platelet secretion from all three granules and leads to a bleeding diathesis 
(Karim, Zhang et al. 2013). In vitro studies with SNARE-containing proteoliposomes 
suggest that SNAP23 phosphorylation enhances membrane fusion rates, though it is not 
required for fusion. Immunoprecipitation studies show that phospho-SNAP23 
preferentially incorporates into SNARE complexes in activated platelets. 
Another noteworthy post-translational modification is acylation. Proteomics 
studies had identified a number of acylated proteins in platelets that have thioester-
linked fatty acids attached to cysteines (Dowal, Yang et al. 2011). This is particularly 
important to syntaxin-11 and SNAP23, which lack classical transmembrane domains 
(TMD) but behave as membrane proteins. Both t-SNAREs contain cysteine-rich domains 
(at the C-terminus for syntaxin-11 and between the two SNARE domains in SNAP23) that 
are thought to be acylated. Consistently, treatment of platelet membranes with a 
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thioesterase releases SNAP-23 and affects secretion in permeabilized platelets (Sim, 
Dilks et al. 2007). The significance of t-SNARE acylation is yet to be understood; 
however, since neither SNARE has a classical TMD, acylation must affect membrane 
fusogenicity. Studies using reconstituted proteoliposome fusion assays show that t-
SNARE TMDs can be functionally replaced by lipid moieties so long as they are 
hydrophobic enough. C15 prenyl groups are not sufficiently hydrophobic but C55 groups 
are (McNew, Weber et al. 2000). Both SNAP23 and syntaxin-11 have multiple potential 
acylation sites; however, it remains to be determined the extent to which t-SNARE 
acylation occurs and is controlled in platelets. In other cell types, removal or 
modification of the t-SNARE cysteine-rich domains does affect secretion (Valdez, 
Cabaniols et al. 1999, Salaun, Gould et al. 2005). 
A recent study by Malmersjo and coworkers suggest that in mast cells, VAMP-8 is 
phosphorylated by PKC (Malmersjo, Di Palma et al. 2016). This phosphorylation occurs 
at multiple residues in a SNARE domain of VAMP-8 and is inhibitory to in vitro and in 
vivo fusion events. Interestingly, the authors also report that these phosphorylation 
motifs are absent in all eukaryotic neuronal VAMPs but present in all non-neuronal ones 
indicating a special secretion regulatory mechanism in non-neuronal cells. 
Subsection Six: Importance of platelet secretion 
As discussed in earlier sections, platelet granule secretion is a critical central 
event that shapes thrombus composition downstream. The importance of this event is 
highlighted by following facts:  
1. Granulopathies- As discussed in detail in previous sections, dense (CHS and HPS) 
granulopathies present a severe bleeding defect while alpha (GPS and ARC) 
granulopathies display a wide array of bleeding diathesis ranging from mild to severe 
defects. This demonstrates that the lack of granule cargo or the failure to release these 
cargoes does have a significant impact on hemostatic balance. 
2. SNPs in VAMPs – Single nucleotide polymorphisms in the VAMP-8 gene may 
potentially affect its expression and are associated with hyperreactive platelets. These 
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events are associated with high susceptibility to acute myocardial infarction. This 
suggests that increased secretion by hyperreactive platelets could skew the hemostatic 
balance leading to hyper-thrombotic events. 
3. Immunological response- Multiple reports indicate that platelets act as immune cells 
(Semple, Italiano et al. 2011, Manne, Xiang et al. 2017) by sensing their micro-
environment by endocytosis and take up viral particles (Simon, Sutherland et al. 2015) 
and bacteria (Gaertner, Ahmad et al. 2017). Consequently, the release of cytokines and 
chemokines from alpha granules and P-selectin exposure help recruit professional 
phagocytic cells to clear up the infection (Etulain, Martinod et al. 2015). Evidently, 
secretion-deficient platelets fail to generate this immune response underlining the 
significance of platelet secretion in immunity and infection (Hwaiz, Rahman et al. 2015). 
In fact, antiplatelet therapies are being tapped to modulate platelet-leukocyte immune 
responses (Evangelista, Manarini et al. 2005). 
4. B cell sialylation- Increasing evidence suggests that the impact of platelet secretion 
may not be limited to only hemostasis and thrombosis. Platelet secretion does play a 
role in facilitating B cell-independent sialylation of IgG by providing necessary substrate 
(CMP-sialic acid) (Jones, Oswald et al. 2016). 
Subsection Seven: Future directions 
Though the relevance of SNAREs is established, the protein-protein interactions 
leading to membrane fusion are not completely defined in platelets. Examples are 
dynamin and the dynamin-related proteins, which affect fusion pore opening and thus 
cargo release (Koseoglu, Dilks et al. 2013). Clearly, there are more secretory machine 
elements yet to be identified, especially given that we have not filled the gaps between 
known signaling cascades and secretory machinery. 
As implied by the phenotypes of the platelets lacking specific SNAREs (V-7-/-, V-8-
/-, syntaxin-8-/-, and syntaxin-11/ FHL4-/-), it seems possible that more than one SNARE 
complex may mediate granule release. Future studies should focus on determining if 
different SNARE combinations convey distinct properties to specific membrane fusion 
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events. It seems possible that some complexes will be more fusogenic than others and 
thus could fine-tune release kinetics by facilitating single or compound fusion event, 
preferentially and perhaps alter platelet releasate composition. 
A major question is, “How is secretion controlled by calcium?”. Calcium is critical 
to most regulated secretory processes; yet in platelets, there are no clear calcium 
sensors that affect secretion. Synaptotagmins, which are calcium sensors in neurons 
have not been characterized in platelets (Rizo and Xu 2015). Platelets contain several 
proteins which contain calcium-binding domains (C2 domains like synaptotagmins) or 
can be phosphorylated by Protein Kinase C. However, direct mechanistic data are 
lacking. 
A second consideration is whether platelet exocytosis is polarized. While at first 
glance, it may seem unlikely, there is clear polarity once platelets are adherent. Given 
the core and shell architecture of a  growing thrombus  (Welsh, Stalker et al. 2014), it’s 
plausible that cargo release is oriented: either toward the vascular wall to affect wound 
healing or toward the vessel lumen to recruit more platelets. Sakurai et al., showed that 
platelet secretion orients to the boundary of a fibrinogen-coated micro-dot to facilitate 
spreading beyond the dot’s edge (Sakurai, Fitch-Tewfik et al. 2015). Additionally, in an 
elegant study, Gaertner and colleagues showed that platelets actively migrate at the site 
of vascular injury and this ability is crucial for their ‘immune cell’ like behavior to collect 
bacteria and aid neutrophil activation (Gaertner, Ahmad et al. 2017). In the context of 
VAMPs, the work of Peters et al., (Peters, Michelson et al. 2012) clearly shows that 
VAMP-8- and VAMP-7-positive granules spatially segregate; is that to mediate different 
release events? Given VAMP-7’s role in spreading and the importance of Ral and 
Exocyst, perhaps the answer is yes.  
Finally, are granules the only things secreted from platelets? Cargoes that are 
generally thought to be markers of cellular organelles (i.e., sugar nucleotides from Golgi; 
Protein Disulfide Isomerase from ER; etc.) are detected in platelet releasates and are 
functionally relevant (Wandall, Rumjantseva et al. 2012, Lee, Nasirikenari et al. 2014, 
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Crescente, Pluthero et al. 2016). Do these release events use the same machinery as 
granules? These are exciting questions that get to the very heart of platelet cell biology 
and its importance. Their answers are destined to change our views of platelet function 
and hemostasis. 
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The focus of the dissertation 
Platelets are crucial for a multitude of pathophysiological processes including 
hemostasis, thrombosis, wound healing, angiogenesis, microbial defenses, and 
immunity, among others. Platelets participate in these processes by releasing their 
granule cargo to modulate the vascular microenvironment. Though a plethora of 
molecules has been identified and credited for platelet secretion (Table 1.3), it remains 
to be seen how secretion takes place on a molecular level and how much secretion is 
sufficient to achieve an ideal hemostatic balance. The work presented in this 
dissertation addresses these questions. The first part of the dissertation discusses 
generation and characterization of platelet-specific VAMP KO mouse strains and how 
defective platelet secretion affects hemostasis. By titrating amounts and types of 
VAMPs in platelets we report for the first time how much secretion is necessary to 
prevent occlusive thrombosis without causing unwanted bleeding. This is the first 
quantitative study to present a therapeutic range that will help identify an optimal 
hemostatic balance. Moreover, these reagents are valuable for future studies to 
determine the contribution of platelets in various physiological and pathological 
processes. 
In the second part of the study, we examined in detail how the rates of alpha-
granule cargo are regulated. These rates decide the fate of thrombus composition and 
therefore should be controlled dynamically. Here using high-pressure freeze technology 
and 3D SIM, we show that progressive dissolution of cargo in time and agonist 
concentration-dependent manner affects platelet alpha-granule morphology during the 
fusion process. We also demonstrate that the degranulation is VAMP-dependent and 
follows granule fusion. 
This is a first comprehensive study investigating the molecular nature of platelet 
granule fusion and the regulation of granule cargo release along with physiological 
implications of this process on maintaining optimal hemostatic balance. Insights gleaned 
from this study are not only valuable to develop anti-platelet therapeutics but are also 
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crucial to determine the efficacy of these therapies on platelets and to determine the 
optimal dosage of medicine to maintain hemostatic balance.  
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Chapter 2 Materials and Methods 
Materials 
Reagents 
Apyrase, human fibrinogen, hirudin, and proteinase K were from Sigma (St. 
Louis, Mo). Thrombin, ADP, and CHRONO-LUME reagents were from Chronolog 
(Havertown, PA). U46619 and prostaglandin I2 (PGI2) was from Cayman (Ann Arbor, MI). 
Paraformaldehyde (P6148, Sigma-Aldrich), 70% glutaraldehyde was from Electron 
Microscopy Sciences (Hatfield, PA). Other reagents used were at least laboratory grade. 
Antibodies 
Mouse monoclonal antibodies against FITC-anti-CD62P and PE-anti-LAMP1 
antibody were from BD Biosciences (San Jose, CA). Rabbit anti-VMAT2 antibody, was 
from Abcam (Cambridge, MA). FITC-anti-CD41/CD61 antibody and PE-Jon/A antibody 
were from Emfret Analytics (Eibelstadt, Germany). Rabbit anti-fibrinogen antibody was 
from Dako (Glostrup, Denmark). Rabbit anti-RabGDI polyclonal antibody was generated 
by Dr. Tara Rutledge in our laboratory using recombinant RabGDIα as antigen (Rutledge 
and Whiteheart 2002). The anti-SNAP23 antibody, (Schraw, Rutledge et al. 2003) anti-
Arf 6 (Choi, Karim et al. 2006), and polyclonal anti-VAMP-8 (Ren, Barber et al. 2007) 
were as described previously. Monoclonal anti-VAMP-2 antibody (SP10) (catalog no-
NBP1-19332), Polyclonal anti-VAMP7 antibody (catalog no NBP2-41183), Polyclonal anti-
VAMP-3 antibody (catalog no NBP 300-510) were from Novusbio (Littleton, CO).  
Methods 
Murine Strains and Genotyping 
The following mice were used for the experiments described in this thesis. 
WT mice (C57BL/6 background), initially purchased from Jackson Laboratory and bred in 
our animal vivarium. 
Global VAMP-3-/- mice 
These mice were bred and genotyped as described (Schraw, Rutledge et al. 2003). 
Forward primer, (3F) 5’-CACAGGCACTCTGTTGCATT-3’, 
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Reverse primer, (6R) 5’-CCACACAGGCTCCTGATCTT-3’, 
Neo primer, (mutant allele) 5’-GAGCAGCCGATTGTCTGTTG-3’. 
The PCR reactions were run for WT (with 3F WT and 6R reverse) and for KO (with Neo 
and 6R reverse). The PCR yields a 500 bp DNA product for WT allele and a 750 bp one 
for the mutant allele. 
The PCR conditions for VAMP-3 reactions were: 94°C for 7 min for 1 cycle, followed by 
30 cycles of 94°C for 1 min, 60°C for 1 min and 72°C for 90 sec, and lastly 72°C for 10 min 
for 1 cycle. 
Global VAMP8 -/- mice 
These mice were a generous gift from Dr. Wanjin Hong (Institute of Molecular and 
Cellular Biology, Proteas, Singapore) and were bred and genotyped as described in 
(Wang, Ng et al. 2004). These mice were on a mixed background of 129 SvJ and 
C57/BL6. 
Primers and genotyping conditions – 
Forward primer- 5’ -GATCCTCTGCTGCCCGGCCTAAT-3’ and  
Reverse primer (WT allele)- 5’ -CCGTGGCTTCCAAGTCCTCTGTC-3’)  
Reverse primer (mutant allele) (5’ -GCCTGCAAAGGGTCGCTACAGAC-3’).  
The PCR reactions were 95°C for 7:00 min for 1 cycle, 95°C for 0:30 min, 65°C for 0:30 
min, 72°C for 1:00 min for 28 cycles, finally 72°C for 10:00 min for 1 cycle 
The PCR products for wild-type allele and mutant allele were 204 bp and 323 bp, 
respectively.  
 
 68 
 
 
Figure 2.1. Conditional expression of tetanus toxin light chain 
Conditional expression of Cre recombinase under control of megakaryocyte-specific PF4 
promoter facilitated removal of floxed stop cassette upstream of GFP- tetanus toxin 
light chain. 
(Schematic based on (Kim, Cook et al. 2009) RC- enhancer sequences used R26 and CAG.  
PF-Parallel fibers) 
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Platelet-specific VAMP-2/3 - /-  strain 
To specifically delete VAMP-2 and -3, we crossed a RC::PFtox strain from Dr. S. 
Dymecki (Harvard Medical School) with a PF4-Cre strain (from Dr. R. Skoda, Basel, (Tiedt, 
Schomber et al. 2007)) The RC::PFtox strain has a genomic insertion encoding the 
catalytic subunit of the tetanus toxin endopeptidase, which can be expressed upon Cre-
mediated excision of a STOP cassette. The STOP cassette consists of the 3′ portion of the 
yeast His3 gene, an SV40 polyadenylation sequence, and a false translation initiation 
codon followed by a 5′ splice donor site. The floxed STOP cassette is inserted between 
the promoter and tetanus toxin coding sequences of a transgene, ensuring that few, if 
any, transcripts containing the coding region are generated (Figure 2.1). Tetanus toxin 
specifically cleaves only VAMP-2 (Schiavo, Benfenati et al. 1992) and -3 (McMahon, 
Ushkaryov et al. 1993) This strategy was needed because VAMP-2-/- mice are embryonic 
lethal (Schoch, Deak et al. 2001) as are VAMP-3/8-/- mice (Whiteheart unpublished). 
These RC::PFtox/PF4Cre mice (referred to as V-2/3-/- in this manuscript) were further 
crossed with a VAMP-8-/- strain (referred to as V-8-/-) to create a 
RC::PFtox/PF4Cre/VAMP-8-/- strain (referred to as V-2/3/8-/-).  
Tetanus toxin harboring strain 
Platelet-specific conditional KO was made according to the strategy described by 
(Kim, Cook et al. 2009) (Figure 2.1). These mice were a generous gift from Dr. Susan M. 
Dymecki (Dept. of Genetics, Harvard Medical school).  
Primers and genotyping conditions- 
Forward primer -5’ GCCGATCACCATCAACAACTTC 3’ 
Reverse primer-5’ GCAGAGCTTCACCAGCAACG 3’ 
The PCR reactions were 94°C for 4:00 min for 1 cycle, 94°C for 0:30 min, 58°C for 0:30 
min, 72°C for 1:00 min for 35 cycles, finally 72°C for 5:00 min for 1 cycle 
PCR reaction yielding about 300 bp DNA production indicates the presence of tetanus 
toxin light chain. 
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Platelet factor 4 (PF4)/cre recombinase harboring strain  
These mice were a kind gift from Dr. Radek Skoda ( University Hospital Basel, 
Switzerland) (Tiedt, Schomber et al. 2007). 
Primers and genotyping conditions- 
Forward primer -5’ CCCATACAGCACACCTTTTG 3’ 
Reverse primer -5’ TGCACAGTCAGCAGGTT 3’ 
PCR reaction conditions were- 94°C for 7:00 min for 1 cycle, followed by 30 cycles of 
94°C for 1:00 min, 50° C for 1:00 min, 72°C for 1:30 min, and finally 72°C for 10:00 min 
for 1 cycle. 
PCR reaction yielding a 450 bp DNA product indicates the presence of PF4-cre gene. 
V-2/3/8-/- mice  
These mice were generated by a cross between platelet-specific V-2/3-/- and V-8-/-mice. 
Genomic DNA isolation from mouse tail tip 
Mouse tail tips (3-5 mm) from 3-4 weeks old weanlings were cut and digested 
overnight (O/N) in 400 µl of tail lysis buffer (50 μM Tris/HCl, pH 7.5, 100 μM EDTA, 100 
μM NaCl, and 1% SDS) containing 30 µl of 10 mg/mL proteinase K at 55° C. 
After digestion was completed, the solution was mixed with 200 μl saturated 6 
M NaCl and centrifuged at 13,000 x g for 30 min at room temperature (RT). The 
supernatant containing DNA was collected and mixed with equal volume of 100% 
ethanol. After incubation for 10 min at RT, DNA was pelleted down by centrifugation at 
13,000 x g for 10 min. DNA pellets were washed once with 1 mL 70% ethanol and then 
dried in a vacuum centrifuge for around 10 min. Genomic DNA was finally dissolved in 
50 μl autoclaved ddH2O. 
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Platelet preparation from mouse blood  
Mice were sacrificed by CO2 inhalation. About 120 µl of 3.8% sodium citrate in a 
1 mL syringe attached to 26 G needle was used to collect blood from the right atrium 
(final concentration 0.38%). Collected blood samples were diluted with 1:1 1X filtered 
PBS. Apyrase (0.2 U/mL) and PGI2 (10 ng/mL) was added and blood was incubated for 5 
min at RT. The samples were then centrifuged at 237 x g at RT. Platelet Rich Plasma 
(PRP) was collected, apyrase and PGI2 were supplemented and centrifuged at 657 x g to 
get platelet pellet. For secretion assays, PRP was incubated with 1uCi [3H] serotonin for 
30 min. Platelet pellet was resuspended in HEPES Tyrode buffer pH 6.5 (10 mM 
HEPES/NaOH, 5.56 mM glucose, 137 mM NaCl, 12 mM NaHCO3, 2.7 mM KCl, 0.36 mM 
KH2PO4, 1 mM MgCl2) with 0.2U/mL apyrase, 10 ng/mL PGI2, 1mM EGTA and 
centrifuged again at 657 x g to recover platelets. The platelet pellet was resuspended in 
HEPES Tyrode buffer pH 7.4. Platelet concentrations were measured using a Z2 Counter 
(Beckman Coulter, Inc., Miami, FL). 
Whole blood count to study hematological parameters 
Blood was drawn via cardiac puncture from KO and control WT littermates in 3.8 
% sodium citrate as described above and whole blood counts were performed using a 
Hemavet (Drew Scientific, Dallas, TX). Statistical analyses were done using the statistical 
software program in SigmaPlot (v13.0). 
Platelet counting  
Washed platelets prepared as described above were diluted 1: 20,000 in HEPES 
Tyrode’s buffer (pH 7.4). The platelet counts were measured in triplicates using a Z2 
Coulter particle counter and size analyzer (Beckman Coulter, Brea, CA). The final count 
was an average of triplicates. The concentration of platelets was adjusted as indicated in 
each experiment. 
Secretion measurement from mouse platelets 
To measure secretion, mouse platelets were collected and isolated as described 
above with incubation with [3H] serotonin (Perkin-Elmer Cetus Life Sciences, Boston, 
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MA). Platelet stock was made at a concentration of 2.5 x 108/mL and 0.7 mM CaCl2 was 
supplemented. After at least 5 min after adding CaCl2, 50 µl of this stock was aliquoted 
in 1.5 mL Eppendorf tubes. Platelets were stimulated with either different 
concentrations of thrombin (0.01, 0.05, 0.1, 0.5 U/mL) or different time points (15, 30, 
45, 60, 90, 120, and 300 sec). Hirudin (2X the concentration of thrombin) was used to 
stop the reaction. Samples were centrifuged at 16.2 x g for 2 min on tabletop centrifuge 
machine. The supernatant was removed to another tube and the pellet was incubated 
with 60 µL of lysis buffer (1% Triton X 100% in 1X PBS) for 45 min on ice. 
Dense granule secretion measurement-  
To measure secretion from dense granules, 25 µL of supernatant or pellet 
samples were added to 3 mL of scintillation cocktail (Econo-safeTM, Research Products 
International Corp, Mt. Prospect, IL) in vials. Protocol 16 was used to measure secretion 
from all the samples in a Tri-Carb 2100TR liquid scintillation analyzer (Beckman, 
Fullerton, CA). 
Alpha granule secretion measurement-  
To measure secretion from alpha granules, a commercial sandwich ELISA assay 
was performed as per the manufacturer’s instructions (R&D). Briefly, clear ELISA plates 
(Costar, #3369, Fisher Scientific) were coated with capture antibody against mouse PF4 
(concentration of antibody) overnight at RT. The next day, plates were washed and 
blocked with blocking buffer (1x PBS + 0.05% Tween twenty+ 1% BSA+5% sucrose) for an 
hour. After washes, diluted supernatant and pellet samples (reagent diluent recipe) 
were added to the plate and incubated at RT for two hours. Recombinant mouse PF4 
was plated in serial dilution to make a standard curve, with a maximum concentration of 
2 ng/mL. After washes, the plate was incubated with biotinylated detection antibody at 
RT for two hours. After washes, streptavidin-conjugated horseradish peroxidase was 
used to detect signal. Release was measured as percent release= [(amount in 
supernatant or pellet)/ (amount in supernatant + amount in pellet)] *100. 
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Lysosomal secretion measurement 
A colorimetric assay was used to measure the activity of β-hexosaminidase 
which is a soluble cargo in lysosomes on PNP gluconic substrate. Briefly, 6 µL of 
supernatant or 3 µL of pellet sample was mixed with 100 µL of citrate citrate-phosphate 
buffer (53.4 mM citric acid, 93.2 mM Na2HPO4, pH 4.5) containing 10 mM p-nitrophenyl-
N-acetyl-β-D- glucosaminide. These samples were incubated at 37°C in a parafilm 
sealed, 96 well plate for 18 hrs. These reactions were then stopped with 100 µL of 2 M 
NaOH. Using a Biotek Elx808 plate reader (BioTek Instruments Inc., Winooski, VT), the 
optical density of each well was measured at 405 nm. Release was measured as percent 
release= [(amount in supernatant or pellet)/ (amount in supernatant + amount in 
pellet)] *100. 
Platelet aggregometry 
Aggregation of washed platelets prepared as described above was measured 
using a Chrono-Log Model 460VS Lumi-aggregometer (Havertown, PA). Mice platelets 
(250 μL of 4 X 108/mL) were placed in siliconized glass cuvette (Chrono-log) with a metal 
stirring bar (Chrono-log), spinning at 800 rpm for 2-3 min at 37°C. Agonists were added 
to initiate platelet activation as indicated. The aggregation traces were monitored using 
Model 810 Aggro/Link computer interface and Aggro/Link software (Chrono-log). 
Platelet ATP release 
Agonist-stimulated ATP release from platelet dense-core granules was 
monitored by the luciferin/ATP-mediated luminescence using a Chrono-Log Model 
460VS Lumi-aggregometer (Havertown, PA). Washed murine platelets (250 μL, 4 x 
108/mL) were preincubated with 12.5 μL of Chrono-Lume reagent (Chrono-log) 
containing luciferin and luciferase for 2 min at 37°C. Addition of thrombin, collagen 
(Chrono- Log), or A2317 (Calbiochem, La Jolla, CA), initiated ATP release from platelets, 
ATP- driven activation of luciferase, followed by production of luciferin which was 
monitored by absorption at 560 nm. Luminescence traces along with aggregation were 
using the same interface and software. 
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Flow cytometry Analysis 
Washed murine platelets (20 µL of 1 x 108/ mL) were either in a resting state (no 
agonist) or were stimulated with thrombin (0.1 U/mL) for 2 min at room 
temperature/RT. The reaction was stopped with the addition of a 2-fold excess of 
hirudin. Platelets were incubated with 2.5 μL FITC-conjugated or PE-conjugated 
antibodies for 15-20 min at RT. The platelets were 10-fold diluted by adding HEPES-
Tyrode’s buffer (pH 6.5) and transferred to a polystyrene Falcon™ tube (BD Biosciences, 
San Jose, CA). Fluorescent intensity was measured using FACScan™ flow cytometer (BD 
Biosciences). The platelet population was detected by adjusting the voltages for forward 
light scattering (FSC; E-01/linear) and side light scattering (SSC; 450/linear). Fluorescent 
intensity was optimized by adjusting the voltages for excitation of blue (FITC) and red 
(PE) channels. Platelet fluorescent intensities were monitored using an acquisition and 
analysis application, CellQuest™ (BD Biosciences). A total of 10,000 events were 
analyzed and fluorescent intensities were plotted as a histogram with statistical values. 
Western blotting and quantification 
Mouse platelets were prepared from the indicated strains as described above. 
After adjusting to 1 x 109/mL, an equal volume of 2X SDS was added and the samples 
were boiled at 95°C for 5 min. The appropriate volume of this stock was loaded to 
achieve 5 x 107 platelets per well onto a 1.5 mm 10% or 12.5% SDS-PAGE gel and the 
separated proteins were transferred to Immobilon- P polyvinylidene fluoride (PVDF) 
membranes (Millipore Corp., Bedford, MA) for 1 hr at 100 V. The PVDF membrane 
containing the transferred proteins was first incubated with the blocking buffer (5% 
nonfat milk in TBST (25 mM Tris, 150 mM NaCl, 0.1% Tween-20, and pH 7.4)) for 1 hr. at 
RT and then in the indicated dilution of primary antibody (in Blocking Buffer) for 
overnight at 4°C. The membrane was washed with TBS-T - 10 min for 3 times and 
incubated with the 1:20,000 dilution of alkaline phosphatase -conjugated secondary 
antibody for 1 hr. at RT. After washing the membrane with TBS-T, Vista- ECF substrate 
(Amersham Biosciences) was incubated with the membrane for 5 min at RT. The 
proteins were visualized with a Typhoon 9400 scanner using excitation at 488 nm and 
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measuring emission at 532 nm and quantified using ImageQuantTL software (v 7.0, GE 
Healthcare). 
Antibody Arrays  
Proteome Profiler Mouse Angiogenesis Antibody Array (ARY 015; R&D Systems) 
was used according to the manufacturer’s instructions. Briefly, the nitrocellulose 
membranes were first incubated in blocking buffer for 1 hr. Platelet extracts (from 108 
platelets) were prepared in 1 ml lysis buffer (1% NP-40; 20 mM Tris-HCl, pH 8.0; 137 mM 
NaCl; 10% glycerol; 2 mM EDTA; and 10× protease inhibitor cocktail) and mixed with a 
cocktail of biotin-labeled detection antibodies against different individual angiogenesis-
related proteins. After incubation for 1 hr., the mixture of the platelet sample and 
detection antibodies were then incubated with nitrocellulose membranes O/N at 4°C. 
The membranes were washed 3 times with wash buffer and incubated with HRP-
conjugated streptavidin for 30 minutes. After washing the membranes 3 times, the 
signals for each array spot were detected with Supersignal ELISA Femto Maximum 
Sensitivity Substrate (Thermo-Scientific) using a ChemiDoc MP System (BioRad). The 
array experiments were run in duplicate. Fluorescence intensities for each spot were 
measured, the background was subtracted, and the KO/WT ratio was calculated for each 
strain and plotted using SigmaPlot (version 13.0; Systat Software Inc.). 
Spreading Assays 
Human fibrinogen-coated slides were prepared by incubating human fibrinogen 
(50 µgs/mL, Enzyme Research Laboratory) in 1X filtered PBS onto Nunc Lab - Tek II 16 
well chamber slide (Thermo Scientific) for overnight at 4°C. The slide was incubated with 
denatured 2% FBS (boiled for 10 min at 95°C) for at least one hr. Washed mouse 
platelets (2 x 107/mL) were prepared as explained earlier and resuspended in HEPES 
Tyrode buffer (pH 7.4) supplemented with 1 mM CaCl2. Platelet-poor plasma (1:100) 
was added in washed platelets before seeding the platelet suspension on the 
fibrinogen-coated slide. The plate was incubated at 37° C. After each time point (as 
indicated in figures- 30, 60, 90, 120 min), unbound platelets were removed by washing 
twice with HT 7.4 and spread platelets were fixed using 4% paraformaldehyde (in 1 X 
 76 
 
PBS) at 4°C for overnight. The next day, after two washes with HT 7.4, plastic sealing 
from the slide is removed with forceps. VectaShield preservative (Vector Laboratories) 
was mounted on a slide and Lab- Tek cover glass is placed. The cover glass was sealed 
with nail polish and samples were visualized using Nikon Eclipse E600 microscope 
(Nikon, Melville, NY) with a 100 X /1.40 Numeric aperture DIC H oil objective lens 
(Nikon). ImageJ (v1.48 NIH) software is used to measure the area of spread platelets.  
Tail Bleeding Assay 
Tail bleeding time was determined as described by (Ye, Huang et al. 2014). 
Briefly, 6-8-week-old mice were anesthetized using ketamine 75 mg/kg i.p. Anesthetized 
animals were kept in a 50 mL conical tube which was perforated for ventilation. A 
transverse incision was made with a scalpel at a position around 3 mm from the tip of 
the murine tail. To avoid operational error, the same person transected tails from all the 
animals. After incision, the tail was immediately immersed into a 15 mL tube filled with 
37°C normal saline. The time from incision to bleeding cessation was recorded as the 
bleeding time. After initial cessation of bleeding, mice were observed for additional 1 
min to exclude re-bleeding. Tails of animals with bleeding times greater than 10 min 
were stopped manually by applying pressure. 
FeCl3-induced arterial thrombosis assay 
FeCl3-induced arterial thrombosis is a method to analyze platelet functional 
defects in vivo. This model is believed to be one of the better models to mimic 
endothelial denudation because it generates a controlled and localized vascular damage 
that the platelets respond to (Hechler, Nonne et al. 2010). Briefly. 8-12 weeks old mice 
were anesthetized with Avertin (0.2 g/kg, i.p.) in a supine position on a 37°C heating 
pad. The toe-pinch reflex was used to monitor the anesthesia state. The left carotid 
artery was exposed using blunt dissection under a dissecting microscope. A miniature 
Doppler flow probe (0.5VB, Transonic system Inc., Ithaca, NY, USA) was placed on the 
carotid artery to monitor blood flow. The position of the probe was adjusted to record 
maximum flow. After baseline readings, the area was dried to prevent dispersion of the 
FeCl3 solution from filter paper to neighboring tissue. Thrombus formation was induced 
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by placing a round filter paper (1 mm diameter) saturated with 5% FeCl3 solution (1 µL) 
in 1X PBS on the top of the vessel for 3 min. After 3 min, the paper was removed, and 
saline was added to facilitate flow. The time from the application of ferric chloride to 
the cessation of blood flow was recorded. The recording was stopped after 30 min of 
application of ferric chloride. To monitor the stability of thrombus, fluctuations in blood 
flow were monitored. A progressive decrease in blood flow followed by a sudden 
increase in flow was characterized as a potential indicator of unstable thrombus at the 
site of injury. 
Coagulation assays 
 Mice platelets were harvested from whole blood as described above. Platelet-
poor plasma was collected and preserved at -80°C. This platelet poor plasma was used 
to measure Prothrombin time (catalog number 5248) and activated Partial 
Thromboplastin Time (catalog number 5389) as per manufacturer’s instructions (Helena 
Laboratories, Beaumont, Texas). 
Electron microscopy studies of mice platelets 
For a resting sample, blood was drawn in a syringe prefilled with Acid Citrate 
Dextrose/ACD (12.5 gm trisodium citrate dehydrate+ 7 gm citric acid+ 10 gm anhydrous 
D (+) glucose in 500 mL of distilled dH2O) and an equal volume of 2X fixative (6% PFA 
and 0.2% glutaraldehyde in 1x PBS). The blood was fixed at RT for 20 min before 
collecting Platelet Rich Plasma (PRP) by centrifugation at 237 x g for 8 min in Sorvall 
legend RT centrifuge (Thermo Scientific). PRP was then centrifuged at 695 x g for 10 min 
to collect platelets and the second fixation was performed with 2.5% glutaraldehyde for 
20 min at RT. 
For the WT stimulation series, washed platelets were supplemented with 0.7 
mM CaCl2. Resting samples were fixed with 2X fixative (2% PFA and 5% glutaraldehyde). 
The activation samples were stimulated with 1U/mL thrombin to achieve a final 
concentration of 0.1 U/mL. The reaction was stopped at various time points (10, 20, 30, 
60, 90, 120 and 300 sec) by adding an equal volume of 2X fixative to attain a final 
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concentration of 1% PFA and 2.5% glutaraldehyde. The samples were fixed for 30 min at 
RT. After fixation, platelets were centrifuged at 695 x g and the platelet pellet was 
resuspended in HEPES Tyrode’s buffer (pH 7.4). 
For morphology study of VAMP KO mutant platelets, experimental sample 
platelets were stimulated with 1 U/mL thrombin to achieve 0.1 U/mL final 
concentrations. The reactions were stopped at either 90 or 300 sec by adding 2X 
fixative. Platelets were fixed at RT for 30 min and were recovered by spinning at 695 x g 
for 10 min. Fixed platelets were resuspended in a small volume of HEPES Tyrode’s buffer 
(pH 7.4) and shipped on ice to the Storrie lab for EM analysis.  
The following procedures were performed by Irina Pokrovskaya at University of 
Arkansas Medical Sciences, Little Rock, AR.  
High-pressure freezing (HPF)/Freeze Substitution (FS) 
Following fixation platelet preparations were washed 3 x5 min with PBS and 
resuspended in PBS containing 2% ultra-low gel agarose (Sigma, St. Louis, MO). Platelets 
were then frozen using a Leica EM PACT2 high-pressure freezer with rapid transfer 
system at high pressure (2,100 bar) and further processed by FS.  
Freeze substitution dehydration 
Samples were transferred under liquid nitrogen to cryovials containing 2% 
osmium tetroxide/0.1% glutaraldehyde/1% H2O in acetone. Samples were freeze 
substituted in a Leica EM AFS2 freeze substitution and low-temperature embedding 
system under the following schedule: -90° C for 22 hrs., warm 3°C/hr. to -60°C, -60°C for 
8 hr., warm 3°C/hr. to -30°C, -30°C for 8 hrs., warm 3°C/hr. to 0°C. Following freeze 
substitution, samples washed 3 x 10 min in acetone followed by tannic acid at 4°C (1% 
tannic acid with 1% H2O in acetone) for 1 hr. Samples were washed 3 x 10 min in 
acetone followed by 1 hr. osmium wash (1% osmium tetroxide/1% H2O solution in 
acetone) at 4°C. Samples were washed 3 x 10 min in acetone and dehydrated over a 
series of ethanol gradations (25%, 50%, 75%, 100%) using automatic resin infiltration 
protocol for PELCO Bio-Wave Pro laboratory microwave system. Specimens final 
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polymerization was done at 60°C for 48 hr. in a regular oven. 
Thin section TEM 
Thin sections were cut at a thickness of 50 nm and post-stained with uranyl 
acetate and lead citrate (EMS).  
Electron microscopy and image handling 
Samples were imaged using a FEI Tecnai TF20 intermediate-voltage electron 
microscope operated at 80 keV (FEI Co.). Images were acquired with a FEI Eagle 4k 
digital camera controlled with FEI software.  
Semi-thick section transmission electron tomography 
Samples were sectioned at 300 nm and post-stained with uranyl acetate and 
lead citrate, followed by carbon coating. 15 nm gold (EMS) was applied to each side of 
the grids. Samples were imaged using a FEI Tecnai TF20, 200 keV field-emission gun, 
using SerialEM software (University of Colorado). Dual axis tilt series were collected ± 
60° with a tilt increment of 1°. Images were taken at 7800x, pixel size 1.42 nm. 
Tomogram reconstructions 
Reconstructions were computed using weighted back projection (IMOD 
software, University of Colorado). STEM tomograms were binned by 2 and post-
processed with an anisotropic diffusion filter.  
Statistical Analysis 
 All statistical analysis was performed using Student’s t-test using Sigma Plot 
(version 13.0; Systat Software Inc.). P value less than 0.05 was considered significant 
The data from bleeding time and occlusion assays were analyzed using the Log-
rank test. The data from secretion assays and FACS-based experiments were analyzed by 
two-way ANOVA. A one-tailed Student’s t-test was used to analyze the properties of 
platelets from KO mice. In all cases, the p values are indicated. 
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Study Approval 
All animal work was approved by the Institutional Animal Care and Use 
Committee at the University of Kentucky. 
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Chapter 3 Fine-tuning hemostasis and thrombosis by altering 
platelet secretion 
 
Introduction 
In addition to hemostasis, blood platelets also play a central role in a myriad of 
other conditions, including angiogenesis, wound healing, infection, inflammation and 
immunity. These functions are mediated by platelet granule exocytosis/secretion in 
which three types of platelet granules, each containing specialized cargo fuse with the 
plasma membrane and release their contents. The importance of these cargoes is 
underlined by the fact that various platelet storage pool deficiencies show a wide array 
of bleeding diathesis ranging from mild to severe, sometimes fatal bleeding defects. This 
suggests that there should be an optimal level of granule cargo that needs to be 
available to attain hemostatic balance, preventing occlusive thrombosis without causing 
spurious bleeding. 
The overarching question we ask is how much platelet granule secretion is 
needed for hemostatic balance? Platelet granule exocytosis is a complex process 
facilitated by a family of membrane proteins termed Soluble N-ethylmaleimide 
Attachment Protein Receptors (SNAREs). Based on their location in platelets, and a 
residue at the center of conserved SNARE domain, these proteins are classified as t- 
target SNAREs/ Q (Glu) SNAREs and v- vesicle SNAREs/ R (Arg) SNAREs, also known as 
Vesicle-Associated Membrane Proteins (VAMPs). Past studies have found that t- SNARES 
such as SNAP23 (Karim, Zhang et al. 2013), syntaxin-11 (Ye, Karim et al. 2012) and 
syntaxin-8 (Golebiewska, Harper et al. 2015) are required for platelet secretion. 
Proteomic studies have found the presence of 6 VAMP isoforms in platelets- (2, 3, 4, 5, 7 
and 8); however, only 2, 3, 7, and 8 are abundant in both mouse and human platelets. 
VAMP-8 (Ren, Barber et al. 2007) and VAMP-7 (Koseoglu, Peters et al. 2015) have been 
shown to play critical roles in platelet exocytosis while VAMP-2 and VAMP-3 have been 
considered as secondary v- SNAREs. The importance of VAMP-8 in platelet exocytosis is 
underscored by genetic studies suggesting that Single Nucleotide Polymorphisms in 
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VAMP-8 are associated with early onset myocardial infarction (Shiffman, Rowland et al. 
2006) and a microRNA that regulates VAMP-8 expression potentially contributes to 
hyperreactive platelets (Kondkar, Bray et al. 2010). Thus, SNAREs potentially control 
platelet secretion and ultimately platelet function.  
In platelets, VAMP-7 (Koseoglu, Peters et al. 2015) and VAMP-8 are primary 
isoforms crucial for granule secretion while VAMP-2 and VAMP-3 are ancillary (Ren, 
Barber et al. 2007). Why is this redundancy in v- SNARE usage valuable? V- SNARE usage 
in few other secretory systems such as neurons (Borisovska, Zhao et al. 2005), mast cells 
(Puri and Roche 2008), and neutrophils (Mollinedo, Calafat et al. 2006) indicate that 
heterogeneous usage of VAMPs influences regulated secretion by altering the rates and 
the extent of secretion or preferentially releasing specific cargo.  
Based on these studies, we hypothesized that by regulating VAMP types and 
amounts in platelets, we could determine the optimal level of platelet exocytosis 
required for an ideal hemostasis. To study this, we generated platelet-specific V-2/3-/- 
and V-2/3/8-/- animals and studied the characteristics of granule secretion. We found 
that the loss of VAMP-2 and VAMP-3 do not have any significant effect on the kinetics 
and the magnitude of the secretion from platelet granules. However, V-2/3/8-/- platelets 
showed significantly diminished secretion from all three granules. Additionally, V-8-/- 
and V-2/3/8-/-  platelets spread remarkably slowly on fibrinogen indicating that secretion 
is necessary for spreading. In vivo assays showed that V-2/3/8-/- animals bled profusely 
and failed to form occlusive thrombus indicating that secretion defects led to a robust 
hemostatic deficiency. Surprisingly, phosphatidylserine exposure was minimally affected 
in V-2/3-/- platelets but significantly depleted in V-2/3/8-/- platelets suggesting that the 
deletion of these VAMP isoforms does have at least some effect on the coagulation 
cascade and this potentially could have exacerbated hemostatic deficiencies. 
The release of platelet granule cargo shapes the thrombus composition. Hence, 
anti-platelet molecules are appealing antithrombotics. However, it is challenging to 
equilibrate platelet function with no clear understanding of the threshold of platelet 
secretion necessary to prevent uncontrolled thrombosis without compromising 
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hemostasis. This is a first systematic quantitative study that addresses this question. 
Additionally, by generating these platelet-specific VAMP KO strains, we have created a 
key reagent system to study the role of platelet secretion in a multitude of other 
processes where platelets play major roles. 
Results  
Generation of platelet-specific V-2/3-/- and V-2/3/8 -/- mouse model 
To overcome the challenges of perinatal lethality of V-2-/- (Schoch, Deak et al. 
2001) and embryonic lethality of V-3/8-/- animals (Whiteheart unpublished), we used 
broadly accepted megakaryocyte/platelet-specific PF4 promoter-driven Cre 
recombinase system (Tiedt, Schomber et al. 2007). Tetanus toxin light chain cleaves 
VAMP-2 (Schoch, Deak et al. 2001) and VAMP-3 (McMahon, Ushkaryov et al. 1993, Ren, 
Barber et al. 2007) while VAMP-8 and -7 are insensitive to this toxin and are not affected 
(Figure 3.1). The mice generated, V-2/3-/- were later crossed with V-8-/- animals (Wang, 
Ng et al. 2004, Ren, Barber et al. 2007) to get V-2/3/8-/- animals.  
Animals from both novel strains – V-2/3-/- and V-2/3/8-/- followed Mendelian 
ratios and were healthy and fertile. They did not have any gross developmental or 
anatomical abnormalities and had a normal lifespan. The average weight of littermate 
control at 12 weeks (24.41 ± 2.96 gm) was comparable with V-2/3-/- (23.48 ± 2.97 gm) 
and V-2/3/8-/- (23.58 ± 1.9 gm) suggesting the absence of growth defects in these 
animals. Hematological parameters including RBC count, platelet number and mean 
platelet volume were comparable to littermate controls (Figure 3.1). Additionally, 
electron micrographs show that the shape and size of platelets were normal in V-2/3-/-, 
V-8-/- and V-2/3/8-/-  indicating normal hematopoiesis (Figure 3.2) in absence of VAMP 
isoforms. Detailed morphological features will be discussed in Chapter 4. 
  
 84 
 
 
Figure 3.1. Characteristics of blood cells from WT and VAMP deficient animals 
Whole blood was collected from WT (n=11), VAMP-2/3-/- (n=6), V-8+/-(2/3)-/- (n=6), and 
V-2/3/8-/- (n=8) animals and a Hemavet instrument was used to measure RBCs (A), WBC 
(B), platelet concentration (C) and mean platelet volume (D).
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Figure 3.2. Ultrastructure of resting VAMP-deficient platelets 
Mouse platelets from WT (A), V-2/3-/- (B), V-8-/- (C), V-2/3/8-/-(D) mice were fixed directly 
while collecting blood by cardiac puncture. High-pressure freeze technique was used to 
process samples. Thin sections (50 nm) were cut and post-stained with uranyl acetate 
and lead citrate. Samples were imaged using an FEI Tecnai TF20 intermediate-voltage 
electron microscope. (Samples prepared by Smita Joshi, imaging by Irina Pokrovskaya) 
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SNAREs in V-2/3-/-, V-8+/-(2/3) -/-.and V-2/3/8 -/- platelets  
To validate the generation of VAMP-deficient strains, western blotting was used 
along with tail DNA PCR. Western blot analysis confirmed the deletion of VAMP-2, and 
VAMP-3, in V-2/3-/- and VAMP-2, VAMP-3, and VAMP-8 in V-8+/-(2/3) -/-.and V-2/3/8 -/-, 
strains (Figure 3.1). The levels of VAMP-8 in V-2/3-/- platelets were increased by about 
10% while they were decreased by about 40% in V-8+/-(2/3)-/- platelets (Figure 3.3 A and 
B). Previously it was noted that global V-2+/-/3-/- platelets had about 30% increase in 
VAMP-8 levels though VAMP-7 levels were not altered (Ren, Barber et al. 2007);  
however, there was no change in expression of VAMP-7 and VAMP-8 in platelet-specific 
V-2/3-/- platelets. Additionally, the loss of VAMP-8 did not change VAMP-7 levels (Ren, 
Barber et al. 2007). Similarly, the loss of VAMP-7 did not result in increased in VAMP-8 
levels (Koseoglu, Peters et al. 2015). Surprisingly, VAMP-7 expression was significantly 
increased (about 2X) in V-8+/-(2/3)-/- platelets while it diminished by about 50% in V-
2/3/8-/-. Since it is well established that VAMP-7 is tetanus toxin insensitive (Galli, 
Zahraoui et al. 1998), it is unlikely that our transgenic strategy affected VAMP-7 
expression. One possibility is that the early loss of multiple VAMP isoforms may have 
interrupted VAMP-7 trafficking from megakaryocytes to proplatelets to ultimately 
platelets resulting in the observed reduction in VAMP-7 levels. VAMP-8 has been 
implicated in endosomal trafficking in other secretory systems and VAMP-3 is crucial for 
platelet endocytosis (Antonin, Holroyd et al. 2000, Banerjee, Joshi et al. 2017). Since V-3-
/- and V-8-/- platelets do not show any defect in VAMP-7 levels, there two VAMP 
isoforms could function in the same pathway and possibly compensate for each other. 
Therefore, complete loss of both isoforms may have contributed to this trafficking 
defect. However, the more detailed analysis is necessary to determine the mechanism 
of VAMP-7 trafficking in platelets.  
The expression of t- SNAREs -syntaxin-11 and SNAP23 were not affected. As 
expected, fibrinogen levels were decreased in V-2/3-/-  and V-2/3/8-/- animals by about 
20% and 50% respectively mainly due to the deficiency of VAMP-3 which plays an 
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essential role in endocytosis (Banerjee, Joshi et al. 2017). Cytoplasmic protein Rab- GDI 
was used as a loading control for the analysis.  
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Figure.3.3. Generation of V-2/3-/- and V-2/3/8-/- animals 
(A) Comparisons of protein levels among V-2/3-/-, V-8+/-(2/3)-/- and V-2/3/8-/- platelets. 
Washed platelet extracts (5 × 107 platelets/lane) were prepared from WT, V-2/3-/-, V-8+/-
(2/3)-/- and V-2/3/8-/- mice, and the indicated proteins were analyzed by western 
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blotting. (B) Quantification of protein levels in V-2/3-/-, V-8+/-(2/3)-/- and V-2/3/8-/- 
platelets was performed using Rab GDI as a loading control and ImageQuantTL software 
was used for image analysis. The data were plotted as the ratio of KO over WT. The 
horizontal solid line indicates the ratio of 1. Data are representative of platelets pooled 
from two mice and at least 2 independent experiments. 
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Role of VAMPs in platelet secretion 
To understand how VAMP-2, -3 and -8 influence the kinetics and the extent of 
granule secretion, we examined the stimulation-dependent and time-dependent release 
of cargo from all three platelet granules: dense, alpha, and lysosomes. Platelet granule 
secretion upon agonist titration indicates the extent of cargo release upon various 
strengths of stimulation while the time-dependent release of cargo aids in the 
understanding of the kinetics of this process. Washed mouse platelets were incubated 
with [3H] serotonin and then stimulated with an agonist for a certain time before 
stopping the reaction with hirudin. Releasate (supernatant) was separated from the 
pellet and tritium was measured in both the fractions to calculate percent release from 
dense granules. A sandwich ELISA assay was used to measure PF4 secretion from alpha 
granules and PNP glucnac was used as a substrate to measure the enzymatic activity of a 
lysosomal enzyme β-hexosaminidase as explained previously (Ye, Karim et al. 2012). 
Role of VAMP-8 in platelets granule secretion 
Increased concentrations of thrombin facilitated release from V-8-/- platelets that 
was delayed and reduced at low concentrations of thrombin but reached comparable 
levels with WT as thrombin concentration increased (Figure 3.4). This shows that VAMP-
8 is probably more important for early stages/burst phase of secretion than in sustained 
release once secretion reaches the maximal extent. VAMP-8 seems to have more 
influence on alpha granule (Figure 3.4 B and E) and lysosomal release (Figure 3.4 C and 
F) than on dense granule release (Figure 3.4 A and D). Evidently, defective dense granule 
secretion that is crucial for availability of secondary agonists such as ADP, ATP etc. may 
have impact on downstream alpha and lysosomal secretion making these events less 
efficient in the context of both the rate and the degree of release (Graham, Ren et al. 
2009, Harper, van den Bosch et al. 2015). Consistent with our previous report, though 
the secretion was diminished, it was not completely abolished in V-8-/- platelets. 
suggesting that the loss of VAMP-8 could be compensated for by residual VAMP 
isoforms at higher agonist concentrations (Ren Q et al, 2007).  
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Role of VAMP-2 and VAMP-3 in platelets granule secretion 
Previously, Ren et al., showed that global V-2+/- animals and global V-2+/-/3-/- 
animals did not have secretion deficiency (Ren, Barber et al. 2007). Similarly, an earlier 
investigation with global V-3-/- animals indicated that lack of VAMP-3 does not affect 
secretion (Schraw, Rutledge et al. 2003). In fact, some reports indicated that the loss of 
VAMP-3 shows a small but significant increase in secretion suggesting that it might be 
an inhibitory v- SNARE (Varlamov, Volchuk et al. 2004). Since global V-2-/- are perinatal 
lethal, we made platelet-specific V-2/3-/- animals to study how it influences platelet 
secretion and function (Figure 2.1). 
Secretion of granule cargo from V-2/3-/-- platelets displayed little change 
compared to WT platelets in response to increased thrombin concentrations (Figure 
3.4). Dense and alpha-granule secretion was not altered however, there was a minimal 
but non-significant decrease in lysosomal secretion (Figure 3.4 C and F). Flow cytometry 
data show that P-selectin (alpha granule membrane marker) exposure is about 10-15% 
reduced in V-2/3 -/- platelets whereas LAMP-1 (Lysosomal membrane marker) expression 
is also decreased by about 20% (Figure 3.6 A and B).  
Secretion deficiency in V-2/3/8-/- platelets 
The lack of VAMP-2, -3, and -8 had a significant impact on granule secretion. V-
2/3/8-/- platelets displayed delayed and decreased dense granule secretion, the most 
rapid among all three granule release events (Figure 3.4 A and D). Dense granules are 
docked and therefore the first and fastest ones to release their cargo upon stimulation 
(Jonnalagadda, Izu et al. 2012, Chicka, Ren et al. 2016). This may be the reason why the 
loss of three major VAMP isoforms has a comparatively lower effect on dense granule 
release. Upon thrombin stimulation at the concentration of 0.05 U/mL, WT platelets 
reached 50% of their maximal release level while V-2/3/8-/- platelets hardly showed any 
release. The maximal extent of V-2/3/8-/- release was about 50% lower than that of WT. 
Consistent with VAMP-8 deficient phenotype, the deletion of VAMP-2, -3, and -8 
severely affected the alpha and lysosomal release than the dense granule release. There 
was about 80% reduction in the extent of the alpha-granule release (Figure 3.4 B and E) 
 92 
 
and about 75% decrease in lysosomal release compared to WT (Figure 3.4 C and F). This 
pattern also indicates the role of dense granule cargo, ADP as a secondary agonist to 
stimulate release from downstream/later granule fusion (alpha and lysosome) events 
(Harper, van den Bosch et al. 2015). 
The only major residual VAMP isoform in V-2/3/8-/- platelets is VAMP-7 and the 
data suggest that it may need higher stimulation to reach WT levels. This pattern was 
evident in both alpha and lysosomal release. It should be noted that since VAMP-7 levels 
were significantly decreased in these platelets, it may have compounded the secretion 
deficiency in all three granules, at least to some extent.  
 The rates of cargo release from V-8-/- and V-2/3/8-/- platelets were also notably 
reduced upon activation with 0.05 U/mL thrombin (Figure 3.4 D, E, and F). This thrombin 
concentration was chosen to study kinetics because it was optimal to observe the 
release kinetics at about half-maximal rate without reaching a plateaued pattern which 
could obscure the subtle differences among strains. 
 In the early phase of secretion, burst phase (first 30 sec on secretion time scale), 
serotonin release from V-8-/- platelets was remarkably slower (Figure 3.4 D). The additive 
loss of VAMP-2 and VAMP-3 significantly delayed this phase further. This pattern of 
delayed release was consistent with all three granule secretion events Additionally, the 
extent of secretion was also significantly affected. While the loss of VAMP-8 resulted 
into about 50% deficit in alpha-granule secretion (Figure 3.4 E) and about 30% decrease 
in lysosomal secretion (Figure 3.4 F), its effect on dense granule secretion extent was 
minimal, mainly affecting rates in early burst phase than the extent. Deficiency of 
VAMP-2, VAMP-3, and VAMP-8 led to about 40% deficit in dense granule, 80% deficit in 
alpha granule and 50% deficit in a lysosomal release (Figure 3.4 D, E, and F).  
To probe if a partial loss of VAMP-8 affects secretion kinetics and extent of V-
2/3-/- platelets, we performed secretion assays. The data show that these platelets did 
not display any secretion deficiency in any of the granules (Figure 3.5). The secretion 
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patterns are like those observed in V-2/3-/- platelets in context of both the extent (Figure 
3.5 A, B, C) and the kinetics (Figure 3.5 D, E, and F). 
To further confirm that primary, as well as secondary VAMPs, are required for α 
granule and lysosome release, exposure of the respective markers P-selectin and LAMP-
1 was analyzed by flow cytometry. Consistently, activation-dependent exposure of P-
selectin was decreased by 90% and LAMP-1 exposure was reduced by about 70% in V-
2/3/8-/- platelets (Figure 3.6 A and B). Additionally, FITC conjugated total integrin 
staining showed that the total integrin levels were significantly reduced in V-2/3-/- and in 
V-2/3/8-/- platelets. Since translocation of integrin to plasma membrane requires 
membrane fusion which is affected in absence of VAMPs, these levels may have been 
affected. The activation of integrins was not affected as probed by PE-conjugated Jon A 
staining (Figure 3.6 C and D). This defect is more pronounced in absence of VAMP-2, -3, 
and -8.  
  
 94 
 
 
Figure. 3.4. The loss of VAMP-2, -3, and -8 affects the kinetics and the extent of 
platelet secretion 
[3H]- Serotonin–labeled platelets from WT, V-2/3-/-, and V-2/3/8-/- mouse were prepared 
as described in Methods. The release of [3H]-serotonin from dense (A and D) granules, 
PF4 from α-granules (B and E), and β-hexosaminidase from lysosomes (C and F) was 
measured, and percent secretion was calculated.as described in methods. For thrombin 
dose-response experiment; platelets were stimulated for 2 min with indicated 
concentrations of thrombin (A, B, and C). For time-course experiment; platelets were 
stimulated with 0.05 U/mL thrombin for indicated times (D, E, and F). Data are mean ± 
SEM of triplicate measurements. Asterisk represents significant P values (P<0.05, 
Student’s t-test) as indicated. 
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Figure. 3.5. Granule secretion is not affected in V-8+/-(2/3)-/- platelets 
[3H]- Serotonin–labeled platelets from WT and V-8+/-(2/3)-/- mice were prepared as 
described in Methods. The release of [3H]-serotonin from dense granules (A and D) using 
scintillation counter, PF4 from alpha granules (B and E) using commercial ELIZA assays, 
and β-hexosaminidase from lysosomes (C and F) using enzymatic activity of β-
hexosaminidase was measured, and percent secretion was calculated.as described in 
methods. For thrombin dose-response experiment; platelets were stimulated for 2 min. 
(A, B and C). For time-course experiment; platelets were stimulated with 0.05 U/ml 
thrombin (D, E, and F). Data are representative of at least two experiments. 
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V-2/3-/- and V-2/3/8-/- have diminished integrin αIIbβ3 levels but not integrin 
activation 
To exclude the possibility that defective platelet activation may impact platelet 
granule secretion, we measured integrin αIIbβ3 activation in V-2/3-/-  and V-2/3/8-/-  
platelets. A flow cytometry assay using FITC-conjugated JonA antibody that recognizes 
an active form of αIIbβ3 was used to probe platelet activation. The data indicate that 
integrin activation is normal in both V-2/3-/- and V-2/3/8-/- strains (Figure 3.6 C). 
Since fibrinogen levels were reduced in V-2/3-/- and V-2/3/8-/- we wanted to test 
if fibrinogen receptor integrin αIIbβ3 levels were affected in these animals. Total surface 
staining for αIIbβ3 integrin showed about a 10-15% decrease in V-2/3-/- platelets and 
about 25% reduction in V-2/3/8-/- platelets may be due to a trafficking defect to the 
plasma membrane. However, these levels did not affect platelet activation. (Figure 3.6 
D). 
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Figure 3.6. Platelets from V-2/3/8-/- mice have lower P-selectin and LAMP-1 exposure 
but a little defect in integrin αIIbβ3 activation.  
Washed platelets (5 × 107) from WT, V-2/3-/-, and V-2/3/8-/-  mice were kept resting or 
stimulated with thrombin (0.05 U/mL) for 2 min and then incubated with FITC-
conjugated anti–P-selectin (A), PE-conjugated LAMP-1(B), PE-conjugated JonA (C), or 
FITC-conjugated CD41/61 (D) Abs for 20 min at RT. Fluorescence intensities were 
measured by flow cytometry. Shown are representative data (WT- black bars, V-2/3-/- - 
light gray bars, V-2/3/8-/- - dark gray bars) and geometric MFI (mean ± SEM) of at least 2 
independent experiments. Significant P values (p<0.05, Student’s t-test) are indicated. 
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Integrin activation and aggregation are not altered in V-2/3/8-/-platelets 
To support our findings from secretion assays, we also used Lumi-aggregometry 
to analyze ATP/ADP release from dense granules. While ATP/ADP release in response to 
0.05, 0.1, and 0.5 U/mL thrombin was minimally affected in V-2/3-/- platelets, it was 
substantially inhibited in V-2/3/8-/- platelets, whereas aggregation was not (Figure 3.7). 
At stimulation with 0.05 U/mL thrombin, there was virtually no ATP secretion and 
therefore no aggregation from V-2/3/8-/- platelets (Figure 3.7 A and D). Minimal ATP 
release at 0.1 U/mL and 0.5 U/mL thrombin might be sufficient to support normal 
aggregation (Figure 3.7 B, E, C, and F).  
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Figure 3.7. Depletion of VAMP-2, -3, and -8 in platelets affects ATP/ADP release, but 
not aggregation 
Aggregation (A-C) and ATP/ ADP release (D-F) were monitored simultaneously in a Lumi-
aggregometer. Washed platelets (4 × 108/mL) from WT (black traces), V-2/3-/- (dark gray 
traces) and V-2/3/8-/- (light gray traces) platelets were stimulated with thrombin (0.05 
U/mL; Thrombin) (A), or 0.1 U/mL (B), or 0.5 U/mL (C) and ATP release and aggregation 
were measured for 5 min. 
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V-8-/-  and V-2/3/8-/-  platelets show defective spreading 
Upon stimulation, platelets spread to increase the surface area that enhances 
interaction with other platelets and aids in thrombus formation. Previous studies have 
reported that granule secretion is important for platelet spreading (Peters, Michelson et 
al. 2012). Loss of VAMP-7 affects spreading on fibrinogen-coated surfaces (Koseoglu, 
Peters et al. 2015). To determine if secretion deficiency in VAMP-deficient strains affects 
the rate and the extent of platelet spreading, we studied their spreading on fibrinogen. 
Washed platelets were supplemented with calcium and plated on fibrinogen-coated 
coverslips and fixed with paraformaldehyde at 30, 60, 90, and 120 min at 37°C. 
Image analysis using ImageJ showed that the platelet spreading was 
heterogeneous. The data show that V-8-/- platelets spread slowly compared to WT 
platelets (Figure 3.8 C), but there was no significant difference between the number of 
platelets spread at each time point in both the WT and V-8-/- platelets (Figure 3.8 D). 
This suggested that granule secretion is important for spreading. Surprisingly the V-2/3-/- 
group had more spread platelets than the control group at the 30 min time point, 
although the area covered by spread platelets did not change (Figure 3.8 A and B). This 
is most likely due to the loss of VAMP-3, which we previously showed causes platelets to 
spread more rapidly (Banerjee, Joshi et al. 2017).  
V-2/3/8-/- platelets spread remarkably slower than WT platelets (Figure 3.8 A). At 
each time point, fewer platelets spread than the platelets in WT samples (Figure 3.8 B). 
The area covered by spread platelets was also significantly reduced in V-2/3/8-/- 
platelets. This supports previous reports that granule secretion deficiency affects 
platelet spreading (Peters, Michelson et al. 2012). Peters et al., showed that human HPS 
platelets that have dense granules show normal spreading, however, human GPS 
platelets with defective alpha granules had impaired spreading. This suggests that 
though dense granules are dispensable, the alpha-granule release is crucial for normal 
platelet spreading. The spreading defect observed in V-2/3/8-/- platelets is the result of 
significantly diminished alpha-granule release in these platelets (Figure 3.4). VAMP-7 
has been suggested to have associations with cytoskeletal elements. Loss of VAMP-7 
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severely affects platelet spreading (Koseoglu, Peters et al. 2015). In the light of this role 
of VAMP-7, it should be noted that reduction in VAMP-7 levels in these platelets may 
have also impacted this spreading, at least to some degree (Figure 3.3). 
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Figure 3.8. V-8-/- and V-2/3/8-/- platelets have a spreading defect 
Platelets from the indicated mouse strains were allowed to adhere and spread on 
fibrinogen-coated coverslips. At the indicated times, the samples were fixed and imaged 
 103 
 
for analysis. (A). Quantification of the area spread by platelets from WT, V-2/3-/- and V-
2/3/8-/- mice. (B). Distribution of spread platelets over time for WT, V-2/3-/- and V-2/3/8-
/- platelets as a percent of platelets imaged. (C). Quantification of the area spread by 
platelets from WT and V-8-/- strains. (D). Distribution of spread platelets over time for 
WT and V8-/- platelets as a percent of platelets imaged. For each time point, >100 
platelets were counted for the quantification. The data are representative of two 
independent assays. Examples of spread platelets from various strains at 120 min are 
shown in (E). Scale bar is 5 µm. 
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V-2/3/8-/-  animals have a severe hemostatic deficiency 
To study how secretion deficiencies affect in vivo hemostasis, we used two 
assays that represent different types of vascular injuries. Tail bleeding time 
measurement mimics transection injury and FeCl3 injury model that mirrors endothelial 
denudation. While tail bleeding time was comparable among- WT, V-3-/-, V-2/3-/-  and V-
8-/- models, it was significantly increased in V-2/3/8-/- (mean time = 571.74 ± 72.61 sec) 
compared to WT animals (mean time = 250.07 ± 86.82 sec) (Figure 3.9 A). The 
measurement of time to form occlusive thrombus post- FeCl3 application indicates that 
in WT animals, thrombus formed in the meantime of around 6.5 min (Figure 3.9 B). This 
time was comparable among other strains tested- V-8+/- (~ 7 min), V-2/3-/- (~ 7 min), V-
8+/-(2/3)-/- (~ 6.5 min). However, it was notably increased in V-8-/- (~ 21 min) animals, 
confirming our previous findings from the laser injury model data (Graham, Ren et al. 
2009). As expected, most V-2/3/8-/- (~ 28 min) animals failed to form occlusive thrombus 
during our observation window suggesting that the loss of these three VAMP isoforms 
responsible for platelet secretion deficiency also leads to in vivo thrombosis defect. 
Additionally, we did not find any sexual dimorphism in these processes (Figure 3.10). 
To test if defective secondary hemostasis impacted coagulation processes and 
contributed to increased bleeding time and decreased thrombosis, we measured 
clotting times using two broadly used tests, PT (prothrombin time) and aPTT (activated 
partial thromboplastin time). PT is mainly used to analyze the role of extrinsic pathway 
while aPTT is more focused on the intrinsic and common pathway. The data show that 
both PT and aPTT times were comparable among all the strains tested (Figure 3.9 C). 
This argues that the coagulation pathways were not affected in the absence of platelet 
secretion. 
Expression of phosphatidylserine/PS upon platelet activation provides a platform 
for thrombin generation. To exclude the possibility that secretion deficiency affected PS 
exposure and ultimately thrombin generation leading to insufficient hemostasis, we 
performed flow cytometry-based assays using FITC-conjugated anti-PS antibody. The 
data show that though mildly reduced, PS exposure was not significantly depleted in V-
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2/3-/- platelets (Figure 3.9 D). In V-2/3/8-/- platelets, however, it was significantly 
diminished by about 50%. This suggests that platelet granule secretion is probably 
necessary for either the release of flippases/floppase/translocases from a 
vesicle/granule is crucial for PS exposure or the trafficking and/or targeting of these 
enzymes to the plasma membrane of these platelets is defective. It should be noted that 
about 25-30% reduction in PS exposure does not cause hemostatic deficiencies in V-2/3-
/- animals. 
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Figure 3.9. Hemostasis and thrombus formation are impaired in V-2/3/8-/--animals 
(A) Tail bleeding times were measured after 3 mm tail transection of WT (n=28), V-3-/- 
(n=38), V-2/3-/- (n= 20), V-8+/- (n=26), V-8-/- (n=31), V-8+/-(2/3)-/- (n=41), and V-2/3/8-/- (n= 
34) mice (B) Thrombus formation in the carotid artery was induced by topical 
application of 5% FeCl3, and blood flow was monitored in WT (n=6), V-8+/- (n=6), V-2/3-/- 
(n=7), V-8+/-(2/3)-/- (n=9), V-8-/- (n=7), and V-2/3/8-/- (n=7) mice. Mean ± SEM and P 
values (log-rank test) are indicated. Red line indicates the mean and the black line 
indicates the median. The box represents 25th-75th percentile. While whiskers/error bars 
above and below the box indicate the 90th and 10th percentiles. Outliers are as shown in 
tail bleeding figure. (C) Activated partial Thromboplastin Times (aPTT) and Prothrombin 
Times (PT) were measured in platelet-poor plasma prepared from WT (n=7), V-8-/- (n=5), 
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V-2/3-/- (n=8), V-8+/-(2/3)-/- (n=3) and V-2/3/8-/- (n=5) mice. (D) Phosphatidylserine 
exposure on the surface of thrombin-stimulated platelets from WT, V-8+/-, V-8-/-, V-2/3-/-, 
V-8+/-(2/3)-/- and V-2/3/8-/- mice were measured by FITC-conjugated lactadherin binding 
and flow cytometry. The data are representative of two independent assays. Asterisk 
represents p-value (paired Student’s t-test, p<0.05) 
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Figure 3.10. Hemostatic deficiencies indicate no sexual dimorphism in VAMP-deficient 
strains 
(A) Tail bleeding times were measured after tail transection of WT (n=28, 13 females, 15 
males), V-3-/- (n=38,18 females, 20 males), V-2/3-/- (n= 20, 9 females, 11 males), V-8+/- 
(n=26, 12 females, 14 males), V-8-/- (n=31, 15 females, 16 males), V-8+/-(2/3)-/- (n=41, 22 
females, 19 males), and V-2/3/8-/- (n=34, 19 females, 15 males) mice (B) Thrombus 
formation in the carotid artery was induced by topical application of 5% FeCl3, and blood 
flow was monitored in WT (n=6, 2 females, 4 males), V-8+/- (n=6, 3 males, 3 females), V-
2/3-/- (n=7, 3 females, 4 males), V-8+/-(2/3)-/- (n=9, 5 females, 4 males), V-8-/- (n=7, 4 
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females, 3 males), and V-2/3/8-/- (n=7, 4 females, 3 males) mice. Mean ± SEM and p 
values (log-rank test) are non-significant (p>0.05). 
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Conclusions 
Platelet granule secretion is central to the platelet function. Lack of granules or 
secretion deficiencies that impact platelet granule cargo release affect the hemostatic 
balance. On the other hand, hyperactive platelets increase the likelihood of thrombotic 
events underlining the importance of the platelet secretion in maintaining hemostatic 
balance. Though our understanding of molecules that play a role in platelet secretion 
has expanded, it is still unclear how much secretion is needed to maintain this 
hemostatic balance to prevent occlusive thrombosis without triggering unwanted 
bleeding. 
In this Chapter, we address this question by using v-SNAREs to regulate the rate 
and the magnitude of platelet secretion. By generating platelet-specific V-2/3-/- and V-
2/3/8-/- mouse models, we show that each VAMP isoform plays a differential role in 
determining the rate and the degree of platelet granule secretion. VAMP-8 is a primary 
VAMP that is crucial for determining the rate of secretion in the early phase of 
secretion. Loss of VAMP-8 leads to defective granule secretion. Residual VAMPs- VAMP-
2, VAMP-3, and VAMP-7 compensate for VAMP-8’s loss indicating at least partial 
functional overlap. The deficiency of VAMP-2 and VAMP-3 in platelets minimally affects 
secretion, however, the additive loss of VAMP-2, VAMP-3, and VAMP-8 significantly 
diminishes secretion. This decrease is more evident in alpha and lysosomal secretion 
than in dense granule release. 
Using tail bleeding and arterial thrombosis assays, we show that the secretion 
deficiency in V-2/3-/- did not cause any hemostatic deficiency. While V-8-/- animals did 
not bleed, they did seem to have at least some protection from arterial thrombosis since 
the thrombus formation was delayed and diminished in these animals. V-2/3/8-/- 
animals bled profusely and failed to form a thrombus. Further investigation showed that 
though coagulation times were not changed, PS exposure was significantly reduced in V-
2/3/8-/- animals potentially affecting thrombin formation that led to a hemostatic 
defect.  
  
 111 
 
Chapter 4 Alpha-granule cargo decondensation is VAMP-
dependent 
 
(This Chapter of the dissertation is a work done as a collaboration with Dr. Brian Storrie 
and Irina Pokrovskaya from the University of Arkansas for Medical Sciences. Credits for 
imaging and analysis has been given under each figure) 
Introduction 
Platelet granule exocytosis is a central event for platelet function in a wide array 
of physiological and pathological conditions including hemostasis and thrombosis. 
Platelets contain three types of granules: dense, alpha and lysosomes. Dense granules 
contain small molecules like ATP, ADP, and calcium that work as secondary agonists. 
Alpha granules contain more than >200 proteins that play roles in angiogenesis, 
infection, immunity and wound healing. Lysosomal contents include β-hexosaminidase 
and cathepsins, important for clot remodeling. These granule cargoes are crucial for 
hemostasis since granulopathies that affect these granules lead to a wide range of 
bleeding disorders (Joshi and Whiteheart 2017). 
Alpha-granule cargoes are the most diverse in their functions and critical for a 
myriad of conditions, hence their composition has been a subject of intense 
investigation. While some reports suggest that each granule contains subpopulations of 
cargo residing at specific zones inside granules, others indicate that cargo is packed in 
subpopulations of alpha granules themselves and their release is agonist-dependent 
(Chatterjee, Huang et al. 2011). Though an appealing mechanism, multiple studies failed 
to find a correlation between the composition of cargo and agonist stimulation or 
function-dependent spatial segregation of cargo (Kamykowski, Carlton et al. 2011). In 
fact, a study by Jonnalagadda et al., showed that there is hardly any difference in cargo 
composition released after stimulation from four different agonists. The stronger the 
agonists, the more cargo molecules come out and the only constant feature is that 
release comes in three waves (Jonnalagadda, Izu et al. 2012). 
 112 
 
Recent advances in electron microscopy have provided necessary tools to 
prevent artifacts during sample preparation, fixation, and the imaging. Using these new 
technologies, the study of alpha granules suggests that they have a dense, condensed 
appearance perhaps due to the accumulation of dehydrated proteins that need to be 
dissolved to be released from granules. Alpha granules form small necks or longer pipes 
to fuse with the plasma membrane which play a role as routes for cargo release or 
conduits to allow an influx of extracellular plasma or water (Eckly, Rinckel et al. 2016, 
Pokrovskaya, Aronova et al. 2016). This influx of a solvent has been credited for the 
progressive increase in granule volume, solubilization of cargo leading to alterations in 
electron density of granules, and subsequent exodus of cargo from a fused granule. A 
granule decondensation has been observed in secretory vesicles (trichocysts) of 
Paramecium cells (Bilinski, Plattner et al. 1981), and mucin granules of Goblet cells 
(Perez-Vilar, Mabolo et al. 2006, Perez-Vilar 2007). However, though expected, the 
decondensing granules have not been yet identified in platelets.  
Here using secretion-deficient mouse strains, we show that the decondensation 
of alpha granules is a time-dependent and agonist concentration-dependent process 
and decondensation constitutes a real intermediate leading to cargo release. We also 
show that this process follows a granule fusion, and therefore VAMP deficiency leads to 
accumulation of these intermediates mainly in V-2/3/8-/- platelets. Secretion deficiency 
in V-8-/- platelets translates into delayed decondensation of alpha granules, while V-2/3-
/-  platelets do not show any differences. V-2/3/8-/- platelets have smaller alpha granules 
suggesting their role in vesicular trafficking.  
Results 
Condensation and decondensation of alpha granules 
Electron micrographs of resting and activated mouse platelets showed a 
heterogeneous population of alpha granules. Alpha granules in resting platelets 
displayed uniform density of contents- with darker nucleoid and lighter material packed 
in a granule (Figure 3.2 A). On the other hand, in agonist-stimulated platelets, various 
types of fusion events- heterotypic (granule to the plasma membrane/simple) (Figure 
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4.1 black arrow), and homotypic (granule to granule fusion/compound) were noted 
(Figure 4.1 red and purple arrows). These granules also differed from each other in the 
density of cargo suggesting an ongoing process of solubilization of cargo that may 
facilitate its release from the fusing granule. To see if these various stages of 
decondensation are really intermediates of granule exocytosis, we decided to conduct a 
detailed morphological study of stimulated platelets. 
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Figure 4.1. Condensed and decondensed alpha granules in activated mouse platelets 
An electron micrograph of a thin section (50 nm) of stimulated mouse platelets (0.1 
U/mL thrombin for 5 min) depicting simple fusion (black arrow) and various stages of 
decondensing compound fusion (red and purple arrows) events. 
(Samples generated by Smita Joshi and processing and imaging by Irina Pokrovskaya) 
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Alpha-granule decondensation is time-dependent 
Our previous experiments showed that the extent of granule secretion increases 
as the time increases, indicating that it is a time-dependent process (Figure 3.4 E). We 
hypothesized that since platelet secretion is a time-dependent process, the form of 
secreting/decondensing granules will alter in a time-dependent manner. To determine 
how the appearance of secreting granules alters over time, we performed a time course 
analysis by stimulating mouse platelets for various time points and fixing them for 
microscopic studies. We measured the frequency of condensed and decondensed 
granules at each time point. Condensed granules have a well-defined dense nucleoid 
like structure and an intact membrane (Figure 4.3 B, white star) while decondensed 
granules are fused to other granules, the plasma membrane or the open canalicular 
system (Figure 4.3 B, white arrowhead). Decondensed granules also vary in the 
appearance of granule cargo since the density of these cargoes is usually lighter than 
the condensed granules. Our data show that as stimulation time increased, the 
frequency of condensed granules decreased while decondensed granules increased. This 
is a classic example of a precursor-product relationship whereas the quantity of a 
precursor decreases, the quantity of a product increases. The data show that the 
frequency of condensed alpha granules decreased progressively with time, going from 
about 5 per platelet profile to less than 1 over 300 sec. Correspondently, the frequency 
of decondensed alpha granules increased for approximately the first 90 sec following 
stimulation. At 90 sec stimulation, the numbers for condensed and decondensed alpha 
granules added together were ~5, the initial value. At later time points, however, the 
sum was less as the frequency of condensed granules continued to decrease while that 
of decondensed granules failed to increase and, in fact, decreased slightly. This could be 
attributed to compound/granule-granule fusion events, which were already apparent at 
90 sec (Figure 4.3 B, arrowheads). Moreover, the gradual change in the appearance of 
decondensed granules may be challenging to detect at the maximal extent of release 
when the cargo become remarkably less dense. These data confirmed that the 
decondensation of granule cargo represents progressive intermediates in the secretion 
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process and the degree of decondensation may represent the extent of the granule 
cargo release.  
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Figure 4.2. A precursor-product relationship between condensed and decondensed 
granules 
The graph shows quantification of condensed and decondensed granules for eight-time 
points upon stimulation of mouse platelets with 0.1 U/mL thrombin. The average 
number of platelet profiles scored per data point was 45, range 19 to 50 and the 
average number of alpha granule profiles scored per time point was 213, range 96 to 
295.  
(Samples generated by Smita Joshi and processing and imaging by Irina Pokrovskaya) 
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Arresting secretion intermediates 
To investigate if and how the appearance of alpha granules changes as secretion 
proceeds, we selected a few time points for a detailed study of the morphology of 
decondensing granules based on earlier profiles (Figure 4.2). Washed mouse platelets 
were either kept resting or stimulated for 90 sec to monitor an intermediate/partial 
release step and for 300 sec to observe a maximal release from granules. These platelets 
were fixed, and microscopy was performed. 
Resting platelets maintained a characteristic discoid shape and contained 
condensed alpha granules with electron-dense matrix (Figure 4.3). Upon stimulus with 
either 0.1 U/mL or 0.5 U/mL thrombin, the platelets became rounded and extended 
pseudopods (Figure 4.3 B-D) indicating activation. Post 90 sec stimulation, alpha-granule 
cargoes appeared more fibrous and less electron dense (Figure 4.3 B, 90 sec stimulation, 
white arrowheads), indicating decondensation. Additionally, these decondensed 
granules also appeared slightly dilated with an increased diameter compared to 
condensed ones.  
The agonist dose affected granule decondensation process by influencing both 
the extent and the frequency of decondensation. First, alpha-granule cargo matrix 
displayed a greater extent of decondensation upon stimulation with 0.5 U/mL compared 
to 0.1 U/mL dose (Figure 4.3 B and D). Moreover, the frequency of decondensed vs 
condensed alpha granules was greater at the higher thrombin dose (data not shown). 
These data show that the stronger stimulation progressively affects granule release 
events and a similar effect could be achieved by a lower dose for a longer duration of 
stimulation. 
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Figure 4.3. A precursor to product relationship between condensed and decondensed 
alpha granules upon thrombin stimulation of wild-type mouse platelets 
A) In electron micrographs of thin sections of resting mouse platelets (0 sec), alpha granules 
appeared as round to ovoid structures marked by an electron-dense matrix. Discoid shape 
indicates a resting state. B) Upon thrombin stimulation (0.1 U/mL for 90 sec), platelets show 
filopodia and lamellipodia formation with decondensed alpha granules that are marked by the 
residual fibrous matrix. White arrows show compound fusion event and the white asterisk 
indicates condensed granules C) Upon longer stimulation (0.1 U/mL thrombin for 300 sec), 
progressive decondensation noted with decondensed granules and compound fusion events are 
indicated with white arrows. D) Higher concentration of agonist (0.5 U/mL thrombin for 90 sec) 
stimulation, showed faster decondensation of granules. Scale bar-1 µm. The average number of 
platelet profiles scored per data point was 45, range 19 to 50 and the average number of alpha-
granule profiles scored per time point was 213, range 96 to 295.  
 (Samples generated by Smita Joshi and processing and imaging by Irina Pokrovskaya) 
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Granule decondensation is VAMP-dependent 
Since the decondensation extent is dependent on the stimulation strength and 
the time, we next asked if granule fusion is required for decondensation to occur. To 
test this, we employed VAMP KO mouse models where multiple VAMP isoforms were 
deleted that resulted in various degrees of granule secretion deficiencies in these 
platelets. Briefly, isolated mouse platelets were radiolabeled with tritiated serotonin 
and were stimulated with 0.1 U/mL thrombin. This concentration was chosen to 
optimally stimulate platelets to monitor morphological differences (Figure 3.4 A, B and 
C). The data show that the deficiency of VAMP-8 leads to decreased dense granule 
secretion suggesting that VAMP-8 is important for dense granule release. The loss of 
VAMP-8 has a greater impact on alpha-granule and lysosomal release compared to 
dense granule release implying that the defective release of secondary agonists from 
dense granules has downstream consequences. The loss of VAMP-2 and VAMP-3 in V-
2/3-/- platelets did not affect dense and alpha-granule release but had a minor defect on 
a lysosomal release. The accumulative loss of all three isoforms in V-2/3/8-/- platelets led 
to a significant decrease in cargo release from all three granules (Figure 4.4). In these 
platelets, dense granule release was affected by 50% and there was about only 25% 
release from alpha-granules and lysosomes indicating severe secretion deficiency. 
To study the morphology of the platelets and platelet alpha granules at each of 
these time points, we stopped the reaction with a fixative and performed an electron 
microscopy. We decided to select a few time points that would yield a good 
representation of degranulation intermediates in this process, so we chose resting, 90 
sec stimulation (early intermediate), and 300 sec (maximal release) points for further 
structural studies based on our earlier analysis with WT mouse platelets (highlighted 
with arrows in Figure 4.4). 
To study if decondensation is VAMP-dependent, we used secretion defective 
VAMP-deficient strains explained in Chapter 3. V-8-/- platelets which have been shown to 
be significantly deficient in secretion showed delayed alpha-granule decondensation 
(Figure 4.5 and Figure 4.6 A). At 90 sec stimulation, decondensed granules were fewer 
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than the condensed ones. However, the loss of VAMP-8 could be overcome by ancillary 
VAMP isoforms at a higher or longer stimulation. This is evident at the 300 sec time 
points where decondensed granules were more prevalent than the condensed ones. 
VAMP-2, -3, and -7 act as ancillary VAMPs in absence of VAMP-8 and their loss had a 
minimal impact on alpha-granule secretion (Figure 4.5 and Figure 4.6 B). These platelets 
showed remarkable decondensation even at the 90 sec time point. In contrast, the loss 
of all these three VAMP isoforms inhibited granule secretion in V-2/3/8-/- platelets 
(Figure 4.5 and Figure 4.6 C). 
In sum, these data strongly indicate that alpha-granule decondensation follows 
VAMP-mediated granule fusion events prior to cargo release to the external 
microenvironment. This cargo decondensation may depend on extracellular solvent 
influx inside the granule.  
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Figure 4.4. Granule secretion is differentially affected in V-8-/-, V-2/3-/- and V-2/3/8-/- 
platelets 
Mouse platelets from indicated VAMP strains were stimulated with 0.1 U/mL thrombin 
for indicated time points and secretion from each type of granule was measured. A- 
Dense, B- Alpha, C- Lysosome. Arrows point out resting, 90 sec and 300 sec time points 
used for further analysis. Statistical analysis done by one-way ANOVA and asterisks 
represent p value<0.05.  
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Figure 4.5. V-8-/- platelets exhibit delayed and diminished alpha-granule secretion 
while it is essentially blocked in V-2/3/8-/- platelets 
(A). Thin section electron microscopy of V-8-/- platelets:  0, 90, and 300 sec stimulation 
with 0.1 U/mL thrombin. (B). Thin section electron microscopy of V-2/3-/- platelets: 0, 
90, and 300 sec 0.1 U/mL thrombin stimulation. (C). Thin section electron microscopy of 
V-2/3/8-/- platelets: 0, 90, and 300 sec 0.1 U/mL thrombin stimulation. The number of 
platelet profiles scored for each time point ranged from 41 to 50 and the total number 
of alpha-granule profiles ranged from 403 to 118, the number decreases with 
compound fusion. Means and standard error of the mean are presented. 
Scale bar equals 1 µm.  
(Samples generated by Smita Joshi and processing and imaging by Irina Pokrovskaya) 
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Figure 4.6. Quantification of condensed and decondensed granules from V-8-/-, V-2/3-/- 
and V-2/3/8-/- platelets. 
Quantification of the effect of VAMP-8 deletion (A), VAMP-2 and VAMP-3 deletion (B) or 
VAMP-2, -3 and -8 deletions (C) on the decondensation kinetics of mouse platelet alpha 
granules. The number of platelet profiles scored for each time point ranged from 41 to 
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50 and the total number of alpha-granule profiles ranged from 403 to 118, the number 
decreases with compound fusion. Means and standard error of the mean are presented. 
 (Samples generated by Smita Joshi and processing and imaging by Irina Pokrovskaya) 
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Alpha-granule decondensation is linked to granule-plasma membrane and granule-
granule fusion 
The data from the time course analysis indicated that decondensation is VAMP- 
dependent and granule fusion-dependent. This means that granule fusion may provide 
entry to an extracellular solvent that is necessary for cargo solubilization facilitating the 
release of these cargoes. To find evidence of this mechanism, we wanted to analyze 
fusion events and see how they correlate with decondensation. In thin sections (50 nm 
thickness), granule fusion events were rare. It was not surprising since the sampling 
volume was comparatively small relative to alpha-granule volume (200-500 nm) and 
platelet size (2-3 µm diameter). To overcome this challenge, we used thick sections (300 
nm) that significantly increase sampling volume for electron tomography. 
As shown in Figure 4.7, various possible routes of granule membrane fusion and 
potential routes of water/solvent influx were noted. These routes include small, short 
necks (Figure 4.7 A, D white arrows), longer pipes (Figure 4.7 B right arrow), and notably 
wider openings (Figure 4.7 B- C). All these routes were marked by residual fibers 
indicating the exodus of the fibrous material from granules. Additionally, multiple 
compound fusion events (granule to granule fusion) were observed where multiple 
granules fused to each other either before or after fusing to the plasma membrane 
(Figure 4.7 C, right arrow). Even in these 300 nm thick sections of platelets, the sample 
volume was insufficient to study the full granule volume and hence a direct linkage 
between membrane fusions and granule decondensation could be established for only a 
small portion of the alpha-granule population. We did not observe any fused granule 
substantially merge with the plasma membrane. In fact, a granule marked with a dilute 
luminal matrix remained present in all instances. This suggests that the granule matrix 
may adhere or associate in some form to the platelet exterior and may also contribute 
to the release of cargo long after the cargo is dispelled from granules. 
Next, we studied the incidence of simple (granule to plasma membrane) or 
compound (granule to granule) fusion events. Three-dimensional structure of activated 
platelets was reconstructed based on z tilt series. This technique facilitated analysis of 
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different modes of fusion, however, though the samples size was bigger (300 nm) 
compared to thin section (50 nm) microscopy, it was sufficient to provide the full 
volume of only a few platelets for fusion measurements. 
Our data show that the incidence of simple fusion events was dominant in all 
WT, V-2/3-/- and V-8-/- platelets. These events were lower at early time points but rapidly 
increased as stimulation time increased (Figure 4.7 E). However, V-2/3/8-/- platelets 
showed minimal simple fusion events supporting their severe secretion deficiency. Our 
data show that the incidence of compound fusion events was about three times higher 
than that of simple fusion events (Figure 4.7 F), perhaps due to some technical 
challenges that affect detection of simple fusion events. V-2/3-/- platelets showed an 
increase in compound fusion events compared to WT platelets while the loss of VAMP-8 
affected the compound fusion events supporting previous reports suggesting the role of 
VAMP-8 in compound fusion events (Eckly, Rinckel et al. 2016). 
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Figure 4.7. Alpha-granule fusion with the plasma membrane strongly correlates with 
granule decondensation 
Examples of simple and compound fusion events are shown with decondensing granules 
containing fibrous material. An alpha-granule fusion with plasma membrane with a 
short neck marked by a white arrow (A), and (C). Decondensing granules also showed a 
wider neck (B). The right white arrow shows a short neck and left arrow shows residual 
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fibrous material near fusion pore (D). Incidence plot for simple (granule to plasma 
membrane) fusion events vs time. The average number of platelet profiles scored was 
16, range 9 to 28 and the average number of fusion events scored per time point was 
3.3, range 0 to 11. Incidence plot for compound (granule-granule) fusion vs time. The 
average number of platelet profiles scored was 16, range 9 to 28 and the average 
number of alpha-granule profiles scored per time point was 9.3, range 0 to 28 (F).  
(Samples generated by Smita Joshi and processing and imaging by Irina Pokrovskaya) 
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VAMP-8 depletion is associated with decreased fusion pore diameter 
To understand if fusion pore size affects the decondensation and secretion process, we 
stimulated platelets with 0.1 U/mL thrombin for either 90 sec or for 300 sec and fixed 
for electron microscopic analysis. We measured the diameters of fusion pores from z 
stack images (Figure 4.8 I-K) and based on the measurements, classified these pores in 
three groups: 0-50 nm, 51-100 nm, and more than 100 nm diameter. The data show 
that fusion pore diameter increases in a time-dependent manner. In WT platelets, upon 
90 sec stimulation, few pores have a diameter more than 100 nm while the number 
increases notably upon 300 sec stimulation time (Figure 4.8 A and E). In absence of 
VAMP-2 and -3, few fusion pores with less than 100 nm diameter are observed at 90 sec 
stimulation (Figure 4.8 B), the number increases upon 300 sec stimulation time (Figure 
4.8 F). The loss of VAMP-8 however, severely affects fusion pore sizes and which are 
recovered upon longer stimulation time (Figure 4.8 C and G). The cumulative loss of 
VAMP-2, -3, and -8 drastically reduces fusion pore size at both shorter and longer 
stimulation times (Figure 4.8 D and H).  
These data suggest that VAMPs may regulate fusion pore size. The loss of VAMPs 
reduced the pore size at 90 sec stimulation but not at longer (300 sec) stimulation time 
suggesting that the absence of VAMP-8 is compensated by other residual VAMPs. In 
contrast, the loss of VAMP-2 and -3 did not have any negative influence at 90 sec 
stimulation however at 300 sec stimulation time, the incidence of the pores wider than 
100 nm slightly decreased. As expected the incidence of fusion events was lower in V-
2/3/8-/- platelets. 
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Figure 4.8. VAMP-8 depletion affected fusion pore size. 
Platelets from the indicated mouse strains were stimulated for 90 (A-D) or 300 (E-H) sec 
with 0.1 U/mL of thrombin and fixed for electron microscopy analysis. Maximum pore 
sizes (diameter) were measured from the appropriate slices of tomograms with a Z-step 
size of 1.8 nm. Pores of given sizes were grouped into three bins, and the total number 
of pores counted was used to calculate an incidence value (# pores in a bin/total pores). 
At the indicated time points, 15-29 platelet profiles were scored for each mouse variant. 
I-J) Example illustrations showing the information gained by tracing the pore formation 
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process at different depths, VAMP-2/3-/- platelets. (I). Arrow points to what appeared at 
-38 nm as a tubular granule extension, in (J) as the maximum diameter membrane 
fusion pore, and an asterisk marks a very small pore of unknown stability and in (K) as a 
small indentation of the plasma membrane.  
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Conclusions 
The rate of alpha-granule cargo release is diverse with three different rates that 
vary from slow to fast release (Jonnalagadda, Izu et al. 2012). Various theories 
suggested that either there might be different subpopulations of alpha-granules that 
contain specific cargoes which are released upon specific agonist stimulation or there 
might be spatial segregation of cargo within the same granule population. A systematic 
study showed that cargo release is dependent on an agonist potency and kinetically, the 
rates at which alpha-granule cargoes come out could be divided into three groups: 
fastest, medium and slow release. Though the kinetic heterogeneity could explain the 
nature of the release, it was not clear how does this heterogeneity arise. 
Here we address this question by using VAMP-deficient mouse strains that show 
secretion defects of various ranges and modern microscopic techniques- high-pressure 
freeze for sample preparation and scanning electron microscopy and three-dimensional 
tomography for imaging. The data indicate that the decondensation of granule cargo is 
an agonist-dependent and stimulation time-dependent process. A granule fusion is 
necessary to occur for cargo decondensation to take place. The rate of solubilization 
may dictate the rate of cargo release even after the complete exodus of cargo from the 
fused granule. 
The insight from this study provides a mechanistic understanding of how the 
rates of release vary depending on the strength of an agonist or the duration of 
stimulation. These findings are crucial for understanding the rates and extents of 
platelet alpha-granule secretion since platelet secretion regulates the thrombus 
composition. This study is unique because it synchronizes the biochemical analysis of 
platelet secretion to granule morphology. Moreover, it also presents platelet secretion 
as a model system to study mechanistic details. 
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Chapter 5 Role of VAMPs in intracellular trafficking 
Introduction 
Intracellular trafficking in platelets is a crucial process for granule biogenesis and 
cargo packaging. Studies focused on dense and alpha granulopathies have been 
instrumental in shaping our understanding of these processes. Lack of granule cargo in 
these SPDs leads to multiple anomalies including lack of pigmentation, significant 
immunodeficiencies, and most importantly, severe bleeding diathesis. Though our 
understanding of these cellular events has expanded in recent years, a clear picture is 
yet to emerge. 
Platelets contain translation machinery, and can de novo synthesize at least 
some part of their proteome such as PF4. Additionally, they also endocytose proteins 
from plasma (e.g., fibrinogen) to survey their microenvironment. Endocytosed cargo 
travels through early and late endosomes and multivesicular bodies, before being 
trafficked to the alpha granules while de novo synthesized cargo could be trafficked to 
the endosomal system or directly to granules (Figure 6.6). Recent reports suggest that 
Nbeal2, VPS 33B, and VPS 16B play roles in these trafficking events, though mechanistic 
details are still unknown (Gissen, Johnson et al. 2004, Lo, Li et al. 2005, Cullinane, 
Straatman-Iwanowska et al. 2010, Albers, Cvejic et al. 2011, Gunay-Aygun, Falik-Zaccai 
et al. 2011, Kahr, Hinckley et al. 2011, Bem, Smith et al. 2015). 
VAMP isoforms are known to play roles in membrane trafficking in other systems 
as discussed earlier in Chapter 1. In platelets, VAMP-3 is crucial for endocytosis. Roles of 
other VAMP isoforms are not clear since V-7-/- and V-8-/- platelets do not show any 
changes in cargo levels suggesting compensation by other VAMPs. We hypothesized 
that deletion of multiple VAMP isoforms will affect intracellular trafficking in both 
endocytic as well as synthetic pathways influencing cargo levels in these platelets. To 
address this, we studied the morphology of VAMP deficient platelets and using arrays 
we probed for the extent of deficits in cargo levels. We found that alpha-granules are 
smaller and more numerous in V-2/3/8-/- platelets and cargo levels are notably 
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decreased. This indicates that the loss of multiple VAMP isoforms affects platelet 
intracellular trafficking.  
Results 
Fibrinogen levels are decreased in V-2/3-/- and V-2/3/8-/- platelets 
Western blot analysis of extracts from V-2/3-/-, V-8+/-(2/3)-/- and V-2/3/8-/- 
platelets show that fibrinogen levels were diminished by about 20%, 20% and 50% in 
these strains, respectively (Figure 3.3). VAMP-3 plays a crucial role in endocytosis and 
the absence of VAMP-3 leads to a defect in fibrinogen uptake. These data show that 
progressive loss of VAMP-8 in addition to the absence of VAMP-2 and VAMP-3 further 
depresses fibrinogen intake in these platelets causing a significant decrease in 
fibrinogen levels in V-2/3/8-/- platelets. A deficiency of VAMP-3 in the global KO mouse 
strain leads to about a 50% decrease in fibrinogen uptake while it is only about 20% 
diminished in platelet-specific V-2/3-/- platelets suggesting that the expression of the 
PF4 promoter-driven Cre recombinase at early stages may contribute to this phenotype. 
Selected dense granule, alpha-granule, and lysosomal cargoes were unaltered in V-8-/-, 
V-2/3-/- and V-2/3/8-/- platelets 
To study if the loss of VAMP-2, -3 and -8 causes any defects in cargo uploading in 
dense granules, we incubated washed platelets with [3H] serotonin for 45 min at 37°C. 
After washing to remove excess serotonin, we stimulated platelets with either various 
concentrations of agonists or at different time points to measure the serotonin release 
from platelets. We calculated total serotonin uptake levels in the supernatant 
(releasate) and pellet. The data showed that there was no significant difference among 
the levels of serotonin uptake in WT, V-8-/-, V-2/3-/- and V-2/3/8-/- platelets suggesting 
that cargo uptake in dense granule is not affected in these strains (Figure 5.1 A). PF4 is a 
de novo synthesized protein in platelets. Using commercial PF4 sandwich ELISA assays, 
we measured the total amount of PF4 in these platelets (releasate +pellet) and found no 
difference among strains indicating that PF4 synthesis and/or trafficking is not altered in 
these strains (Figure 5.1 B). Similarly, we also measured the soluble lysosomal cargo β-
hexosaminidase levels among these strains and found no difference (Figure 5.1 B). 
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These data show that soluble cargo levels in dense, alpha and lysosomes were not 
affected in these strains. 
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Figure 5.1. Dense, alpha, and lysosomal cargo levels are normal in V-8-/-, V-2/3-/- and 
V-2/3/8-/- platelets 
Cargo levels were calculated from in vitro platelet secretion assays. Total serotonin 
levels indicate tritiated serotonin uptake in platelets PF4 levels were calculated from 
sandwich ELIZA and β-hexosaminidase levels were calculated based on the colorimetric 
assay (see methods for details). Cargo levels in KO strains were normalized by levels in 
WT platelets. Data are representative of three independent experiments Student’s t-test 
indicates no significant difference.  
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Figure 5.2. Dense, alpha and lysosomal cargo levels are normal in V-8+/-(2/3)-/- 
platelets 
Cargo levels were calculated from in vitro platelet secretion assays. Total serotonin 
levels indicate tritiated serotonin uptake in platelets PF4 levels were calculated from 
sandwich ELIZA and β-hexosaminidase levels were calculated based on the colorimetric 
assay. (see methods for details). Cargo levels in KO strain were normalized by levels in 
WT platelets. Data are a representative of two independent experiments. Student’s t-
test indicates no significant difference.  
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V-2/3/8-/- platelets have smaller alpha-granules 
To study if the loss of multiple VAMP proteins affects platelet morphology, we 
used a novel approach. It has been shown that even minimal handling and washing 
could stimulate platelets (Pokrovskaya, Aronova et al. 2016). To prevent that, platelets 
were immediately fixed while drawing blood through cardiac puncture and prepared for 
microscopic studies. 
SEM images show that the gross morphology of platelets was not affected in 
these VAMP KO strains. Platelet granules, mitochondria, and microtubules were evident 
in micrographs. Though the size of alpha-granules was not affected in V-8-/- and V-2/3-/- 
platelets, alpha-granules in V-2/3/8-/- platelets were about 30% smaller than controls 
suggesting that the granule genesis might be affected in these platelets. Though smaller 
in size, the number of alpha-granules was not increased in these platelets. The loss of 
VAMP-8 or the loss of VAMP-2 and -3 did not influence the granule size or number 
suggesting that the loss of one or two isoforms does not influence granule formation. 
  
 140 
 
 
Figure 5.3. The loss of VAMP-2, -3 and -8 affects alpha granule size but not granule 
numbers per platelet. 
Thin section, electron microscopy images of platelets from the indicated mouse strains 
were analyzed for granule number per platelet profile (A). and cross-sectional granule 
area (B). Fifty platelet profiles were scored for each mouse strain and the averages and 
standard deviations are presented. Student’s t-test was used to establish statistical 
significance as indicated. 
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V-2/3-/- and V-2/3/8-/- platelet granules have a trafficking defect 
We used antibody arrays to determine if these platelets have any cargo defects. 
We measured alpha-granule cargo platelet factor 4\PF4 using ELISA assays which 
showed no significant difference among these strains (Figure 5.1 B). PF4 levels were 
used as an internal control to interpret the results from antibody arrays. Array data 
showed that PF4 levels were not altered significantly in V-8-/- (Figure 5.4), V-2/3-/- (Figure 
5.5), or in V-2/3/8-/- (Figure 5.6) validating our findings from ELISA assays and indicating 
that the cargo deficits noted using these antibody arrays could be reproducible. The 
results show that there is a global deficit in protein levels in these platelets. VAMP-8 
deficient platelets show a milder defect than V-2/3-/-  platelets. This defect progressively 
gets worse in V-2/3/8-/- platelets. It should be noted that nothing is completely missing 
from V-2/3/8-/- platelets. All proteins tested are present, but the efficacy of biogenesis/ 
trafficking/packaging seems to be much more heterogeneous. To see if a specific cargo 
is more affected than another, we analyzed pro- vs anti-angiogenic molecules, growth 
factors, tissue factors, chemokines, and cytokines and found that all classes of proteins 
were decreased in some extent indicating that overall trafficking might have been 
affected. 
Protein levels in V-8-/- platelets (Figure 5.4 and Table 5.1) were not much 
affected but levels in V-2/3-/- platelets (Figure 5.5 and Table 5.1) were noticeably 
decreased supporting our earlier report of the role of VAMP-3 in endocytosis and 
vesicular trafficking in platelets. Loss of all three isoforms further affected the levels. 
VAMP-2/3/8-/- platelets showed that more than 50% of cargo tested diminished by at 
least 20% or more indicating that the loss of multiple VAMP isoforms has a global effect 
on intracellular trafficking (Figure 5.6 and Table 5.1). 
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Conclusions 
The role of SNAREs in intracellular trafficking is well known, however, it is not yet 
clear how they participate in trafficking in platelets. A recent report shows that VAMP-3 
is crucial in platelet endocytosis though the roles of other VAMPs remain unclear. Here 
using our wide array of VAMP deficient strains, we address the question how the loss of 
VAMPs affects intracellular trafficking in platelets.  
Using antibody arrays, we found that there is a global defect in cargo levels in 
absence of VAMP isoforms and the extent of this defect increases with the loss of 
multiple VAMP isoforms. This suggests that individual VAMP isoforms facilitate 
intracellular trafficking, however, their loss is compensated by other residual VAMP 
isoforms. V-8-/- and V-2/3-/- platelets show some decrease in cargo levels suggesting that 
the functional redundancy among VAMPs may have dampened the effects of their loss. 
However, deletion of three major isoforms in V-2/3/8-/- cannot be efficiently 
compensated for by residual VAMP-7, which is also reduced by about 50%. This leads to 
smaller and more numerous alpha-granules with remarkably diminished cargo levels in 
V-2/3/8-/- platelets. 
Thus, findings from these studies show that VAMPs are indispensable for 
trafficking and further studies are needed to specifically determine roles of each 
isoform. The results from these studies will have a major impact not only hemostatic 
functions of platelets but also immunological roles of platelets that are newly emerging. 
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Figure 5.4. V-8-/- platelets have a complex granule cargo defect 
 Platelet extracts were prepared from WT or V-8-/- mouse and probed using duplicate 
Mouse Angiogenesis Antibody Arrays (see Methods). The fluorescence intensity from 2 
individual experiments was used to calculate a V-8-/- /WT ratio for each protein detected 
on the array. The average of the 2 calculated ratios is plotted. Note that the y-axis is a 
log scale. The red arrow on the x-axis shows the normalized levels of PF4.  
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Figure 5.5. Granule cargo deficiency in V-2/3-/- platelets 
Platelet extracts were prepared from WT or V-2/3-/- mouse and probed using duplicate 
Mouse Angiogenesis Antibody Arrays (see Methods). The fluorescence intensity from 2 
individual experiments was used to calculate a V-2/3-/- /WT ratio for each protein 
detected on the array. The average of the 2 calculated ratios is plotted. Note that the y-
axis is a log scale.  
The red arrow on the x-axis shows the normalized levels of PF4.  
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Figure 5.6. V-2/3/8-/- platelets have reduced granule cargo levels 
Platelet extracts were prepared from WT or V-2/3/8-/- mouse and probed using 
duplicate Mouse Angiogenesis Antibody Arrays (see Methods). The fluorescence 
intensity from 2 individual experiments was used to calculate a V-2/3/8-/- /WT ratio for 
each protein detected on the array. The average of the 2 calculated ratios is plotted. 
Note that the y-axis is a log scale.  
The red arrow on the x-axis shows the normalized levels of PF4.  
 
 146 
 
Table 5.1 Summary of cargo levels in V-8-/-, V-2/3-/- and V-2/3/8-/- platelets 
 
Amount of cargo V-8-/- V-2/3-/- V-2/3/8-/- 
25% or less 0 1(2%) 5(9%) 
25-50% 14(26%) 22(42%) 26(49%) 
50-75% 27(51%) 23(43%) 20(38%) 
75-100% 11(21%) 6(11%) 2(4%) 
100% and above 1(2%) 1(2%) 0 
Total 53(100%) 53(100%) 53(100%) 
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Chapter 6 Discussion 
Overview 
Cardiovascular diseases/CVDs contribute to more than 30% of all deaths 
worldwide (American Heart Association Statistics, 2017). Previously thought to be 
diseases of affluence, CVDs have noticeably permeated the developing world and has 
become the number one contributing factor to morbidity and mortality, causing one out 
of every four deaths. Despite impressive advances in anticoagulant and antiplatelet 
therapies in the last few decades, the current antithrombotic repertoire still lacks 
precision at which occlusive thrombosis could be prevented without risking spurious 
bleeding (Khurram, Chou et al. 2006, Holmes, Kereiakes et al. 2009, Berger, Bhatt et al. 
2010, Hira, Kennedy et al. 2015). The ongoing debate on the efficacy of combined 
antiplatelet drugs such as aspirin and clopidogrel with potent anticoagulant like warfarin 
suggests that new armamentarium of antiplatelet drugs that will achieve this much 
desired hemostatic balance is urgently needed (Dewilde and Berg 2009, Gao, Zhou et al. 
2011, Zhao, Zheng et al. 2011). Platelets are indispensable in maintaining the vascular 
integrity and therefore, a clear understanding of the optimal level of platelet secretion 
will aid in the management of anti-thrombotics without unwanted bleeding. 
Platelet secretion at the site of vascular injury decides the fate of thrombus 
formation and subsequent recovery. A plethora of research has been done on a wide 
range of molecules that play roles in platelet secretion. These molecules include, but are 
not limited to, SNAREs- (both v and t - SNAREs) (Ren, Barber et al. 2007, Koseoglu, 
Peters et al. 2015), SNARE regulators (STXBP5/Tomosyn), Rab effectors (granuphilin), 
tethering factors (Munc 18b, Munc 13b), GEFs (Cal DAG) and GAPs (RASA3), trafficking 
molecules (Rab 27b) and endocytosis players (dynamin). These molecules have been 
attributed to a wide range of hemostatic roles and could be used as potential 
therapeutic targets. However, uncertainty about how much secretion from platelets is 
necessary to balance hemostasis occludes their therapeutic promise. 
Platelet granule release is a remarkably dynamic event. These small cellular 
fragments are expected to rapidly form a dense aggregate under high-pressure blood 
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flow in a closed vascular system to stop bleeding. Localized release at the site of 
vascular injury to stop bleeding is inefficient considering the high shear force present in 
vessels. To overcome this challenge, platelets are armed with various strategies that 
help control the nature of the fusion event and the cargo release. It is essential to 
appreciate this complexity to control platelet function and find an ideal hemostatic 
balance. 
With advancing technologies, our understanding of platelet secretion has 
significantly improved in the last two decades, however, on a cellular level, many 
mechanistic details of cargo release are still under investigation. First, what determines 
the rates and the extent of granule cargo release? Do these factors have a similar effect 
on all granule release events, i.e. dense, alpha and/or lysosomal release? Does the 
nature of fusion events- simple vs compound- contribute to determining the rate and 
the degree of granule secretion? Does the composition of granule cargo, solubility 
and/or a presence of a scaffold protein decide the nature of fusion event? Could these 
characteristics of the rate and the degree of secretion be manipulated to control 
thrombosis upon vascular injury? This Chapter describes how my work addresses these 
important questions. The first part of this dissertation addresses the questions about 
how much granule secretion is necessary to attain hemostatic balance where occlusive 
thrombosis is prevented without triggering spurious bleeding while the second part 
describes how granule cargo release is dependent on multiple factors that ensure the 
optimal effect of diverse cargo at the site of vascular injury. 
Part I- Titrating VAMPs to achieve hemostatic balance  
The nature of platelet secretion is a decisive factor in maintaining hemostatic 
balance. Multitudes of reports indicate that defective or diminished platelet secretion 
affects hemostasis in varying degrees. These defects either disturb platelet granule 
formation as noted in granule storage pool deficiencies/SPDs or they influence cargo 
trafficking and or granule fusion machinery (Joshi and Whiteheart 2017). Additionally, 
GWAS studies indicate that SNPs in some platelet secretion machinery such as VAMP-8 
(Shiffman, Rowland et al. 2006, Shiffman, O'Meara et al. 2008) and microRNAs that 
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control their expression (Kondkar, Bray et al. 2010), contribute in hyperreactive platelets 
leading to increased susceptibility of these individuals to cardiovascular events. Though 
its importance is well established, the exact nature of platelet secretion remains elusive. 
To decode the nature of platelet secretion we addressed the following series of 
questions. We asked how the rates and the extent of cargo release are controlled. How 
the nature/mode of granule fusion affects the secretion. How the dense granule vs 
alpha-granule release regulates the progression and the architecture of thrombus 
formation. And most importantly, how much platelet secretion is necessary to achieve 
hemostatic balance. 
To address these questions, we turned to the platelet secretion machinery. 
Though t-SNARE usage syntaxin-11, syntaxin-8, and SNAP23 are imperative for platelet 
secretion, v- SNARE usage was not clear. Using V-8-/- animals and tetanus toxin treated 
platelet permeabilization assays, we showed that in platelets, VAMP-8 is a primary v-
SNARE while VAMP-2 and -3 play accessory roles (Ren, Barber et al. 2007). Recently, 
VAMP-7 has been shown to play a role in platelet secretion as well (Koseoglu, Peters et 
al. 2015). Based on these data, we decided to create a system by altering the types and 
amounts of various VAMP isoforms in platelets. Our hypothesis was that each VAMP 
isoform differentially contributes to granule secretion process. By manipulating the 
levels and types of these isoforms, we could determine the threshold level of secretion 
that will inhibit occlusive thrombosis without triggering unwanted bleeding.  
Quantification of VAMPs in murine strains 
Using the quantitative data based on western blots, we could estimate how 
much of total VAMP isoforms are left in each of these VAMP-deficient strains. There are 
multiple studies on platelet proteomics, both human (Burkhart, Schumbrutzki et al. 
2012) and mouse (Zeiler, Moser et al. 2014) platelets with minor differences. We used 
quantitative blot data (Graham, Ren et al. 2009) to compare and analyze various results 
presented here (Table 6.1 and Figure 6.1 A). Based on this quantitation, we show that 
our mouse models display an impressive, wide array of VAMP isoforms and amounts in 
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mouse models. These include amounts from 100% in WT to about 13% in V-2/3/8-/- 
animals. 
Secretion and hemostatic balance 
The loss of a primary v-SNARE, VAMP-8, leads to a significant secretion deficiency that is 
mainly manifested in alpha and lysosomal release other than in dense granule release 
(Figure 6.1 C). These deficiencies do not lead to any bleeding defect but instead delay 
and diminish thrombus formation (Graham, Ren et al. 2009). On the other hand, VAMP-
2/3-/- platelets secrete normally and do not have any hemostatic or thrombotic 
deficiencies indicating their ancillary roles in platelet secretion (Figure 6.1 C and D). V-
2/3/8-/- platelets show significantly reduced secretion from all three granules but 
predominantly affect alpha and lysosomes. These animals represent an extreme 
imbalance in hemostasis with increased bleeding and failure to form a thrombus. The 
only major VAMP isoform that is present in these strains is VAMP-7. The Flaumenhaft 
group showed that V-7-/-  platelets had ATP secretion defects as well as alpha-granule 
secretion deficiency (Koseoglu, Peters et al. 2015). In fact, the loss of VAMP-7 displays 
similar patterns of dense and alpha-granule secretion deficit as observed in V-8-/- 
platelets (Table 6.1). However, these defects do not translate into elevated bleeding 
times or defective thrombus formation post laser injury indicating that VAMP-7 loss 
could be well compensated by VAMP-8 and the secondary VAMPs (Koseoglu, Peters et 
al. 2015). These data beg the question of what causes this difference in hemostasis and 
thrombosis in V-7-/- vs in V-8-/- animals. 
Mass action and/or intrinsic property 
Since both VAMP-7 and VAMP-8 are critical for platelet secretion and are 
abundantly present in platelets, the question arises of whether their abundance makes 
them vital for secretion or whether there is an intrinsic property of these isoforms that 
is central to their roles in secretion. Based on our quantitative analysis and its 
correlation with secretion events and hemostasis, an abundance of VAMP isoforms is 
not the only decisive factor in secretion process (Figure 6.1). It is mainly evident in case 
of V-8+/-(2/3)-/- platelets that harbor only about 30% of total VAMP isoforms (Table 6.1) 
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and yet do not have any secretion deficiency or hemostatic defects (Figure 3.5 and 
Figure 6.1).  
To address this question, we compared protein sequences of mouse VAMP-2, -3, 
-7 and -8 and using alignment analysis studied how identical all these isoforms are from 
each other. We found that VAMP-2 and -3 share about 70% identity on the entire 
protein sequence (Figure 6.2 and Table 6.2) and about 98% identity within SNARE 
domains, which could explain their redundant roles in secretion (Figure 6.3 and Table 
6.3). On the other hand, VAMP-7 and -8 share only about 30% amino acid sequence 
identity and their SNARE domains share only about 40% identity with each other (Figure 
6.3 and Table 6.3). Despite these different SNARE domains, VAMP-7 and -8 have almost 
similar rates and extents of cargo release. One possibility might be that the differences 
in SNARE domain and transmembrane/TM domains influence fusogenicity of these 
isoforms. The role of TM domains of v-SNAREs has been vigorously studied. 
Replacement of the VAMP-2 TM domain with membrane spanning lipids led to SNARE 
complex formation but not fusion (McNew, Weber et al. 2000). Similarly, point 
mutations in TM domains failed to fuse, underlining the importance of TM domains in 
granule fusion (Fdez, Martinez-Salvador et al. 2010, Shi, Shen et al. 2012). Though most 
of these studies focused on VAMP-2, it is reasonable to expect a similar pattern with 
other VAMP isoforms. These data suggest that minor differences in TM domains may 
become instrumental in the transduction of force on lipid bilayer that changes the 
outcome of a fusion event.  
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Table 6.1 Summary of characterization of VAMP KO strains 
Mouse 
Strain 
% 
Remaining 
Alpha 
(%) 
Dense 
(%) 
Lysosome 
(%) 
Bleeding Time 
(sec) 
Thrombosis 
Time (min) 
PS 
exposure 
Spreading 
WT 100 100 100 100 250.07±86.82 6.55±2.48 100  
V-3-/- 89.5 100 100 100 275.08±92.27 NA NA Increased 
V-7-/- 87 55 66 NA NA (no defect) NA NA Decreased 
V-8+/- 80 100 100 100 288.27±104.42 7.16±2.53 100 NA 
V-2/3-/- 53 100 100 100 279.85±107.06 7.12±1.87 70 No change 
V-8+/-(2/3) -/- 33 100 100 100 269.05±108.98 6.75±2.9 70 NA 
V-8-/- 60 62 85 70 281.23±71.24 21.27±8.68 100 Decreased 
V-2/3/8-/- 13 12 49 50 571.74±72.61 28±5.29 40 Decreased 
NA- Not Available 
Percent of VAMPs remaining is based on quantitative blotting data from (Graham, Ren et al. 2009).  
The table is based on the characterization of V-3-/- (Schraw, Rutledge et al. 2003), V-8-/- (Ren, Barber et al. 2007) and V-7-/- (Koseoglu, 
Peters et al. 2015) while V-2/3-/-, V-8+/-(2/3)-/- and V-2/3/8-/- are characterized in this dissertation work. The quantification of granule 
secretion percentage is based on 0.05U/mL thrombin stimulation for 2 min (see figure 3.4) 
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Figure 6.1. Correlating VAMP-mediated exocytosis to platelet function  
VAMP levels (per molecule), secretion, and function are graphically correlated using our 
data and that from (Koseoglu, Peters et al. 2015). (A). Predicted VAMP levels remaining, 
relative to WT, in each VAMP-deficient strain were calculated from data in (Graham, 
Ren et al. 2009). (B). The VAMP levels in each strain are plotted as gray fill and the red 
line indicates alpha-granule secretion and the blue line indicates dense granule 
secretion. Secretion data are based on platelet stimulation with 0.05 U/mL thrombin for 
2 min (see Figure 3.4). Secretion from dense and alpha-granules of V-7-/- platelets (open 
symbols) are estimated based on ATP release and P-selectin exposure, respectively 
(Koseoglu, Peters et al. 2015). All values are normalized to WT. (C). Dense granule 
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release and (D). alpha-granule release values are same as in B and are plotted as gray 
fill. The red line indicates tail bleeding times and the blue line indicates the occlusive 
thrombosis times in the FeCl3 injury model. Data are normalized to WT. 
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Another possibility for different fusion rates and extents is if VAMPs represent a 
specific type of granule and regulate its size and composition. It remains to be seen if 
VAMP distribution on granules is exclusive with only one VAMP isoform decorating the 
granule. Peters et al., showed that VAMP-3 and VAMP-8 positive granules are 
centralized and form a granulomere while VAMP-7 positive granules translocate to 
periphery upon platelet spreading. However, it is not clear if or what percent of a 
granule population was labeled with multiple VAMP isoforms.  
Furthermore, in a recent study, Jena et al., showed that VAMP-3, -7 and -8 
specific vesicles isolated from human platelets exhibit distinct sizes and proteomes 
(Jena, Stemmer et al. 2017). The authors used osmotic lysis of platelets to isolate 
vesicle/granule populations and immunoprecipitation to further separate specific 
VAMP-containing vesicles. They performed atomic force microscopy and mass 
spectrometry to further characterize these vesicles. They found that vesicles harboring 
VAMP-3 were about 50% smaller than the vesicles displaying VAMP-8 (Jena, Stemmer et 
al. 2017). Considering smaller spherical vesicles would be more fusogenic than the 
bigger ones due to high curvature stress, the lack of VAMP-3 should decrease or at least 
delay the release of these vesicles which is not in agreement with previously published 
findings and data presented in this work (Schraw, Rutledge et al. 2003). Though these 
experiments were done in human platelets and there might be some species-specific 
differences, it seems improbable that granules will be decorated with only one type of 
VAMP isoform. However, the distribution of VAMP isoforms may offer some variability 
in the fusion rates. Further studies are underway to study this mechanism and since our 
animal models have a gradient of various VAMP isoforms and their levels, they will be 
instrumental in the further investigation. 
Thrombus architecture and secretion deficiency 
Thrombus architecture has been an active area of research for decades. In a 
series of reports, the Brass group illuminated how thrombus formation is 
heterogeneous by using experimental and computational models. They showed that the 
thrombus core is formed by maximally stimulated platelets (P-selectin positive) while 
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the shell is composed of minimally stimulated platelets (P-selectin negative) that are 
barely tethered to each other. The activation gradient from the central core to the outer 
shell layer controls the thrombus porosity regulating trafficking of agonists and other 
molecules (Stalker, Welsh et al. 2014, Tomaiuolo, Stalker et al. 2014, Welsh, Stalker et 
al. 2014, Welsh, Poventud-Fuentes et al. 2017). From our data, we can speculate that 
low agonist doses and early time points in time course analysis resemble platelet 
activation and secretion in shell region while data at high agonist concentrations and 
later time points in time course analysis resemble what occurs in a core region of a 
thrombus. Based on the correlation between a dense and alpha-granule release with 
hemostasis and thrombosis, it seems that the loss of VAMP-2, -3 and -8 affected alpha-
granule release to a greater extent than it did dense granule release, and this may be a 
deciding factor in thrombosis (Figure 6.1 and Table 6.1). This is also evident in dense and 
alpha- granulopathies where patients with HPS and CHS who lack dense granules, have 
severe bleeding defects, as well as Munc13-4 KO mice which are deficient in dense 
granule secretion, also have a severe bleeding defect (Ren, Wimmer et al. 2010). In 
contrast, patients with GPS and ARC syndrome have a wide range from mild to severe 
bleeding diathesis. This pattern in hemostatic deficiencies in these SPD patients suggests 
that dense granules are probably more significant for hemostasis than alpha-granules. 
Alpha-granules are perhaps more critical for thrombosis. From our data, VAMP-8 
deficiency falls in a threshold range where the rate and the degree of thrombosis are 
affected but a stable thrombus does form without causing bleeding (Figure 3.9 and 6.1).  
Implications of the rate and extent of granule secretion 
Two parameters crucial to decide the fate of thrombosis are how fast/slow the 
cargo from platelet granules is released and how much of it is released. As discussed 
earlier, based on dense storage pool deficiencies/SPDs, the extent of cargo release is 
crucial for thrombosis. Lack of dense granules in HPS and CHS leads to severe bleeding. 
The extent of alpha-granule secretion does not seem to be as critical since a wide range 
of bleeding defects- mild to severe are observed in patients with GPS and ARC 
syndrome, major alpha-granule SPDs. V-8-/- platelets show slower and lower release at 
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early time points and at lower agonist concentrations, but the extent of secretion 
increases at later time points and higher agonist concentrations. These animals are 
protected from occlusive thrombosis and spared from bleeding defect (Figure 6.1). This 
argues that if the extent of cargo release is within a reasonable range of that of control, 
the rate of release has a minimal impact on thrombus formation. However, significantly 
delayed secretion may not be effective to recruit and retain other platelets affecting 
thrombus growth. The rate of cargo release is important in burst phase because it 
dictates how fast/slow the thrombus will form. Slower release affects the buildup of the 
thrombus as seen in V-8-/- animals because of delayed platelet recruitment that limits 
thrombus growth while, as seen in V-2/3/8-/-, the low extent of release may be 
insufficient to provide the necessary stimulus to recruit and hold on to other platelets. 
Based on our in vitro assays measuring platelet granule secretion and various in vivo 
studies to assessing hemostasis and thrombosis, we show that the loss of about 40-50% 
of secretion is well tolerated to gain protection from thrombosis without causing 
bleeding. 
Limitations of the study 
The observations in this study are mainly based on in vitro assays using platelet 
suspension or in vivo assays- tail bleeding and FeCl3 arterial injury assays. Experiments in 
suspension fail to consider the in vivo system where the interaction among platelets, 
endothelial cells, and blood cells facilitate platelet adhesion to vascular bed and 
subsequent activation and aggregation. These experiments were unable to account for 
platelets’ ability to sense their environment and respond accordingly (Sakurai, Fitch-
Tewfik et al. 2015). In fact, many reports show that minor defects discovered using in 
vitro assays may have a significant impact in vivo (Ye, Huang et al. 2014, Ouseph, Huang 
et al. 2015). This clearly shows that the in vivo assays are more sensitive than in vitro 
analysis. 
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Figure 6.2. Sequence alignment of mouse VAMP-2, VAMP-3, VAMP-7, and VAMP-8 
amino acids 
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Table 6.2 Percent identity matrix of mouse VAMP-2, VAMP-3, VAMP-7, and VAMP-8 
proteins created by Clustal2.1 
 
 VAMP-2 VAMP-3 VAMP-8 VAMP-7 
VAMP-2 100 73.79 35.05 29.31 
VAMP-3 73.79 100 34.02 29.13 
VAMP-8 35.05 34.02 100 32.67 
VAMP-7 29.31 29.13 32.67 100 
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Figure 6.3. Sequence alignment of SNARE domains from mouse VAMP-2, VAMP-3, 
VAMP-7, and VAMP-8 
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Table 6.3 Percent identity matrix of SNARE domains of mouse VAMP-2, VAMP-3, 
VAMP-7, and VAMP-8 proteins created by Clustal2.1 
 
 VAMP-2 VAMP-3 VAMP-7 VAMP-8 
VAMP-2 100 98.39 37.1 33.9 
VAMP-3 98.39 100 35.48 33.9 
VAMP-7 37.1 35.48 100 40.68 
VAMP-8 33.9 33.9 40.68 100 
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Figure 6.4. Sequence alignment of transmembrane- domains from mouse VAMP-2, 
VAMP-3, VAMP-7, and VAMP-8 
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Table 6.4 Percent identity matrix of transmembrane domains of mouse VAMP-2, 
VAMP-3, VAMP-7, and VAMP-8 proteins created by Clustal2.1 
 
 VAMP-7 VAMP-8 VAMP-2 VAMP-3 
VAMP-7 100 42.11 22.22 26.32 
VAMP-8 42.11 100 41.18 26.32 
VAMP-2 22.22 41.18 100 36.84 
VAMP-3 26.32 26.32 36.84 100 
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Part II- Titrating VAMPs to study the nature of fusion event 
Thrombus formation occurs in a closed vasculature under high shear pressure. 
Rapid release of the entire granule cargo in a bolus would not be able to achieve the 
desired targeted outcome if it is washed away downstream of vascular injury without 
any local effect. To circumvent this, the process of granule release is controlled 
differentially. It is well accepted that dense granules are generally docked and are quick 
to release upon stimulation (Chicka, Ren et al. 2016). Unlike dense granules, alpha-
granule cargo is released in three different waves and these waves are independent of 
an agonist or the function of the cargo (Jonnalagadda, Izu et al. 2012). While the 
differential packaging of cargo in different subtypes of alpha granules or specific areas in 
alpha granules could explain the various rates, these hypotheses could not be supported 
by more extensive studies (Jonnalagadda, Izu et al. 2012). So, what determines the rates 
of release? 
To address this question, we studied the morphology of stimulated platelets. Our 
image analysis shows that the decondensation of granule cargo is dependent on agonist 
concentration and the duration of stimulation. To investigate if this process is secretion- 
dependent, we employed secretion-deficient VAMP KO mouse strains. We stimulated 
VAMP deficient platelets at lower and higher concentrations of an agonist and for 
various time points and studied the morphology of these stimulated platelets. Analysis 
of intermediate structures that represent variable decondensation of alpha-granule 
cargo suggested that cargo decondensation follows the granule fusion and is VAMP-
dependent.  
This work provides a critical piece of the puzzle to address how the rates of 
granule cargo release differ. Granules form a short neck or a longer pipe to fuse with the 
plasma membrane/OCS (Pokrovskaya, Aronova et al. 2016). This probably facilitates the 
influx of solvent inside the granule which is densely packed with abundant proteins. 
Hydration of these cargo helps reduce the density of the packed material and gives a 
characteristic appearance to fused granule (Figure 4.1 red and purple arrows). Thus, the 
rate at which these cargoes are dissolved may regulate their exodus. Second, the 
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incidence of decondensed granules increases with stronger agonist dose or longer 
stimulation time while defective fusion, as seen in V-8 -/- and V-2/3/8-/-, decrease this 
incidence. This argues that the rate and the extent of decondensation are dependent on 
the nature of stimulation and granule fusion to the plasma membrane is required for 
solubilization of cargo. Furthermore, the fibrous material is always present in 
decondensed granules with lack of complete fusion with the exterior of the plasma 
membrane. This may indicate that the cargo scaffold in alpha-granules that hold the 
cargo together adheres to the platelet plasma membrane and may facilitate cargo 
release long after fusion is completed.  
These findings are instrumental in broadening our understanding of how the 
kinetics and the extent of alpha-granule cargo release are determined. As discussed in 
Chapter 3 and earlier sections in this Chapter, the rates and the degrees of granule 
cargo release govern the thrombus architecture and mechanistic details that control 
these events are crucial to balancing hemostasis. The findings from this study provide a 
glimpse of a previously unknown layer of regulation that determines cargo release rates. 
Decondensation of granule cargo 
Morphological analysis of activated mouse platelets presented heterogenous 
population of alpha-granules that differ in cargo density (Figure 4.1 red and purple 
arrows). Further analysis indicated that these granules represent various stages of 
granule secretion and cargo decondensation. Upon granule fusion external 
solvent\water enters the granule through the fusion pore and cargo is 
dissolved\solubilized before leaving the granule. The entry of water could be facilitated 
by aquaporins on the plasma membrane or granules in platelets. Several studies have 
reported that aquaporins facilitate water influx in secretory granules which lead to a 
spontaneous increase in granule volume, followed by a reduction suggesting a cargo 
release (Kelly, Cho et al. 2004). So far, this mechanism has been studied in zymogen 
granules (Cho, Sattar et al. 2002, Cho and Jena 2006), synaptic vesicle release (Kelly, Cho 
et al. 2004), and to some extent in platelets (Lee, Agrawal et al. 2012, Goubau, Jaeken et 
al. 2013). Goubau and colleagues showed that a homozygous mutation in aquaporin 7 
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leads to altered platelet morphology and subclinical platelet secretion defects. Human 
platelets with these mutations are circular in shape and the granules are centrally 
located. ADP secretion is affected in these platelets. The group showed that aquaporin 7 
is colocalized with CD61/LAMP-1 but not with an alpha-granule marker, vWF. Though 
aquaporin 7 is found in the releasate, it is not clear if it was secreted or if it was 
associated with the membrane (Goubau, Jaeken et al. 2013). Other than aquaporin 7, 
only aquaporin 6 has been implicated to exist in platelets. Using mercuric chloride that 
inhibits all aquaporin isoforms except aquaporin 6, Lee et al. showed that it is present in 
platelets (Lee, Agrawal et al. 2012). The group used mastoparan to activate G proteins 
and demonstrated the presence of Gα0 and Gαi in platelets. The roles of aquaporins in 
platelets are still under-investigated. In fact, the literature is sparse in various isoforms 
present in human and mice platelets, their location and functions. Recent mass 
spectroscopic studies failed to find any aquaporins in mouse platelets (Zeiler, Moser et 
al. 2014). The mechanistic details of their roles will be crucial to understanding granule 
secretion. 
Granule cargo scaffold 
Serglycin is a proteoglycan which is critical for storage of secretory proteins in 
neutrophils, mast cells, and cytotoxic T lymphocytes. By using a serglycin KO (Woulfe, 
Lilliendahl et al. 2008) mouse model, Wolfe et al., showed that the lack of serglycin 
leads to dense and alpha-granule secretion defect. Though P-selectin exposure was not 
affected in serglycin KO platelets, PF4 levels were significantly reduced. Additionally, 
these mice had a significant thrombosis defect suggesting that serglycin is critical for 
protein retention and granule secretion in platelets. These data also suggest that 
serglycin may function as a platform/scaffold to support granule cargo. Serglycin binds 
to negatively charged glycosaminoglycans/GAGs such as heparin. Multiple studies have 
reported that the lack of heparin synthesis or serglycin in mast cells affect granule 
morphology (Forsberg, Pejler et al. 1999, Humphries, Wong et al. 1999) suggesting a 
role of serglycin in granulopoiesis. 
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In our study, though we observed various stages of decondensation, surprisingly 
we hardly observed any decondensing granule that has fused completely with the 
plasma membrane. Each decondensing granule had at least some associated fibrous 
material. This raises the possibility that the granule scaffold such as serglycin holds 
cargo together. Upon stimulation, the exodus of this cargo and scaffold occurs 
simultaneously; in fact, the solubilization of scaffold could determine the rate of cargo 
release. Furthermore, observed fibrous material may present remnants of this scaffold 
that could adhere to platelet surface and further control the release of cargo still 
associated with it. 
Another interesting possibility is the association of serglycin to porosomes. The 
porosome is a supramolecular structure shaped like an inverted cup that facilitates 
granule fusion to the plasma membrane (Schneider, Sritharan et al. 1997). It has been 
reported that porosomes are about 150 nm in diameter and are present in pancreatic 
acinar cells (Schneider, Sritharan et al. 1997), growth hormone-secreting cells of 
pituitary (Cho, Jeftinija et al. 2002), chromaffin cells (Cho, Wakade et al. 2002), β cells of 
pancreas and nerve terminal where they have smaller about 10-12 nm diameter (Cho, 
Jeremic et al. 2004). Furthermore, t-SNAREs such as syntaxin-1 and SNAP25 are 
concentrated in porosomes in mouse insulinoma Min6 cells suggesting that they might 
provide a preferred site for granule fusion (Naik, Kulkarni et al. 2016). Similarly, 
syntaxin-11 and SNAP23 are trafficked to lipid rafts upon platelet stimulation and their 
association to the plasma membrane by acylation is critical for platelet secretion (Zhang, 
Huang et al. 2018). Taken together, it can be argued that despite the lack of direct 
evidence, porosomes may exist on the platelet membrane and it will be interesting to 
see if there is any association between serglycin and porosome-like structures. 
The nature of fusion – simple vs compound 
Along with the entry of water into the granule and dissolving the cargo, and the 
composition of cargo scaffold, the nature of fusion event- heterotypic, simple (granule 
to plasma membrane) or homotypic, compound (granule to granule) may also dictate 
the rate and the degree of secretion. While simple fusion is certainly faster than the 
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compound fusion events, compound fusion events are crucial for the extent of release 
since cargo from multiple granules could be released from a single fusion event.  
Using tannic acid staining and Focused Ion beam-scanning electron 
microscopy/FIB-SEM, Eckly et al., showed that VAMP-8 plays a major role in compound 
exocytosis as well as a minor role in simple exocytosis (Eckly, Rinckel et al. 2016). Weak 
stimulation leads to simple fusion events while strong stimulation results in compound 
fusion. Only single fusion events were observed in the case of dense granules, unlike 
alpha-granules which fuse with either simple or compound fusion events. Our findings 
support Eckly et al., in that VAMP-8 is crucial for compound fusion events (Figure 4.7F). 
Deficiencies of VAMP-2 and -3 did not influence simple or compound fusion events 
(Figure 4.7E and F). It is still not clear what role VAMP-7 plays in these events. VAMP-7 
has been shown to interact with VARP and Arp2/3 in platelets (Koseoglu, Peters et al. 
2015). These proteins are important for neurite outgrowth and actin polymerization. 
Since VAMP-7 is shown to translocate to the periphery when platelets spread, it seems 
possible that these associations with cytoskeletal elements may enable it to undergo 
simple fusion events. However, a detailed analysis is warranted to determine which 
events required VAMP-7. 
An intriguing question from these data is what is the sequence of a compound 
fusion event where one of the granules is fused to plasma membrane? Does simple 
fusion happen first, followed by compound fusion or after compound fusion, one of the 
granules fuses to the plasma membrane discharging cargo? Though it is challenging to 
answer this question directly, it seems that the compound fusion event probably follows 
simple granule to plasma membrane fusion. Compound fusion events show that the 
granules are in decondensed state suggesting that there must be some outlet that 
allows the entry of water and subsequent solubilization and exodus of cargo from these 
fused granules. It is possible that a simple fusion between a granule and plasma 
membrane occurs first (Figure 6.5 step no. 3) and then a second condensed granule 
fuses to fused granule (Figure 6.5 step no. 4). 
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Figure 6.5. Progressive decondensation upon granule fusion decides the rate of 
granule cargo release 
The schematic represents the progressive change in decondensation process. The data 
presented in this report support following steps- 
1- An intact granule/condensed granule 
2. Granule -plasma membrane fusion/simple fusion event initiating release of cargo 
in the extracellular environment. Decondensation starts with fusion as depicted by 
the change in density around inside periphery of the fused granule. 
3. The progressive release of cargo changes the density of decondensing granule. 
Note that the cargo scaffold/matrix also appears to be dissolved. 
4. An example of homotypic granule to granule/compound fusion. This may occur 
before or after simple fusion of one of the granules to the plasma membrane. 
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Part III- Role of VAMPs in intracellular vesicle trafficking 
Platelet granule cargo is instrumental in platelet function. Platelets inherit some 
of these cargoes from their precursor cells, megakaryocytes, during granule formation. 
Platelets can synthesize at least some cargo in the ER in addition to endocytosing 
proteins from plasma. Cargo synthesized in the ER is trafficked to the endosomal 
system. In the case of dense granules, BLOC complexes (1,2 and 3) process these 
cargoes and transport them to mature dense granules. In the case of alpha-granules, 
cargo travels from endosomal system to the multivesicular body along with 
endocytosed cargo and after progressive maturation, alpha-granules are formed (Figure 
6.6).  
The role of SNAREs in intracellular trafficking is well studied (Rothman 1994). 
VAMP isoforms could play roles in any or every one of these events indicated by arrows 
in Figure 6.6. We recently showed that VAMP-3 is essential for endocytosis (Banerjee, 
Joshi et al. 2017). As discussed in Chapter 1, VAMP-8 was identified as an endosomal v-
SNARE and has been implicated in trafficking in other cell types. However, the loss of 
VAMP-7 or VAMP-8 did not cause morphological changes in platelets or alter cargo 
levels (Ren, Barber et al. 2007, Koseoglu, Peters et al. 2015), suggesting that either these 
VAMPs do not play role in trafficking or the presence of residual VAMPs may have 
contributed to compensate for them. However, the question remains: which of these 
trafficking events are carried out by which VAMP isoforms? To address this question, we 
studied how trafficking occurs in VAMP deficient strains and if we could allocate specific 
VAMP isoforms to each of the trafficking steps. The data presented here are preliminary 
and work is ongoing. 
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Figure 6.6. Intracellular trafficking in platelets 
Platelets endocytose cargo through the endosomal system and traffic the cargo to early 
and late endosomes. Progressive maturation of cargo occurs in multivesicular bodies 
before packaging it in alpha granules\dense granules\lysosomes. Moreover, platelets 
can also synthesize cargo which travels through the endosomal system and may also get 
transported to multivesicular bodies before getting packaged in various granules. Each 
trafficking event shown with arrows here potentially can be mediated by one or more 
VAMPs. 
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Role of VAMPs in endocytosis 
We previously showed that VAMP-3 is crucial for platelet endocytosis (Banerjee, 
Joshi et al. 2017). V-3-/- platelets showed about a 50% decrease in fibrinogen uptake. 
Consistently, platelet-specific V-2/3-/- and V-8+/-(2/3)-/-  platelets also showed about a 20-
30% decrease in fibrinogen levels while V-2/3/8-/- platelets have about a 50% decrease 
(Figure 3.3). Through the pattern in the reduction of fibrinogen levels is as expected, 
quantitative differences might be due to different backgrounds of these strains. 
Additionally, the timing of PF4 Cre expression might have some influence on this 
process.  
Based on our secretion assays we measured serotonin uptake, PF4 and β-
hexosaminidase levels (Figure 5.1). None of these levels were affected indicating that 
serotonin transporters on platelet membranes and dense granules (Vesicle monoamine 
transporter/VMAT2) are not affected in absence of VAMP isoforms. It also shows that 
de novo synthesis of alpha-granule cargo is normal in these platelets. Morphological 
analysis, however, indicated that V-2/3/8-/- platelets have smaller and more numerous 
alpha-granules. These data imply that the loss of VAMP-2, -3 and -8 disturbs trafficking 
in platelets. Surprisingly, instead of a compensatory increase in VAMP-7 levels which is 
the only residual VAMP isoform still present in these platelets, its levels decreased 
remarkably by about 50%. This again shows that the trafficking or targeting of cargo is 
affected. 
To understand the global impact of defective trafficking in these platelets, we 
used antibody arrays. In these arrays, 53 different molecules (including- pro- and anti-
angiogenic factors, growth factors, tissue factors, cytokines, chemokines, 
metalloproteases etc.) were probed in duplicates. The data were normalized to WT 
levels. These data hint at various levels of biogenesis/trafficking defects  
PF4 levels could be used as an internal control since based on ELIZA assays, we 
know that these are not changed. In our arrays, we find PF4 levels close to WT levels, 
validating our results. The loss of VAMP-8 did not affect cargo levels as much, though 
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about 25% proteins were reduced by about 50% or more (Figure 5.4 and Table 5.1). In V-
2/3-/- platelets, cargo levels were significantly reduced as more than 40% of proteins 
were reduced by 50% or more (Figure 5.5 and Table 5.1). These defects were further 
aggravated in absence of all three isoforms in V-2/3/8-/- platelets (Figure 5.6 and Table 
5.1). About 60% of proteins were reduced by 50% or more. In fact, only 4% of proteins 
were at the level of 75% or above compared to WT levels indicating that the loss of all 
three isoforms has a significant impact on cargo levels. Noticeably, though the levels 
were reduced variably in these VAMP KO strains, all cargoes were present, albeit at 
different levels. This argues that though intracellular trafficking may have been 
impacted to some extent, the effect was not absolute. The loss of VAMP isoforms may 
be overcome by other trafficking factors to execute these events. More detailed studies 
are necessary to validate these results and determine trafficking steps mediated by 
VAMPs.  
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Chapter 7 Summary and future directions 
 
Summary of the work 
The work done in this thesis indicates following findings- 
1. Various VAMP isoforms play redundant roles in regulating the rates and the 
extents of granule secretion. 
2. Titration of the types and amounts of VAMP isoforms provide crucial insight into 
the process of secretion and how it affects in vivo hemostasis and thrombosis. 
3. Based on in vivo studies, we argue that the therapeutic window is represented 
by about 40-50% loss of secretion which could offer protection from thrombosis 
without triggering unwanted bleeding. Beyond 50%, a reduction in secretion 
leads to a severe hemostatic deficiency and defective thrombosis. 
4. Upon granule fusion to the plasma membrane, outside solvent enters the fused 
granule and dissolves the cargo. This aids in the exodus of cargo from granule. 
The rate at which the cargo is dissolved could determine the rate of their 
release. 
5.  The process of granule decondensation follows granule fusion and it is 
dependent on the strength of platelet stimulation- potency of an agonist, the 
dose of an agonist and the duration of stimulation -all factors contribute in 
determining the rates and the degrees of granule cargo release. 
6. Platelet granules appear to contain a scaffold and it aids in retention of cargo 
inside a granule. The interaction of this scaffold with cargo and the rate of 
solubilization of scaffold may play a role in regulating the rate of cargo release. 
The presence of residual scaffold outside fused granule may also indicate 
alternative mechanism through which this scaffold could control the cargo 
release. 
7. VAMP isoforms are crucial for intracellular trafficking. Their loss has a global 
impact on cargo levels. Alpha granules are much smaller in absence of VAMP-2, -
3 and -8 suggesting defective granule formation. 
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Importance of the work 
These findings are important on many levels- 
1. This is the first, systematic study of VAMP redundancy in vivo, showing how 
secretion events alter in the presence or absence of primary/secondary VAMPs.  
2. This is the first quantitative study targeting the contribution of platelet granule 
secretion in thrombosis. It argues that manipulating the types and amounts of 
VAMPs and systematic characterization of secretion profiles enable us to roughly 
pinpoint the range (40-50%) of acceptable secretion deficiencies that could help 
prevent occlusive thrombotic events responsible for cardiovascular diseases 
without causing bleeding. More than 50% loss of platelet granule secretion leads 
to severe hemostatic deficiency and thrombotic defects. This insight could be 
used to develop novel therapeutics to combat thrombotic diseases given our 
understanding of multiple new players found to contribute to platelet secretion 
and related processes. Additionally, this therapeutic range could also be used to 
manage current antithrombotic regimen more effectively by maintaining the 
platelet secretion level in this range. 
3. This is the first orchestrated study that uses genetic tools and biochemical 
analysis with morphological evidence to understand the fine mechanics of 
platelet granule secretion process. 
4. The strains generated for this study- V-2/3-/- and V-2/3/8-/- have been used in 
deciphering platelet autophagy (Ouseph, Huang et al. 2015). Additionally, these 
animals could be immensely useful as invaluable reagents to study the role of 
platelet secretion in various pathologies including but not limited to metabolism, 
wound healing, angiogenesis, immunity, infection, and inflammation.  
Future directions 
First, it remains to be seen what role VAMP-7 plays in diverse exocytotic events. 
Though the loss of VAMP-7 leads to secretion deficiencies like V-8-/- platelets, it does not 
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affect thrombosis (Koseoglu, Peters et al. 2015). These data argue that perhaps the 
secretion deficiency in absence of VAMP-7 is different than the secretion defects 
observed upon VAMP-8 loss. However, it is not clear how. Peters et al., showed that 
VAMP-7 positive alpha-granules travel to the periphery while VAMP-3 positive and 
VAMP-8 positive granules form a central granulomere (Peters, Michelson et al. 2012). 
These findings also support the role VAMP-7 plays in platelet spreading. What is not yet 
clear is whether VAMP-7 is preferentially important for simple and/or compound fusion 
events that would explain the rates and extents of secretion in these animals. It will also 
provide insight into the secretion pattern that is expendable. More investigation is 
necessary to study this mechanism. 
Second, it remains to be seen if VAMP isoforms are distributed differentially on 
granules. Based on some preliminary data from the Storrie laboratory, it is unlikely that 
specific VAMP/VAMPs decorate granules exclusively but is it possible that the ratio of 
types of VAMPs present on vesicles may decide the fate of that granule and the nature 
of its secretion events. Fusogenicity of SNARE complexes is contingent upon the v- and 
t- SNAREs forming it. We speculate that in platelets, VAMP-8 and VAMP-7 containing 
complexes may be more fusogenic than the ones containing VAMP-2 and VAMP-3 since 
the abundance of VAMP-2 and VAMP-8 is comparable but only the loss of VAMP-8 leads 
to secretion deficiency (Ren, Barber et al. 2007). This could explain the rates and the 
extents of granule secretion we observed in various VAMP deficient strains. 
Alternatively, the distribution of VAMP isoforms may also contribute to secretion of 
granules they reside on. It remains to be seen if VAMP distribution on granules is 
random or if they are distributed to certain regions bestowing polarity to granules. 
Third, though platelet granule secretion is a well-studied process, its potential is 
not much appreciated beyond hemostasis. Given the dynamic roles of platelets in a 
wide variety of physiological processes, not all cargo molecules that are released from 
platelets have been accounted for their location in platelets or the nature of their 
release. One example is an important ER resident protein-protein disulfide 
isomerase/PDI which is mainly known for its chaperone activity. PDI has been shown to 
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be essential for thrombosis (Jasuja, Passam et al. 2012) but it is not clear how it is 
released from platelets. Is it released in the SNARE-dependent manner? Does release 
from other intracellular organelles which are not granules depend on SNAREs? The 
second example is CMP sialic acid and sialic acid transferases. These enzymes and their 
substrates are found in platelets, but their role is not yet clear. Jones et al., showed that 
the CMP sialic acid release from platelets is crucial for B cell-independent sialylation of 
IgG. It will be interesting to see where exactly these enzymes are located and if their 
release is SNARE-dependent (Jones, Oswald et al. 2016).  
Fourth, the role of VAMPs in intracellular trafficking should be studied in detail. 
As preliminary data presented in Chapter five suggest, both endocytosed and 
synthesized\megakaryocyte originated cargo levels are depleted in VAMP deficient 
strains, indicating possible trafficking defects. The development of super-resolution 
techniques offers a great tool to study how VAMPs contribute to granule biogenesis and 
cargo trafficking. These discoveries are crucial not only for hemostatic functions but also 
immunological functions of platelets (Banerjee and Whiteheart 2016). 
Furthermore, platelet trafficking has a broader influence on platelet function. 
Platelet metabolism is a critical piece of cell biology and physiology of platelets. Roles of 
VAMPs in glucose transporters/GLUT translocation are well known. In myoblasts, VAMP-
2 mediates insulin-stimulated GLUT4 translocation to the plasma membrane 
(Randhawa, Bilan et al. 2000). Previous reports argue that in adipocytes, GLUT4 is found 
in two pools of vesicles- endocytic pool (including trans- Golgi network) and non- 
endocytic pool that consists of special vesicles called GLUT4 storage vesicles (GSVs). 
These different pools of vesicles release GLUT4 in agonist-dependent and VAMP 
isoform-dependent manner. VAMP-3 facilitates GLUT4 translocation from the 
endosomal pool in guanosine-59-O-(3-thiotriphosphate) (GTPγS) dependent manner 
while VAMP-2 is important for insulin-stimulated GLUT4 translocation. VAMP-3 is also 
associated with both insulin and GTPγS stimulated GLUT1 translocation contrary to 
VAMP-2 which does not have any impact on GLUT1 translocation (Millar, Shewan et al. 
1999). Recently, it has been shown that in adipocytes, VAMP-8 is important for GLUT4 
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endocytosis from the plasma membrane (Williams and Pessin 2008). Though it is known 
that platelets contain GLUT3 transporter and utilizes glucose, it is not clear how the 
energy needs alter based on resting/activated states and how/which metabolic 
pathways are employed. The animal models we generated in this study could uniquely 
help address these questions.  
Finally, in vitro experiments were used to study the dynamics of the secretion process in 
VAMP deficient platelets in which a platelet suspension was used. However, there is a 
possibility that platelet behavior may be altered, had they been on the adherent 
surface. Some reports suggest that platelets could have some polarity, and this affects 
how secretion takes place. Supporting evidence comes from multiple reports where 
mild deficiency in platelet secretion led to robust hemostatic defect (Adam, Kauskot et 
al. 2010, Ye, Huang et al. 2014). In a growing thrombus under shear pressure from blood 
flow, platelets form layers of adhesive surface to form the core of thrombus while 
activating and recruiting more platelets to form the less activated shell. These functions 
could be differentially executed by polar surfaces. Moreover, some reports suggest that 
platelets can sense their surroundings and use matrix cargo from alpha granules (such as 
fibrinogen/fibronectin) to enhance their adhesion on the vascular surface beyond 
subendothelial matrix (Sakurai, Fitch-Tewfik et al. 2015). Data presented in Chapter 
three indicate that VAMP-mediated secretion is crucial for platelet spreading. It will be 
interesting to see if this spreading defect is limited to certain adhesive proteins. Could 
these platelets spread beyond the matrix?  
In summary, the work presented in this thesis offers a valuable insight into the 
process of platelet granule secretion. We show that about 40-50% loss of secretion 
could be well tolerated for hemostatic balance, while beyond a 50% reduction, both 
hemostasis and thrombosis are affected. These results will be instrumental not only in 
the development of therapeutics but also for the management of current anti-platelet 
therapies. This window could provide a starting point that is helpful to maintain the 
hemostatic balance. Using novel microscopic tools, we show that the rate of cargo 
decondensation follows granule fusion and plays a crucial role in determining the rates 
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and extents of granule cargo release. This may have a significant impact on the 
thrombus formation.  
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